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ABSTRACT 
Aimee Angela D’Aloisio: Evaluation of Insulin-like Growth Factor Polymorphisms  
with Prevalence and Size of Uterine Leiomyomata  
 (Under the direction of Jane C. Schroeder, DVM, PhD) 
 
 
 
Genetic factors influence circulating insulin-like growth factor-one (IGF-I) and IGF 
binding protein-3 (IGFBP-3) levels.  Prior studies with multiple IGF-I and IGFBP-3 
polymorphisms have been limited, especially among African Americans.  We evaluated 
30 IGF-I and 15 IGFBP-3 single nucleotide polymorphisms (SNPs) and estimated 
diplotypes in relation to plasma levels of both proteins among 984 premenopausal 
African Americans and Caucasians from the National Institute of Environmental Health 
Sciences Uterine Fibroid Study.  In both racial groups, IGFBP-3 rs2854746 (Ala32Gly) 
was associated with plasma IGFBP-3, (CC versus GG: Caucasians: 631 ng/ml, 95% 
confidence interval (CI): 398, 864; African Americans: 897 ng/ml, 95% CI: 656, 1138).  
Relative to diplotypes with the rs2854746 CG genotype, IGFBP-3 diplotypes with the 
GG genotype had lower mean plasma IGFBP-3 while IGFBP-3 diplotypes with the CC 
genotype had higher mean plasma IGFBP-3.  The IGFBP-3 promoter SNP, rs2854744, 
which was in strong linkage disequilibrium with rs2854746 in Caucasians only, was 
associated with plasma IGFBP-3 in both races.  Eight additional IGFBP-3 SNPs were 
associated with plasma IGFBP-3, with generally consistent associations between races.  
Twelve IGF-I SNPs were associated with plasma IGF-I; however, associations were 
discordant between races, and were not consistent with diplotype findings.  
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Uterine leiomyomata (fibroids) are responsible for substantial morbidity, especially 
among African Americans.  Gene expression studies suggest IGF-I involvement in 
fibroid pathogenesis; IGFBP-3 may be important based on biological interrelations with 
IGF-I.  IGF-I and IGFBP-3 polymorphisms have not been previously studied with 
fibroids.  We evaluated the IGF-I and IGFBP-3 SNPs and estimated diplotypes from our 
first study in association with fibroid prevalence in our African American and Caucasian 
study population.  Relatively precise prevalence differences (PD) with IGF-I and IGFBP-
3 SNPs were predominantly estimated among African Americans, including IGFBP-3 
SNPs of rs9282734 (His158Pro) (PD = -0.130, 95% CI: -0.294, 0.034) and rs2475551 
(splice site) (PD = 0.208, 95% CI: 0.095, 0.320) and IGF-I SNP rs35767 (promoter) (PD 
= 0.208, 95% CI: 0.095, 0.320).  Associations with larger fibroids (2+ cm) were 
consistent or slightly weaker than with any fibroids.  Diplotype associations were not 
consistent with SNP findings.  Future research should validate our findings and examine 
additional genes within the IGF-I pathway.    
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CHAPTER I 
REVIEW OF THE LITERATURE 
 
Epidemiology of uterine fibroids 
Uterine leiomyomata (fibroids) are hormonally-dependent benign tumors of smooth 
muscle origin that commonly result in pelvic pain and menstrual irregularities including 
heavy bleeding in addition to potential fertility problems (1).  Uterine fibroids are the 
principal indication for hysterectomies in the United States, resulting in more than 
200,000 of these surgical procedures per year (2, 3).  The National Institute of 
Environmental Health Sciences (NIEHS) Uterine Fibroid Study estimated the risk of 
developing fibroids by age 50 to be over 80% among African Americans and over 60% 
among Caucasians (4), which is in contrast with previous estimates that focused their 
definition of fibroids on women with diagnoses based on clinical symptoms or 
hysterectomy, without accounting for asymptomatic cases.      
The most consistent risk factors for uterine fibroids are age, race, and reproductive 
history.  Fibroid prevalence increases with age up to menopause (4-7); the onset of 
menopause can initiate regression of uterine fibroids, which is most likely due to declines 
in reproductive hormone levels.  Most epidemiologic studies have supported a greater 
prevalence and higher degree of related morbidity from uterine fibroids among African 
Americans compared to Caucasians (4, 5, 8).  In particular, the Nurses’ Health Study II 
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reported an earlier age of onset and higher age-adjusted incidence rates of hysterectomy 
or ultrasound confirmed fibroids among African Americans (30.6 per 1,000 woman-
years) compared with Caucasians (8.9 per 1,000 woman-years) (5).  Only one case-
control study did not support an association between African American race and fibroids, 
but its study population was less than 10% African American (6).   In addition, African 
American women have been reported to have more fibroid-related morbidity, a greater 
number and size of tumors, and an earlier age of diagnosis compared to Caucasians (9).  
Early menarche has been related to fibroid prevalence in three studies (8, 10, 11) in 
addition to the NIEHS Uterine Fibroid Study (unpublished) although a small case-control 
study did not support this finding (6).  Causal explanation for relations between early 
onset of menarche and fibroids involve possible alterations in estrogen and progesterone 
levels in adults, but this mechanism is not established, and  early age at menarche may 
instead act as a marker for other hormonally-related exposures that promote fibroids (12).   
Parity has been inversely associated with uterine fibroids (13, 14); however, the 
timing of births may be a more important factor than the overall number (8) since 
stronger associations have been observed with births after 24 years of age (15).  Baird et 
al. postulated that the protective association of live births after age 24 with fibroids is due 
to uterine remodeling subsequent to each completed pregnancy, which may eliminate 
small fibroids.  According to this hypothesis, only births during mid-reproductive years, 
which is the time of peak tumor development, would decrease fibroid prevalence (15).  
Others have suggested that the inverse associations between fibroids and parity may be 
confounded by infertility or breastfeeding; however, the parity association was not 
reduced by exclusion of infertile women in two large cohort studies (10, 11), and 
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breastfeeding has not been associated with fibroids in the few studies that have evaluated 
it as a risk factor (6, 11).   The relation of infertility with uterine fibroids has not been 
resolved.  Some studies find associations (10, 16), but this could be due to reverse 
causation and possibly common causes.   
Smoking has been inconsistently associated with uterine fibroids (8, 13, 14, 16), with 
inverse associations attributed to reduced estrogen levels in smokers versus non-smokers.  
However, neither the Nurses’ Health Study II (17) nor the Black Women’s Health study 
(18) found an association between smoking and fibroids.  Obesity has been positively 
associated with fibroids, possibly as a consequence of elevated estrogen levels (8, 16, 17, 
19).  Although relations between physical activity and fibroids are highly plausible, 
epidemiologic investigations have been very limited.  Specifically, physical activity has 
been associated with increased levels of estrogen metabolites with low receptor affinity 
among premenopausal women in Bentz et al. (20), but Campbell et al. did not confirm 
this finding (21).  The NIEHS study noted an inverse association between an index of 
current physical activity and fibroid prevalence (22), and Frisch et al. reported reduced 
clinically diagnosed fibroids among former college athletes compared to non-athletes 
(23).   Two studies have reported positive associations between alcohol intake and 
fibroids.  In the NIEHS Uterine Fibroid Study, there was a threshold effect in which even 
low levels of alcohol consumption (at least 0.5 drinks per week) were associated with an 
increased fibroid prevalence among Caucasians, while consumption of over 2 drinks per 
week were positively associated with fibroids in African Americans (24).  These results 
are somewhat consistent with the Black Women’s Health Study, which suggested that 
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strongest associations were for consumption of at least 7 drinks per week (especially beer 
intake) and duration of consumption of at least 20 years (18).   
Associations between fibroids and oral contraceptive use have been inconsistent, 
with some studies reporting inverse  associations with current oral contraceptive use (8, 
25) and duration of oral contraceptive use (8, 14), while another reported a positive 
association with ever use of oral contraceptives (16).  The Black Women’s Health and 
Nurses’ Health Studies did not find an association with current oral contraceptives 
overall, but instead suggested that use during teenage years may be associated with 
increased fibroid risk (10, 11).  Originally, estrogen was regarded as the main hormone 
involved in fibroid development, but more recently progesterone also has been 
considered important in growth promotion of fibroids (26, 27).  A hypothesis involving 
indirect effects of estrogens or progesterones on fibroids through accelerating 
transcription of cytokines or growth factors has been proposed (28, 29).     
Early research suggested that reported positive associations with hypertension and 
uterine fibroids were due to fibroid-mediated hypertension secondary to obstruction of 
the urinary tract by the growing uterine tumors (30, 31).  However, two recent studies 
have refuted this hypothesis because they did not support hypertension occurring 
subsequent to fibroids and instead suggest that fibroids and hypertension may share a 
common pathogenic mechanism (32, 33).  Shared associations with race, obesity, blood 
pressure, and physical activity, support a recent hypothesis that atherosclerosis and 
uterine fibroids share a common biologic mechanism involving hyperinsulinemia (1, 33).  
In addition, smooth muscle proliferation is involved in the pathogenesis of both 
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atheromatous plaques and fibroids (34).  However, fasting insulin was not associated with 
increased prevalence of fibroids in the NIEHS Uterine Fibroid Study (unpublished). 
Studies of genetic susceptibility to fibroids among women in the United States have 
been limited; however, Al-Hendy et al. reported that a catechol-o-methyltransferase 
(COMT) polymorphism (Val158Met) (35) and an estrogen receptor-α polymorphism (36) 
were both related to fibroids, and that the proportion of women with high-risk genotypes 
was greater among African Americans than Caucasians or Hispanics.  However, Gooden 
et al. reported no association between the COMT Val158Met single nucleotide 
polymorphism (SNP) and fibroids within the NIEHS Uterine Fibroid Study (37).  A 
relative increase in the prevalence of fibroids was noted among Taiwanese women with 
SNPs in the progesterone receptor, epidermal growth factor receptor and tumor-necrosis 
factor-alpha genes (38-40) in addition to associations with a CAG trinucleotide repeat 
polymorphism and a TA dinucleotide repeat polymorphism in the androgen and estrogen 
receptor genes respectively (41, 42).  Also, uterine fibroids have been associated with a 
DNA repair gene (XRCC1) polymorphism among Koreans (43), and a cytochrome P450 
(CYP17) polymorphism in a small South African study (44).  Three small German case-
control studies reported that uterine fibroids were not associated with estrogen receptor-
alpha (45), COMT (45), or angiopoietin-2 polymorphisms (46), but were associated with 
a p53 polymorphism (46) and possibly with three cytochrome P450 polymorphisms 
(CYP17A (45), CYP2A13 (47), CYP1A1 (47)).  Null findings were reported in two 
Japanese studies investigating a cytochrome P450 (CYP17) polymorphism (48) and 
matrix metalloproteinase polymorphisms (49).  Overall, conclusions that may be inferred 
from these genetic susceptibility studies are limited due to their inconsistent findings, 
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small sample sizes, emphasis on statistically significant findings, examination of only 
clinically diagnosed or hysterectomy treated fibroids, and lack of representative controls 
(45-47).   
 
Insulin-like growth factor overview  
Insulin-like growth factors (IGFs), formerly known as somatomedins, are a family of 
molecules that include two IGFs (IGF-I and IGF-II), two IGF receptors (IGF-IR and IGF-
IIR), six IGF binding proteins (IGFBP-1 through IGFBP-6), and several IGFBP 
proteases.  IGF-I and IGF-II are polypeptides that are structurally similar to insulin, and 
have mitogenic properties.  IGF-I synthesis is regulated by growth hormone and occurs 
predominantly in the liver, but is also produced in other tissues.  In contrast, IGF-II 
production is not dependent on growth hormone.  IGF-I has historically been the focus of 
research because of its potential role in disease.  Specifically, IGF-I has been implicated 
in many biologic processes, including stimulation of cell cycle activities, differentiation, 
proliferation, hormone secretion, and inhibition of apoptosis.  IGF-II also has important 
roles in cell processes, especially in the context of fetal growth and bone development, 
but it has been less studied regarding its possible involvement in adult disease.  Binding 
to the IGF-IR, which has structural resemblance to the insulin receptor, often precedes 
IGF-I or IGF-II involvement in cellular processes.  IGF-IR has much stronger binding 
affinity to IGF-I than to IGF-II or insulin (50, 51).    
IGFBPs attach to free IGFs in circulation and have even greater binding affinities to 
IGFs than the IGF-IR.  Some IGFBPs reduce the level of IGFs available to act on cells, 
which suggests that they may inhibit IGF-mediated disease processes; however, IGFBP 
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binding also could prevent IGF natural degradation in the blood.  In addition, IGFBPs 
may have independent effects such as through interactions with cell surface molecules 
that may stimulate apoptosis of cancer cells (50, 51).  The function of IGFBPs and the 
preferential binding affinities for IGF-I or IGF-II vary for the six peptides.  IGFBP-3, the 
most studied of the IGFBPs, binds approximately 90% of circulating IGF-I (52).  
Possible independent effects of IGFBP-3 have included preventing cell growth and 
inducing apoptosis of breast cancer cells (53, 54) but these findings have not been 
confirmed.  
 
Insulin-like growth factor involvement with uterine fibroids 
Biologic evidence has accumulated in support of the role of IGFs, especially IGF-I, 
in fibroid development, including in vitro evidence of the promotion of fibroid cell 
growth by IGF-I (55) and increased expression of IGF-I mRNA or peptides (56-58) as 
well as elevated IGF-IR levels in fibroid tumor tissue as opposed to myometrium (57-60).  
Wolanska, et al. reported that the relative increase in IGF-I protein detected in fibroids 
versus normal myometrium was positively related to tumor size (56).  Van der Ven et al. 
reported that increased IGF-I peptide and IGF-IR mRNA levels in fibroids versus 
myometrium occurred in the absence of differences in IGF-I mRNA levels, which may 
indicate IGF-I was elevated due to increased binding by IGF-IR rather than increased 
production of IGF-I in tumor versus myometrial cells (58).   
Treatment of fibroids with gonadotropin-releasing hormone analogue, which 
substantially reduces estrogen and progesterone hormone levels, has been associated with 
reductions in tumor size and IGF-IR, but not changes in IGF-I protein levels (61).  One 
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study did not find IGF-I mRNA differences between fibroids and myometrium (62) but 
another reported a decrease in IGF-I mRNA and protein levels in both tissues after 
treatment with a gonadotropin-releasing hormone analogue (62).  Finally, another study 
detected no differences with IGF-I mRNA but reported increased IGFBP-3 mRNA in 
fibroids versus myometrium upon gonadotropin-releasing hormone analogue treatment; 
however, there was elevation of IGF-I mRNA measured in untreated fibroids that were 
undergoing the proliferative phase of the menstrual cycle (63).    
Two studies have supported the involvement of both IGF-I and IGF-II in fibroids 
(57, 64, 65) based on differential expression in tumors versus the myometrium.  
Specifically, Boehm, et al. reported elevation of both IGF-I and IGF-II mRNAs (65) in 
fibroids, and Vollenhoven et al. observed no difference in IGF-I mRNA but increased 
IGF-II mRNA and reduced IGFBP-3 mRNA in fibroids relative to myometrium (64).  
Gloudemans, et al. did not support IGF-I or IGF-II involvement with fibroid pathogenesis 
based on no IGF-I or IGF-II mRNA or protein differences for fibroids versus 
myometrium (66).   
We have hypothesized that inverse associations between IGFBP-3 and fibroids 
would support IGF-I versus IGF-II involvement in tumor development, especially if 
increased levels of free IGF-I promote tumor growth.  However, it is possible that 
positive associations between IGFBP-3 and fibroids would also support IGF-I 
involvement if IGFBP-3 binding to IGF-I increases IGF-I half-life by preserving it from 
destruction.  In addition, effects of IGFBP-3 that are independent of IGF-I binding could 
affect the estimated association between IGFBP-3 and fibroids.  
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A recent systematic review of microarray gene expression studies (67) emphasized 
IGF-II involvement with fibroids by noting that elevated IGF-II mRNA expression in 
fibroid tumor cells versus normal myometrium is one of the most consistent findings (67-
71) (72-74).  Microarray studies are a useful screening tool to identify genes that may be 
involved in fibroid pathogenesis, but results should be interpreted with caution prior to 
confirmation by other types of studies (75).  A recent microarray study reported elevated 
expression of IGF-I mRNA and protein, along with differences in two factors involved in 
IGF-I pathways (MAP kinase phosphatase-I and A-myb), in fibroids relative to 
myometrium after estrogen treatment (76).   
 IGF-I mRNA concentration is increased in fibroids during the follicular phase 
relative to the luteal phase of the menstrual cycle (63, 65), which is consistent with IGF-I 
regulation by estrogen rather than progesterone; however, menstrual cycle variation in 
IGF-I has not been detected in all studies (77).  Englund et al. found evidence of 
hormonal regulation of IGF-I in fibroids based on positive correlations between 
circulating estradiol levels and IGF-I expression in fibroid tumors compared with 
myometrium (77).  IGF-I may promote fibroid growth by elevating expression of 
proliferating cell nuclear antigen (PCNA) and may inhibit apoptosis by promoting Bcl-2 
expression in tumor cells (78).   
Previous studies have focused primarily on the role of estrogen in regulation of IGF-I 
in fibroid pathogenesis, but more recent studies have focused on the role of progesterone.  
Yamada et al. reported that treatment with progesterone but not estrogen was associated 
with reduced IGF-I mRNA expression in cultured fibroid cells, while neither hormone 
altered IGF-IR mRNA expression (79).  Treatment with a gonadotropin-releasing 
  
 10
hormone analogue resulted in decreased expression of progesterone receptor mRNA and 
protein and IGF-I mRNA as compared to untreated women in the proliferative phase, but 
progesterone receptor and IGF-I expression was similar in fibroid and myometrium tissue 
(62). 
In summary, evidence of higher IGF-I mRNA levels in fibroids versus myometrium, 
variation in the expression of IGF-I according to menstrual cycle phase, and in vitro 
stimulation of fibroid growth by IGF-I supports the role of IGF-I in fibroid development; 
however, IGF-II is also implicated because of consistent results from microarray studies.  
Studies with increased IGF-IR expression in fibroids relative to myometrium can support 
involvement of either IGF-I or IGF-II since both IGFs can bind with this receptor, 
although IGF-II has lower affinity than IGF-I.  In addition, the activity of both IGFs is 
influenced by IGFBPs, IGF-IR, hormonal regulation and other cellular factors that can 
affect fibroid associations.   
 
Circulating insulin-like growth factor levels 
Genetic factors regulating IGF serum levels have been estimated to account for 
nearly 40% to 50% of the interindividual variation in IGF-I (80, 81) and approximately 
60% of the variation in IGFBP-3 (80, 82).  In adults, age is the most consistently reported 
nongenetic factor associated with IGF-I blood levels (52, 83-92) and to a lesser extent 
with the IGF-I:IGFBP-3 ratio, (86, 87, 91, 92) with lower circulating IGF-I levels (52, 
83-92) and IGF-I:IGFBP-3 ratio (86, 87, 91, 92) associated with increasing age.  Women 
have lower circulating IGF-I (84, 87, 88, 90, 92, 93) but higher IGFBP-3 concentrations 
(84, 87, 88, 92, 93) than men.  In addition, post-menopausal women generally have lower 
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IGF-I levels than pre-menopausal women; however, distinguishing between age and 
hormonal influences on pre- and postmenopausal IGF-I levels is difficult.  Studies of 
racial differences in circulating IGF levels among women have been limited, but a few 
studies have suggested that African American women have greater circulating IGF-I 
concentrations than Caucasians (88, 94).  IGF-I levels among adolescent girls were 
increased in Caucasians relative to African Americans after adjustment for sexual 
development and body fat, but mean values were higher in African Americans prior to 
adjustment (95) .   
Blood measurements of IGF-I and IGFBP-3 have been inconsistently associated with 
BMI (85, 88, 92, 96-98), smoking (84, 85, 93), alcohol consumption (88, 90, 99-101), 
and physical activity (85-87, 92, 97).  Variations between studies may be at least partly 
due to analytic differences including adjustment for exogenous hormones and factors 
associated with endogenous hormone levels.  Holmes et al., from a cross-sectional 
analysis of a sample from the Nurses Health Study, found an inverse association between 
parity and plasma IGF-I levels (85).   
Oral contraceptive use was inversely associated with circulating IGF-I but positively 
related to IGFBP-3 levels in a cross-sectional study of premenopausal nulliparous women 
(94, 99).  The Jernstrom et al. analysis including only Caucasian women also reported 
that the estradiol dose within oral contraceptives was inversely associated with 
circulating IGF-I but not IGFBP-3 (99), and the Jernstrom et al. analysis of the entire 
study population found that inverse associations between IGF-I and oral contraceptives 
were present among Caucasians but not African Americans (94).  Two U.S. cross 
sectional studies from Holmes et al. and Chang et al. reported inverse relations between 
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hormone replacement therapy (HRT) and circulating IGF-I (85, 93). Holmes et al. 
measured the lowest levels of plasma IGF-I and IGFBP-3 among postmenopausal women 
taking estrogen only, followed by women taking estrogen plus progesterone hormone 
replacement therapy (HRT) (85).   
Jernstrom et al. reported a positive association between age at menarche and plasma 
IGF-I levels among oral contraceptive users only, but no association with plasma IGFBP-
3 levels (99).  Probst-Hensch et al., from a cross-sectional analysis of a sample from the 
Singapore Chinese Health Study, found that women who reported age at menarche age 
was less than 17 years had lower serum IGF-I than women who reported menarche 
occurred at 17 years or older (87).   However, an Italian cross-sectional study, with 
participants from a breast cancer chemoprevention trial (unaffected or early invasive 
breast cancer), reported that women with age at menarche below 13 years had higher 
circulating concentrations of both IGF-I and IGFBP-3 than women age 13 or older at 
menarche (91).  Although the plasma IGF-I:IGFBP-3 ratio increased as nonusers of oral 
contraceptives,  progressed from the follicular phase to the luteal phase until the start of 
menses in Jernstrom et al. (99), Helle et al. reported that plasma IGF-I levels were highest 
in the follicular phase of a Norwegian pilot sample (102), and Wang et al. reported no 
menstrual cycle variation of serum IGF-I and IGFBP-3 in a small sample of women from 
Taiwan (103).   
Dietary factors have also been investigated in relation to circulating IGF levels.  
Specifically, dietary and supplementary calcium was positively associated with IGF-I, 
IGFBP-3, and IGF-I:IGFBP-3 serum levels in Probst-Hensch et al. (87), and milk 
consumption was related to increased plasma IGF-I levels in Morimoto et al. (cross-
  
 13
sectional study of controls from The Seattle Colon Cancer Family Registry) and  Holmes 
et al. (92, 101).  Holmes et al. reported that plasma IGF-I was positively associated with 
dietary calcium and Vitamin D but not supplement sources of these nutrients (101).  
Saturated fat was inversely associated with plasma IGFBP-3 in three studies (87, 101, 
104), including Probst-Hensch et al, who also reported positive relations between IGFBP-
3 and dietary fiber and omega-3 polyunsaturated fat (87).  Circulating IGF-I was 
inversely associated with fish intake in a Hawaiian cross-sectional study (105) and with 
consumption of carbohydrates and bread in a small Greek cross-sectional study (104).  
Holmes et al. also reported that plasma IGF-I was associated with energy intake among 
women with normal BMI, protein intake due to dairy foods, and zinc intake regardless of 
the source (101).  Nutritional relations with IGFs were fairly inconsistent although an 
inverse association between saturated fat and IGFBB-3 was detected in three separate 
studies.   Overall conclusions from these nutritional studies with IGF circulating levels 
can be difficult because of correlations between nutritional factors and discrepancies in 
associations with food sources, dietary micronutrients, and supplement sources.   
 
Circulating insulin-like growth factor levels and cancer 
Several studies have focused on IGF-I, and to a lesser extent on IGFBP-3 in 
association with cancer, especially breast cancer.  A small U.S. case-control study 
reported that circulating IGF-I was associated with overall breast cancer risk (106) while 
two case-control studies nested within the Nurses’ Health Study cohort and a New York 
cohort found positive relations with IGF-I but not IGFBP-3 among premenopausal 
women only (107, 108).  A Chinese population-based case-control study reported 
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positive associations between breast cancer and both IGF-I and IGFBP-3 levels among 
women regardless of menopausal status (109), while small U.S. and Italian nested case-
control studies and a case-control study with breast cancer cases pooled from three 
cohorts (Italy, Sweden, U.S.) reported these positive associations among premenopausal 
women only (110-112).   Two case-control studies nested within Dutch and U.S. cohorts 
of postmenopausal women reported null findings for associations between breast cancer 
and circulating IGF-I or IGFBP-3 (113, 114).  A meta-analysis of 21 studies involving 
circulating IGFs in association with common cancers reported that elevated IGF-I 
(OR=1.65; 95% CI: 1.26, 2.08) and IGFBP-3 (OR=1.51; 95% CI: 1.01, 2.27) levels were 
associated with premenopausal breast cancer (115).    
A case-control study nested within the Northern Sweden Health and Disease Cohort 
reported positive associations between circulating both IGF-I and IGFBP-3 and colon 
cancer, but inverse associations with rectal cancer (116).  Increased IGF-I and reduced 
IGFBP-3 in circulation were associated with colorectal cancer among women (117) and 
among men (118) from two case-control studies nested within the Nurses’ Health Study 
and Physicians’ Health Study cohorts respectively.  However, a Chinese nested case-
control study found no relation between serum IGF-I and colorectal cancer in men but 
instead reported positive associations with circulating IGFBP-2 and IGFBP-3 levels 
(119).  Circulating IGF-I and IGFBP-3 were not related to endometrial cancer in a 
Swedish case-control study, although there was a suggestion of a positive association 
with IGFBP-1 among hormone replacement users (120).  A case-control study of ovarian 
cancer nested within three cohorts (Italy, Sweden, U.S.) reported a strong, but imprecise 
positive association with circulating IGF-I but not IGFBP-3 (121).    
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In conclusion, there has been some consistency across studies suggesting a positive 
relation (including postmenopausal breast cancer) between circulating IGF-I and 
premenopausal breast cancer, but studies of other cancers have conflicting results and are 
too few in number.  Evaluation of cancer study results for relations with IGFBP-3 are 
inconclusive.   
 
Insulin-like growth factor polymorphisms 
The IGF-I gene, which is approximately 84.6 kb, is located on chromosome 12q22-
q23.  It has multiple transcription variants, which explains why it has been reported to 
have between 4 to 5 exons (122, 123).  Based on mapping information from the Entrez 
Gene website sponsored by the National Center for Biotechnology Information (NCBI),  
the IGF-I gene is shown with four exons.  Several studies have focused on cancer 
development in association with IGF-I polymorphisms, while fewer studies have 
examined variation in the IGFBP-3 gene. 
The focus of epidemiologic studies within the IGF-I gene has been on the 
dinucleotide CA repeat polymorphism (position -969) located in the promoter 
approximately one kb upstream of the transcription site.  The number of IGF-I 
dinucleotide CA repeats within individuals has been reported to typically range from 15 
to maximum of 23, although as few as 11 repeats have been reported. Substantial racial 
variation exists in the frequency of the predominant 19-repeat allele, which is detected in 
60 to 70% of Caucasians (94, 124, 125, 126, 127) compared with approximately 40% or 
less of African Americans (94, 124, 126, 127).  Inconsistent relations between the CA 
repeat polymorphisms and circulating IGF-I levels have been reported.  Two studies 
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reported that having two copies of the 19 CA repeat allele versus other genotypes was 
inversely associated with plasma IGF-I levels (128), although one found this relation only 
among oral contraceptive users (94).  Two other studies also suggested a relative decrease 
in plasma IGF-I among oral contraceptive users with at least one 19 CA repeat allele 
compared with other genotypes (99, 129).  Specifically, Jernstrom et al. (94) reported that 
racial differences in the association between oral contraceptive use and plasma IGF-I 
were explained by the race-stratified distribution of the IGF-I  CA repeat polymorphism 
(19 repeat allele).  The Rotterdam Study reported that a decline in circulating IGF-I with 
advancing age was only measured for persons having two copies of the 19 CA repeat 
(130).  Lai et al. (131) measured slightly lower IGF-I levels in association with increasing 
number of 19 CA repeat alleles, but only among postmenopausal women.  In contrast, a 
nested case-control study within the Nurses’ Health Study cohort and a study of a 
population-based sample from the Rotterdam cohort reported a positive association 
between circulating IGF-I and the homozygous 19 CA repeat genotype compared with 
having no copies of this allele (132, 133), but three studies found no association between 
the 19 CA repeat allele and circulating IGF-I (127, 134, 135). 
A small case-control study (over 50% African American) reported a positive 
association (OR= 2.87; 95 percent CI: 1.16, 7.06) with breast cancer among women with 
at least one 19 CA repeat allele relative to women with no 19 CA repeat alleles.  In 
addition, they reported that plasma levels of IGF-I synergistically modified this 
association (136).  The Long Island Breast Cancer Study reported a positive association 
with breast cancer (OR=3.31; 95% CI: 1.47, 7.48) among premenopausal women 
carrying at least one allele with less than 19 CA repeats relative to women with at least 
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one 19 CA repeat allele.  There was no independent association with the 19 CA repeat 
allele, although there was suggested modification by hormonal contraceptives and 
postmenopausal BMI (125).  Various IGF-I repeat genotype classifications were 
evaluated in a nested case-control study within the Nurses’ Health Study cohort, but none 
were clearly associated with breast cancer although weak, nonsignificant effect estimates 
were reported for some genotypes (132).  The Multiethnic Cohort Study also did not 
provide strong support for involvement of the IGF-I 19 CA repeat with breast cancer, 
even though nonsignificant, positive associations were reported for Latin American and 
African American women (127).  In addition, they evaluated 29 tagging SNPs as well as 
35 other SNPs to capture IGF-I variation, but found no evidence for involvement with 
breast cancer (137). 
The IGF-I CA repeat polymorphism was not associated with colorectal adenomas 
(135) or colorectal cancer, except for a possible interaction with another insulin-related 
gene that increased cancer risk (138).  However, an inverse association with colorectal 
cancer was reported for two copies of the 19 CA repeat allele versus all other genotypes 
among persons who engaged in high vigorous activity (139).  A Chinese nested case 
control study that assessed the CA repeat polymorphism and an IGF-I SNP (-533 T/C) 
also located in the promoter, reported an inverse association between colorectal cancer 
among persons having two copies of the 21 CA repeat alleles versus other genotypes.  In 
addition, having at least one copy of the variant allele (C) at the -533 C/T SNP decreased 
the risk of colon cancer but not rectal cancer (140). 
IGFBP-3 is a highly conserved gene on chromosome 7p13-p12 with a length of 
approximately 9 kb and 5 exons.  The IGFBP-3 -202 A/C SNP (rs2854744) located 
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approximately 200 bp in front of the transcription site in the promoter has the most 
substantiated evidence for influence on circulating IGFBP-3.  Deal et al. (141) noted that 
the -202 A/C SNP was the most prevalent of the five IGFBP-3 SNPs examined in 
Physicians’ Health Study participants, and that it was strongly correlated with plasma 
IGFBP-3.  Six studies reported higher circulating IGFBP-3 among women with two 
copies of the A allele compared with women who had no A alleles and intermediate 
levels among -202 A/C heterozygotes (99, 131, 142-145).  Three studies found no 
association between the  -202 A/C SNP and colorectal cancer (138-140).  The 
Multiethnic Cohort Study examined the -202 A/C SNP and a nonsynonymous SNP 
(G2133C, rs2854746) in relation to circulating IGFBP-3 and found that only G2133C 
retained an association after accounting for both SNPs in the model; therefore, G2133C 
was evaluated with colorectal cancer using a dominant model in which having at least 
one variant allele resulted in increased (OR=1.32; 95% CI: 1.07, 1.62) colorectal cancer 
risk (145). 
The Nurses’ Health Study did not detect an association between the -202 A/C SNP 
and breast cancer despite reporting that -202 A/C influenced circulating IGFBP-3 (142), 
and a German case-control study also reported no association of the IGFBP-3 -336 A/C 
SNP with breast cancer (146).  A Chinese population-based case-control study (143) 
evaluated five IGFBP-3 SNPs including -202 A/C (variant allele = C among Chinese) 
and estimated haplotypes in relation to breast cancer, and they reported a positive 
association (OR=2.3; 95% CI:1.3, 3.9) with the haplotype including five variant alleles 
compared to the wildtype haplotype (143) among women under 45 years of age.  
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A case-control study nested within the European Prospective Investigation into 
Cancer and Nutrition measured five IGF-I SNPs and eight IGFBP-3 SNPs in relation to 
breast cancer (144).  The homozygous variant genotype (GG) of the IGF-I intron 1 
(rs2162679) SNP was inversely associated with breast cancer risk but was not associated 
with circulating IGF-I relative to women with the homozygous wildtype genotype.  For 
the IGFBP-3 SNPs, -202 A/C (rs2854744) and three other SNPs in the same haplotype 
block were associated with circulating IGFBP-3.  The -202 A/C homozygous genotype 
(AA) was associated with the highest IGFBP-3 levels; however, there was no consistent 
evidence for a relation between any of the IGFBP-3 SNPs and breast cancer (144).   
A recent British population-based case-control study of breast cancer analyzed nine 
IGF-I SNPs and four IGFBP-3 SNPs in association with circulating IGFs and breast 
cancer (147). Al-Zahrani et al. also based their conclusions regarding associations 
between IGF SNPs and their blood levels on the analysis of a middle-aged British cohort 
of men and women conducted immediately prior to the case-control study.  Five IGF-I 
SNPs were associated with circulating IGF-I, and four of these SNPs, along with another 
IGF-I SNP, were associated with breast cancer.  After simultaneously accounting for the 
effects of all of the IGF-I SNPs, there was only one SNP (rs1520220) associated with 
circulating IGF-I and with breast cancer (OR=1.41; 95% CI: 1.11, 1.79) when comparing 
the homozygous variant genotype (CC) to the homozygous wildtype genotype (GG).  
Specifically, the rs1520220 homozygous variant genotype (CC) was associated with the 
highest circulating IGF-I levels, followed by the heterozygous genotype (CG).  Three of 
the four IGFBP-3 SNPs evaluated were associated with circulating IGFBP-3, and two of 
these SNPs were associated with breast cancer.  The -202 A/C SNP had the highest minor 
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allele frequency (MAF) of the four SNPs and was positively associated with circulating 
IGFBP-3 levels such that levels among those with the homozygous variant genotype 
(AA) were 19% higher than mean IGFBP-3 levels among participants without a copy of 
the A allele (heterozygous genotype: 9% relative increase in IGFBP-3 levels).  Also, a 
weak protective association (OR=0.87; 95% CI: 0.77, 0.99) was estimated with breast 
cancer for the AA genotype relative to the homozygous wildtype genotype (CC) (147).  
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 CHAPTER II 
STATEMENT OF SPECIFIC AIMS 
 
Study questions 
The purpose of this dissertation is to examine whether variation in two genes, IGF-I 
and IGFBP-3, as studied by specific SNPs and estimated diplotypes (paired haplotypes) 
is associated with: 1) circulating IGF-I and IGFBP-3 levels and 2) prevalence of uterine 
leiomyomata (fibroids).  Because of biological interrelations between IGF-I and IGFBP-
3, variants in each gene (IGF-I and IGFBP-3) were evaluated in association with 
circulating levels of both proteins.  We hypothesized that IGF-I and IGFBP-3 variants 
would be associated with prevalence of fibroids based on evidence of IGF-I involvement 
with fibroid pathogenesis from gene expression studies.  Specifically, we conducted two 
separate analyses to evaluated relations with prevalence of fibroids defined by 1) any size 
and 2) at least 2 cm in diameter), which the latter may be more clinically relevant.  We 
hypothesized that IGF-I, which acts as a potent mitogen that is structurally similar to 
insulin, would promote fibroid growth rather than their incidence.  Therefore, IGF-I and 
IGFBP-3 variant associations would be stronger with prevalence of larger fibroids rather 
than with fibroids of any size.  Given that there are substantial allele frequency 
differences by race, analyses of IGF-I and IGFBP-3 variants will be performed separately 
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within African Americans and Caucasians.  The results of this study could help identify 
factors that contribute to the racial disparity in the prevalence and size of these 
hormonally-dependent benign tumors.   
 
Primary aims 
1) To describe the prevalence of SNPs and estimated diplotypes for IGF-I and IGFBP-3 
among African Americans and Caucasians.   
2) To estimate associations between IGF-I and IGFBP-3 gene variants (diplotypes and 
individual polymorphisms) and plasma IGF-I and IGFBP-3 levels among African 
Americans and Caucasian women. 
3) To estimate association in genetic polymorphisms and estimated diplotypes for IGF-I 
and IGFBP-3 in relation to the prevalence of uterine fibroids (any size and 2+ cm in 
diameter) among African American and Caucasian women.  
  
CHAPTER III 
METHODS 
 
Study population 
From 1996 to 1999, a random sample of 2,384 George Washington University health 
plan members who were 35 to 49 years of age was contacted for potential enrollment into 
the NIEHS Uterine Fibroid Study (1-3).  The study was approved by Institutional Review 
Boards at NIEHS and George Washington University.  Approximately 50% of the health 
plan population was thought to be African American.  Of the approximately 30,000 
health plan members, most were enrolled through their employers, except for about 1,000 
Medicaid patients.   The parent Uterine Fibroid Study was conducted to ascertain the 
prevalence of uterine fibroids within premenopausal women and to estimate the age-
specific incidence.  A second aim was to investigate the etiologic factors for fibroids, 
including genetic variants that could increase the likelihood of their development.  
Because these benign tumors can develop and continue to grow until menopause, the 
parent study population was restricted to a narrow age range including the late 
premenopausal years, in order to approximate the lifetime risk of developing uterine 
fibroids (1).   
Almost 90% of the random sample (2,102 women) was contacted by telephone and 
consented to eligibility screening for the parent study.  The study criteria were satisfied 
by 1,786 women.  Approximately 70% of excluded women were ineligible because they 
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no longer attended the Washington DC clinic where fibroid screening would be 
performed.  Others were deemed ineligible because they were misidentified as female, 
had no further access to a telephone, were not within the required age range, or did not 
speak English.  Approximately 20% of eligible women refused participation in the study, 
resulting in 1,430 participants (2).   
The prevalence of uterine fibroids and the distribution of IGF gene variants differ 
between racial groups; therefore, to facilitate race-specific analyses, we restricted the 
current study population to African American and Caucasian women.  We also excluded 
postmenopausal women from the current investigation because they did not have the 
clinic visit to draw blood and screen for fibroids since these tumors can regress following 
menopause.  Race and menopausal status criteria were met by 1,146 women from the 
parent study.  Based on availability of DNA samples for genotyping, we further limited 
the study population to 984 women (582 African Americans and 402 Caucasians).  The 
study consent form specified use of specimens for genetic polymorphism analyses. 
 
Preliminary data 
The distribution of study characteristics stratified by race is displayed in Table 3.1.  
The prevalence of fibroids was 72% among African Americans and 50% among 
Caucasians.  A greater proportion of African Americans (24%) had large fibroids (≥4 cm) 
in comparison to Caucasians (11%).  African Americans (11%) were more likely than 
Caucasians (4%) to experience menarche at less than 11 years of age.  The majority of 
women did not have births after 24 years of age (51% of African Americans, 63% of 
Caucasians).  African Americans (60%) reported a greater use of oral contraceptives 
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during teenage years than Caucasians (33%), but few women in either group were taking 
oral contraceptives when they entered the parent study.  There were more African 
Americans classified as overweight or obese than Caucasians, and there were fewer 
African Americans with high levels of physical activity than Caucasians.  In addition, a 
greater proportion of African Americans (30%) reported current smoking than 
Caucasians (8%).  However, fewer African Americans (42%) consumed alcohol on a 
regular basis (at least 0.5 drinks per week in the past year) compared to Caucasians 
(78%).  
 
Data collection 
Uterine fibroids 
Since women can have asymptomatic fibroids, a primary goal of the NIEHS Uterine 
Fibroid Study was to provide a better estimate of fibroid prevalence among 
premenopausal women than previous studies based on clinical diagnosis or treatment by 
hysterectomy alone.  Therefore, transabdominal and transvaginal ultrasound 
examinations were performed to screen for fibroids.  Ultrasound examinations were 
considered the gold standard for measurement of uterine fibroids (4) since very high 
sensitivity (0.99) and specificity (0.91) have been reported in comparison to pathologic 
verification in hysterectomy specimens (5).  Criteria used for ultrasound identification of 
fibroids in this study were based on Muram, et al. (6) with modifications to reflect 
technological changes that have decreased the limits of detection (7), so that tumors of 
0.5 cm diameter can be detected.  
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Both transabdominal and transvaginal ultrasounds were performed at a clinic visit 
that occurred within three months of study entry.  Trained sonographers endorsed by the 
American Registry of Diagnostic Medical Sonographers performed these examinations 
under the supervision of a radiologist who verified their assessments (1).  
Transabdominal ultrasounds for evaluating the superior portion of the uterus were 
performed using 3.5 to 5.0 MHz probes, and transvaginal examinations were conducted 
using 5.0 to 7.0 MHz probes (1) with ATL HDI 9 (ATL, Bothell, WA), Acuson 128 XP 
(Siemens, Issaquah, WA), or Diasonics DRF 400 (GE, Milwaukee, WI) ultrasound 
systems.  Information collected by sonographers included the size and location of the two 
largest fibroids and the number of tumors within the uterus (1).   
Study sonograms were not performed for women who had a recent ultrasound at the 
clinic that conducted study sonograms.  Instead, medical records were abstracted to 
obtain fibroid information for these women, which represent approximately 20% (N = 
204) of the current study sample (African American and Caucasian premenopausal 
women with extracted DNA from blood samples).  In addition, 19 women in our study 
sample were classified with regard to the size and presence of fibroids based on self-
report of previous diagnoses only.  Fibroid status was not assessed in seven African 
Americans and eight Caucasians in our study sample; however, these women were 
genotyped and included in current study for analyses with circulating IGF-I and IGFBP-3 
levels. 
Sample collection and assays 
Approximately 50 cc of blood were obtained from the premenopausal women in the 
parent study who attended the clinic visit.  Blood samples were collected through 
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venipuncture after an 8-hour fast and processed for plasma.  Plasma aliquots were stored 
at -80°C until analysis. 
Plasma was analyzed for IGF-I and IGFBP-3 as nanograms per milliliter (ng/mL) at 
NIEHS.  Quality control for both IGF-I and IGFBP-3 measurements was performed by 
verifying that standard curve parameters and controls were reproduced for each assay.   
IGF-I was measured by radioimmunoassay using a kit with instructions from Nichols 
Institute Diagnostics (San Juan Capistrano, CA).  The first step involves extraction of 
IGF-I from binding proteins through octadecasilyl-silica cartridges (C18 Sep-Pak, Waters 
& Associates, Milford, MA).  Prior to extraction, approximately 200 µL of EDTA plasma 
is divided into 4 tubes of 50 µL of EDTA plasma, and then each tube is acidified with 
950 µL of 0.5 N HCL.  The C18 Sep-Pak column is pretreated with 5 mL isopropyl 
alcohol followed by 5 mL methanol and 10 mL 4% glacial acetic acid/HPLC H20.  The 
acidified EDTA plasma is then loaded onto the prewashed column, and it is sequentially 
washed with 10 mL 4% glacial acetic acid/HPLC H20 and 2 mL methanol to extract IGF-
I.  The extracted IGF-I samples are dried in nitrogen gas within a 37°C H20 bath, and the 
radioimmunoassay is then performed.  This extraction technique is very reproducible and 
is rapidly completed.   
For the radioimmunoassay, standards for IGF-I range from 0.3 to 4.8 ng/mL, and two 
human EDTA plasma controls with specified IGF-I concentrations were provided by the 
manufacturer for validation.  IGF-I labeled with 
125
I and antiserum for IGF-I from rabbits 
were used for detection in the assays.  Cross-reactivity of antiserum to IGF-I with IGF-II 
has been reported to be <0.5%.  Intra-assay and inter-assay variances for this procedure 
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are 2.3% and 11.4% respectively using samples averaging approximately 1 ng/mL of 
IGF-I.  The reported detection limit of this technique is 0.06 ng/mL.    
 IGFBP-3 was measured by immunoradiometric assay using a kit with instructions 
from Diagnostic Systems Laboratories, Inc. (Webster, TX).  Prior to the assay, a 1:100 
dilution of 10 µL EDTA plasma with a 1 mL 0 ng/mL IGFBP-3 standard consisting of 
bovine serum albumin (BSA) buffer with sodium azide is performed.  IGFBP-3 standards 
ranging from 2.0 to 100.0 ng/mL (in BSA buffer) and controls consisting of 
manufacturer-specified IGFBP-3 concentrations (in BSA buffer preserved with sodium 
azide) were used for validation of the immunoradiometric assay.  The kit contains tubes 
with immobilized antiserum for IGFBP-3 polyclonal immunoglobulin from goats to bind 
IGFBP-3.  Goat antiserum to IGFBP-3 polyclonal immunoglobulin in BSA buffer with 
sodium azide labeled with 
125
I was used to detect IGFBP-3 on the inside walls of the 
tubes.  The IGFBP-3 intra-assay and inter-assay variances ranged from 1.8 to 3.9% and 
0.6 to 1.9% respectively, with a reported detection limit of 0.05 ng/mL.  Less than 3 
ng/mL of IGFBP-3 was reported using other IGF binding proteins as standards.   
Whole blood samples were sent to BioServe Biotechnologies (Laurel, MD) for 
extraction of genomic DNA.  Initially, a phenol:chloroform procedure was utilized for 
DNA extraction.  However, a more efficient and safe modified salt precipitation kit 
(GenQuik Protocol) was adopted when it became available, and was used for the majority 
of samples.   
Genetic polymorphisms 
 
We selected single nucleotide polymorphisms (SNPs) in IGF-I and IGFBP-3 for 
evaluation based on previous research, functional significance, or haplotype-tagging 
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properties (Tables 3.2-3.3; Figures 3.1-3.2).  Because there are substantial differences in 
allele frequencies and in the pattern of linkage disequilibrium among populations, 
haplotype-tagging SNPs were selected separately for African Americans and Caucasians 
according to Genome Variation Server (GVS) software sponsored by the Seattle SNPs 
Program for Genomic Applications (PGA) (8).   We selected the Seattle SNPs database, 
which sequences genes to search for SNPs, as the reference population for IGF-I; 
however, we used the HapMap population for IGFBP-3 because it has not been evaluated 
by Seattle SNPs (8). We expanded coverage for selection of haplotype-tagging SNPs to 
include those within 5 kilobases (kb) of the 5’ and 3’ ends of each gene, and we used a 
value of 0.8 for the pairwise correlation coefficient (r
2
) for identifying haplotype-tagging 
SNPs.  Only haplotype-tagging SNPs with greater than 5% minor allele frequency (MAF) 
among African American or Caucasian reference populations were chosen for 
genotyping.  According to the GVS software, there were 29 haplotype-tagging SNPs for 
IGF-I and 12 haplotype-tagging SNPs for IGFBP-3.  In addition, we selected four SNPs 
a priori based on functional significance, including one nonsynonymous IGF-I SNP 
(rs17884626), one synonymous IGF-I SNP (rs3729846), and two nonsynonymous 
IGFBP-3 SNPs (rs2854746, rs9282734) and an IGFBP-3 promoter SNP (-202 A/C, 
rs2854744) a priori based on previous studies of associations with circulating IGF-I and 
IGFBP-3 levels and health outcomes (9-16). 
Genotyping of SNPs was performed using the TaqMan genotyping approach under 
the supervision of Dr. Jason Luo, Director of the Mammalian Genotyping Core at the 
Lineberger Comprehensive Cancer Center (Chapel Hill, NC).  The TaqMan genotyping 
procedure is advantageous because it is highly accurate, rapid and reliable, and utilizes 
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only small amounts of DNA (17-19).  This method can only measure one SNP at a time 
and may not be as cost-effective as high-throughput methods when genotyping large 
numbers of SNPs (19, 20); however, the number of selected SNPs in our study is small 
enough to make TaqMan genotyping a cost-efficient method.  Specifically, the TaqMan 
procedure utilizes two allele-specific olignonucleotide probes that match the two possible 
alleles of a SNP. Each probe includes a distinct fluorescent reporter dye on its 5’ end and 
a nonfluorescent quencher on its 3’ end that suppresses the reporter dye signal in the 
absence of amplification.  During the polymerase chain reaction (PCR), the allele-
specific probe that corresponds to the target sequence will be disintegrated by Taq DNA 
polymerase, and the fluorescent signal from the reporter dye will strengthen with each 
cycle of DNA amplification due to the absence of the quencher.  In contrast, the 
mismatched allele-specific probe will be dislodged by DNA polymerase without being 
cleaved so that its fluorescent signal remains suppressed by the quencher (18, 19).  
Allele-specific oligonucleotide probes for 39 selected SNPs were purchased from 
Applied Biosystems (ABI; Foster City, CA) “TaqMan® Validated and Coding SNP or 
Pre-Designed SNP Genotyping Assays” (previously known as Assays-On Demand, 
AOD), and ABI attempted to develop custom assays for the 6 remaining SNPs through 
their “Custom TaqMan® SNP Genotyping Assays” service (previously known as Assays-
By-Design, ABD).  Two IGF-I haplotype tagging SNPs were excluded from analyses, 
including one for which a custom assay could not be developed, and one with a pre-
designed assay that did not meet ABI technical specifications.   
We evaluated whether the race-specific distributions of SNP genotypes in our study 
population were consistent with Hardy-Weinberg equilibrium (HWE) based on the exact 
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test statistic with one degree of freedom (21) estimated in Haploview software (22).  We 
genotyped an alternate IGF-I haplotype-tagging SNP (rs9308315) to substitute for a SNP 
(rs4764883), that seemed inconsistent with HWE among African Americans in our study 
population.  Therefore, we genotyped 30 IGF-I and 15 IGFBP-3 SNPs in total, including 
40 haplotype-tagging SNPs and 5 SNPs selected a priori.  Tables 3.4 and 3.5 list the p 
values from exact tests evaluating HWE and the observed genotype frequencies for IGF-I 
and IGFBP-3 SNPs respectively.      
PCR amplification was performed on an ABI GeneAmp® PCR System 9700 thermal 
cycler with dual 384-well-blocks, and then endpoint plates were read using the ABI 
7900HT system.  VIC and 6-FAM reporter dyes were used as the fluorescent signals to 
distinguish wild type and variant alleles.  Alleles were called automatically through 
Sequence Detection System (SDS) 2.3 software, and output was reviewed by experienced 
operators.  DNA concentration of samples from 984 women was validated using a 
NanoDrop® ND-1000 Spectrophotometer prior to diluting them to a concentration of 5 
ng/ul (using DNA grade sterile water).  All of the samples were placed in eleven 96-well 
microtiter plates and then were aliquoted into three 384-well PCR plates for analysis.  
Each of the 11 microtiter plates contained four randomly assigned controls represented by 
two blank samples and two samples consisting of a known DNA standard (Control DNA 
CEPH Individual 1347-02, ABI).  Quality control measures also included blinded 
genotyping of 28 duplicate samples representing 22 women, which produced concordant 
results for all samples.  The overall call rate was 98.8%, and only 5 women had less than 
50% of complete allele calls for the 45 SNPs assayed. 
  
 45
Covariates 
Data on potential covariates were obtained through telephone interview, self-
administered mail questionnaires, or the initial clinic visit.  Age was calculated according 
to date of study entry using birth date information provided at telephone interview.  The 
following age categories were created for analyses: 35 to 39, 40 to 44, and ≥45 years.  
Highest level of education was assessed from categorized responses in self-administered 
mail questionnaires.  
Complete reproductive history including detailed information related to pregnancies, 
menstrual cycles, and contraceptive use was provided at telephone interview.   Previous 
research from the parent study identified an inverse association between number of births 
and prevalence of fibroids, specifically for births occurring after age 24.  The 
hypothesized mechanism was apoptosis of early lesions during postpartum remodeling of 
the uterus (23).    The number of births after age 24 was classified into the following 
categories: 0, 1, 2, and ≥3 births.  Oral contraceptive use was assessed at study entry and 
during teenage years based on two studies that found positive associations between early 
initiation of oral contraceptive use and fibroids (24, 25). 
Current body mass index (BMI) in kg/m
2
 was calculated from self-reported height at 
telephone interview and weight at clinic visit.  BMI was categorized as normal (<25), 
overweight (25 to <30), and obese (≥30).   
Information on current physical activity was obtained at the telephone interview 
through separate questions on the duration of vigorous and moderate recreational 
activities.  In addition, women reported the time spent walking and performing household 
chores.  Responses to all of these questions were used to classify overall physical activity 
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into an index calculated at equivalent to hours of vigorous physical activity.  Current 
physical activity index was categorized according to its overall distribution. 
Smoking status was categorized as nonsmoker, former smoker, and current smoker 
based on information given in the telephone interview.  Women were considered 
nonsmokers if they responded “no” when asked if they ever smoked an average of at least 
one cigarette a day for six months or more.  The remaining women were classified as 
either former smokers, if they did not currently smoke at least one cigarette per day, or as 
current smokers. 
Racial classification was based on self-report from mail questionnaires having the 
following categories: White, not Hispanic; White, Hispanic; Black, not Hispanic; Black, 
Hispanic; Asian/Pacific Islander; American Indian/Eskimo/Aleut; and Other.  Women 
who reported “Other” were given the option of describing their race-ethnicity.  Because 
race represents an important variable in all potential analyses of factors related to 
fibroids, additional efforts were made to obtain racial information from women who did 
not return mail questionnaires (N=65, 6.6% of the study sample for the current 
investigation), including follow-up telephone calls and medical records abstraction (only 
if calls could not be completed).  Women were categorized as African American if they 
indicated their race as “black” regardless of whether they also reported other race-
ethnicity groups.  They were considered Caucasian if they specified their race as “white” 
and did not also record their race as “black”.  Women who were not classified as either 
African American or Caucasian will be excluded from the present investigation. 
Alcohol intake was estimated from two self-administered questionnaires.  The first 
questionnaire inquired about usual intake within the past 12 months and at 30 years of 
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age, without regard to the type of alcohol consumed.  Specifically, women selected the 
most appropriate categories for how often and how many alcohol drinks they typically 
consumed.  The second source of data was from a modified Block food frequency 
questionnaire (FFQ) (26, 27) that assessed alcohol intake during the past 12 months.  
Women chose their usual serving size and the collective category reflecting the typical 
number of drinks and frequency for beer, wine, and liquor separately.  We computed the 
drinks per week from each questionnaire by multiplying the midpoints of the frequency 
and amount categories for the two time points (current and 30 years of age) from the first 
questionnaire and the serving size and combined frequency and amount category from the 
FFQ.  There was a strong correlation (Spearman rank correlation coefficient = 0.90) 
between the two reporting sources for estimated drinks per week within the past year. 
Because of concerns with underreporting of alcohol intake (28), we used the maximum 
value of self-reported drinks per week within the past twelve months to reflect current 
intake.  Women were classified as current drinkers (≥0.5 drinks per week) or nondrinkers 
(<0.5 drinks per week) based on previous analyses of parent study data that supported a 
threshold effect of alcohol intake in which even low levels of consumption are associated 
with an increased prevalence of fibroids (29). 
 
Analytical Approach 
Diplotype estimation 
We estimated race-specific diplotypes for groups of related SNPs within each gene, 
as described below.  We excluded one SNP (rs4764883), which appeared inconsistent 
with HWE among African Americans, from African American diplotype analyses since 
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including SNPs with a deviation from HWE can reduce reliability of diplotype 
estimation.  In addition, SNPs were excluded from race-specific diplotype analyses if 
their MAF in our study population was below 5% for haplotype-tagging SNPs or below 
3% for a priori SNPs within the racial group being evaluated.  Women missing genotype 
data for more than 50% of the SNPs included in diplotype analyses within a gene were 
excluded from diplotype estimation for that gene (1 Caucasian and 3 African Americans 
for IGFBP-3 analyses, 3 Caucasians and 2 African Americans for IGF-I analyses).  To 
determine which SNPs in each gene could be combined for diplotype estimation, we 
examined race-specific linkage disequilibrium (LD) patterns using Haploview software 
(22).  We identified LD blocks consisting of individual SNPs (with MAF at least 5%) in 
strong LD based on the Gabriel, et al. definition (95% of pairwise SNP comparisons with 
one-sided 95% confidence intervals for the D prime statistic within 0.7 to 0.98) (30).  We 
also used the Tagger approach (31) in Haploview to identify pairs of redundant SNPs in 
strong LD (pairwise r
2
 values of at least 0.8), and excluded one member of each 
redundant pair from diplotype estimation unless both SNPs were selected a priori.  Race-
specific pairwise r
2
 values are available for IGFBP-3 and IGF-I SNPs in Tables A.1-A.4. 
Race-specific diplotypes representing defined groups of SNPs within each gene were 
estimated using PHASE version 2.1, a software program that employs a Bayesian method 
to determine the phase of ambiguous haplotypes (32, 33).  Specifically, this approach 
involves a Markov chain-Monte Carlo (MCMC) algorithm to allocate the most likely 
diplotype for each person, with the prior assumption that frequently observed haplotypes 
with less ambiguity due to homozygotes are more probable for assignment.  This 
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software program also provides an estimate of the posterior probability, which expresses 
the uncertainty associated with each diplotype assignment.   
Analytic methods to account for diplotype uncertainty in models of gene-disease 
associations have been debated in the literature, but they have focused primarily on case-
control studies (34, 35).  One of these methods assigns individuals to their most probable 
diplotype while eliminating persons with posterior probabilities under a pre-specified 
value.  However, this approach can bias effect estimates towards the null if the criterion 
is set too low (i.e. posterior probability of 70%) or inflate variance estimates when the 
criterion is set too high (i.e. posterior probability of 90%) due to the increased number of 
excluded observations (34).  Excluding persons with posterior probabilities less than 90% 
also may bias estimates due to the systematic removal of observations with a sizeable 
number of heterozygous genotypes (34).  We considered more complex methods to 
account for diplotype uncertainty in our study, but there were still potential issues with 
bias and estimating appropriate variances.  In addition, more complex methods often 
imposed analysis restrictions such as types of estimates for evaluating diplotype 
associations with outcomes.   
We chose to assign the women in our study population to their most probable 
diplotype since this method offered the most flexibility with our analyses.  We eliminated 
women with uncertain diplotypes using a high criterion for the posterior probability 
(90%) to lessen misclassification bias with assigned diplotypes.  To reduce the number of 
women excluded from diplotype analyses, we examined LD patterns as previously 
described using Haploview software (22) to determine which combinations of SNPs 
would estimate diplotypes with a high degree of certainty (posterior probability ≥ 90%) 
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for the greatest proportion of our study population.  Specifically, we created race-specific 
diplotype groups by combining individual SNPs that were not included in a block with an 
adjacent block, and combining adjacent blocks with each other, when doing so resulted in 
estimated diplotypes with at least 90% certainty (posterior probability) for at least 90% of 
observations.  Otherwise, diplotype groups represented individual SNPs not included in a 
block, or SNPs within a single block only.  We assigned women to their most probable 
diplotype for each group, or we classified them as missing for the diplotype group if their 
most probable diplotype had a posterior probability below 90%.   
Overview of analyses and confounding 
All statistical analyses were stratified by race and conducted using SAS V9.1 (SAS 
Institute Inc., Cary, NC).  We evaluated IGF-I and IGFBP-3 variants (individual SNPs 
and estimated diplotypes) as the exposures of interest in association with: 1) circulating 
IGF-I and IGFBP levels and 2) prevalence of fibroids (any size and at least 2 cm in 
diameter). 
A priori investigation of potential confounders using a directed acyclic graph (DAG) 
found that race was the only confounder for the association between IGF-I and IGFBP-3 
variants and their circulating protein levels and for the association between IGF-I and 
IGFBP-3 variants and fibroids (Figure 3.3).  Rather than adjusting for race, we stratified 
all analyses by race (African American or Caucasian) and reported race-specific 
estimates.  Population stratification could still bias our race-specific estimates if outcome 
distribution (plasma levels or fibroid prevalences) and genotype frequencies differ among 
ethnic subgroups within the African American or Caucasian populations in our study.  
There is stronger potential for admixture within African Americans based on their 
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extensive genetic heterogeneity compared to Caucasians and findings from the literature 
(36-38).  However, a breast cancer study applied the approach provided by the 
Wacholder, et al. evaluation of Caucasians (38) and found that ignoring race in analyses 
did not bias results in a population well represented by both African Americans and 
Caucasians (39).  The findings of two recent simulation studies, including one that used 
African American data, suggest that population stratification results in negligible bias 
when there is substantial ethnic heterogeneity within racial groups, but that bias could 
increase when the number of ethnic subpopulations is small (36, 40).  Although we do 
not have additional information on the ethnic background of Caucasians and African 
Americans in our study population, we expect that conducting separate analyses by race 
may be sufficient to limit bias from population stratification in our study. 
Paper 1 analyses 
We evaluated whether IGF-I and IGFBP-3 variants were associated with IGF-I and 
IGFBP-3 plasma levels using the race-specific ordinary linear regression models for gene 
variants.  Because of biological interrelations between IGF-I and IGFBP-3 plasma, 
variants in each gene were analyzed for associations with circulating levels of both 
proteins.   
For the analysis of individual SNPs, we first considered a codominant (general) 
model of inheritance in which heterozygous and homozygous variant genotypes were 
separately evaluated relative to the wildtype genotype.  Codominant models make the 
fewest assumptions with regard to the inheritance pattern but were not feasible for less 
common variants.  Therefore, when there were 10 or fewer women with the homozygous 
variant genotype, we assumed a dominant model that compared a single index category, 
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including homozygous variant and heterozygous genotypes, to the homozygous wildtype 
genotype.  We compared race-specific associations with IGF-I or IGFBP-3 levels for 
individual SNPs with similar models of inheritance for both racial groups.  Specifically, 
we combined data from both racial groups and estimated racial differences in mean 
plasma levels (i.e., differences of mean differences) associated with variant vs. referent 
genotypes.  We fit linear regression models that included multiplicative gene by race 
interaction terms along with separate parameters for race and genotypes.  When there 
were differences by race in homozygous wildtype (referent) genotypes for SNPs, we used 
the referent genotype for Caucasians in regression models including both racial groups.   
To estimate diplotype associations with IGF-I or IGFBP-3 plasma levels, we used 
separate race-specific models for each diplotype group, with the most frequent diplotype 
as the reference category.  Imprecision and bias (away from the null) with regression 
estimates were especially problematic for associations with diplotypes based on few 
observations.  We did not estimate associations with individual rare diplotypes (assigned 
to 5 or fewer women), but instead combined them into one “rare diplotype” category for 
each group.  However, due to the heterogeneity of the “rare diplotype” category, we were 
not able to interpret associations with this category.  Despite the creation of “rare 
diplotype” categories, some of the diplotype groups had multiple diplotype categories 
that were not considered rare but were based on small numbers of observations.   
  We used a shrinkage (empirical-Bayes) method of information-weighted averaging 
(41) to improve the validity and precision of diplotype regression estimates.  Specifically, 
we assumed a prior mean of 0, since we did not have prior information to group 
diplotypes according to the anticipated direction or strength of potential associations with 
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plasma levels, and specified a prior variance corresponding to +/- one standard deviation  
(2*standard deviation /3.92)
2
 of the mean plasma level of IGF-I (prior variances: African 
Americans, 1,419; Caucasians, 901) and IGFBP-3 (prior variances: African Americans, 
186,819; Caucasians, 174,161) in the study population.  We applied the shrinkage 
estimator for each diplotype and reported posterior medians (50
th
 percentile of the 
posterior probability distribution) and 95% posterior limits (2.5
th
 and 97.5
th
 percentiles of 
the posterior probability distribution).  With this method, imprecise regression estimates 
based on fewer observations were shifted further toward the prior mean than more precise 
regression estimates.  Despite the increase in bias (toward the prior mean) with posterior 
medians, the reduction in the overall mean square error based on a greater reduction in 
variance of estimates is an advantage with this approach (42).   
Paper 2 analyses 
We estimated race-specific prevalence differences (PDs) to evaluate associations 
between IGF-I and IGFBP-3 gene variants and prevalent fibroids.  We performed two 
separate analyses to 1) estimate associations with gene variants and prevalence of any 
uterine fibroids versus no uterine fibroids, and 2) estimate associations with prevalence of 
fibroids at least 2 cm in diameter versus a combined category including no fibroids and 
fibroids < 2cm.  We used the latter analysis, which excludes women with smaller tumors 
from the fibroid definition, to explore the hypothesis that IGF-I stimulates fibroid growth 
rather than incidence.  We estimated 95% confidence intervals for crude prevalence 
differences (PD) using SAS V9.1, which calculates standard errors from the square root 
of the sum of the fibroid prevalence variances based on formula for independent 
proportions.   
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For the analysis of individual SNPs, we first considered a codominant (general) 
model of inheritance in which heterozygous and homozygous variant genotypes were 
separately evaluated relative to the homozygous wildtype genotype.  However, 
codominant models were feasible only for common variants.  Therefore, for less common 
variants, we used a dominant model in which homozygous variant and heterozygous 
genotypes were combined and compared to those with the homozygous wildtype 
genotype.  When there were 5 or fewer women in a racial group with heterozygous and 
homozygous variant genotypes combined, we did not estimate associations with 
individual SNPs since validity of estimates would be questionable. 
We estimated associations between IGF-I or IGFBP-3 diplotypes and fibroids using 
separate race-specific models for each diplotype group, with the most common diplotype 
as the reference category.  Due to convergence issues with binomial regression models, 
we used Poisson regression with the robust variance option in PROC GENMOD to 
estimate prevalence differences with 95% confidence intervals (43).  Diplotypes assigned 
to 5 or fewer women were combined into a “rare diplotype” category; however, because 
of the heterogeneity of diplotypes within these categories, their estimated associations 
with fibroids could not be interpreted.   
Imprecision and bias (away from the null) were a limitation for interpreting 
estimated associations with diplotypes based on smaller numbers of observations.  
Therefore, we used a shrinkage (empirical-Bayes) method of information-weighted 
averaging (41) to improve the validity and precision of regression estimates.  We 
assumed a prior mean of 0 since we did not have information to group diplotypes 
according to the direction or strength of their potential associations with fibroids.  We 
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specified a prior variance ((0.5/3.92)
2
 ≈ 0.016), which assumed with 95% probability that 
regression estimates would vary within a range of ± 0.25.  For each diplotype, we applied 
the shrinkage estimator and reported posterior medians (50
th
 percentile of the posterior 
probability distribution) and 95% posterior limits (2.5
th
 and 97.5
th
 percentiles of the 
posterior probability distribution).  Imprecise estimates based on few observations were 
shrunk further toward the prior mean than more precise regression estimates.   
Power calculations 
Table 3.6 depicts statistical power to estimate a range of statistically significant 
prevalence differences (α = .05) for dichotomous genotypes (SNPs) based on values 
generated by the PS program (44).  In this scenario, the genotype frequency reflects 
heterozygous and homozygous variant genotypes grouped together in order to maximize 
power.  Estimated values for baseline fibroid prevalence (any size) in calculations were 
based on known values in the study population of 73% and 51% among African 
Americans and Caucasians, respectively.   
  For heterozygous and homozygous variant genotypes with frequencies of at least 
20%, estimated power is over 80% for prevalence differences as low as 0.15 for African 
Americans and 0.20 for Caucasians.  There will be limited power to estimate weaker 
associations (i.e. PD of 0.10 or less) or fibroid relations with rare gene variants.  Power 
estimates were not calculated for diplotype analyses using information-weighted 
averaging (41), but this approach may enhance statistical power over conventional 
regression methods.   
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Table 3.1. Characteristics of premenopausal women with available DNA by race 
from NIEHS Uterine Fibroid Study  
 
Characteristic 
African American (N=582) 
N (%) 
Caucasian (N=402) 
N (%) 
Age (years)   
35-39 219 (37.63) 137 (34.08) 
40-44 205 (35.22) 135 (33.58) 
45+ 158 (27.15) 130 (32.34) 
Education   
High school 121 (20.8)* 12 (3.0) 
Some postsecondary 265 (45.5) 33 (8.2) 
College degree 123 (21.1) 133 (33.1) 
Graduate degree 68 (11.7) 217 (54.0) 
Missing 5 (0.9) 7 (1.7) 
Age at menarche (years)   
<11   65 (11.17) 16 (3.98) 
11 94 (16.15) 62 (15.42) 
12 159 (27.32) 111 (27.61) 
13 138 (23.71) 132 (32.84) 
14 55 (9.45) 44 (10.95) 
>14 68 (11.68) 35 (8.7) 
Missing 3 (0.52) 2 (0.5) 
Oral contraceptive use  
 
  
Current† 28 (4.8) 37 (9.2) 
Teenage years 350 (60.1) 131 (32.6) 
Births (25+ years of age)   
0 295 (50.69) 255 (63.4) 
1 181 (31.10) 57 (14.2) 
2 85 (14.60) 80 (19.9) 
3+ 21 (3.61) 10 (2.5) 
Body mass index    
Under- normal weight (<25) 147 (25.26) 236 (58.7) 
Overweight (25-<30) 178 (30.58) 95 (23.6) 
Obese (30+) 257 (44.16) 71 (17.7) 
Physical activity (index)‡   
0 to <2 223 (38.3) 114 (28.4) 
2 to 4 163 (28.0) 127 (31.6) 
>4 to <6 96 (16.5) 74 (18.4) 
6+ 97 (16.7) 86 (21.4) 
Missing 3 (0.5) 1 (0.25) 
Smoking status   
Current smoker 172 (29.6) 31 (7.7) 
Former smoker 133 (22.9) 139 (34.6) 
Never smoked 277 (47.6) 232 (57.7) 
Alcohol intake (past year)   
<0.5 drinks/week 300 (51.5) 60 (14.9) 
≥0.5 drinks/week   245 (42.1) 314 (78.1) 
Missing 37 (6.4) 28 (7.0) 
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Uterine fibroids   
None 154 (26.46) 194 (48.26) 
Any 421 (72.34) 200 (49.75) 
<2 cm 94 (16.15) 69 (17.16) 
2 - <4 cm 187 (32.13) 87 (21.64) 
≥4 cm 140 (24.05) 44 (10.95) 
Missing 7 (1.20) 8 (1.99) 
 Mean (SD) Mean (SD) 
Plasma IGF-I (ng/mL)† 165 (74.0) 172 (58.7) 
Plasma IGFBP-3 (ng/mL)† 4085 (859.7) 4524 (822.3) 
* Includes 11 women with less than high school education. 
† N missing: oral contraceptives: 4 African Americans, 3 Caucasians; plasma IGF-I and IGFBP-3:  
 8 African Americans, 1 Caucasian. 
‡ Calculated at equivalent to hours of vigorous physical activity. 
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Table 3.2. IGF-I single nucleotide polymorphisms (SNPs) selected for genotyping in the NIEHS Uterine Fibroid Study*  
 
Reference SNP ID Alternate Name Chromosome 
Position 
Location Alleles  Amino Acid 
Change 
TaqMan 
Assay 
rs35767  101399699 promoter A, G N/A Validated 
rs5742612  101398994 promoter A, G N/A Pre-designed 
rs5742614  101397367 intron 1 C, G N/A Pre-designed 
rs17032634†  101395474 intron 1 A, G N/A Pre-designed 
rs3729846 Thr52Thr 101393615 exon 2 C, T None Validated 
rs12821878  101391797 intron 2 A, G N/A Validated 
rs10860869  101389182 intron 2 A, T N/A Pre-designed 
rs1019731  101388555 intron 2 A, C N/A Validated 
rs7956547  101382946 intron 2 C, T N/A Pre-designed 
rs5742626  101382039 intron 2 C, T N/A Pre-designed 
rs17880975  101376814 intron 2 A, G N/A Custom 
rs2033178  101371206 intron 2 A, G N/A Pre-designed 
rs17884646  101369945 intron 2 C, T N/A Custom 
rs5742657  101358998 intron 2 A, G N/A Pre-designed 
rs5742663  101348120 intron 2 G, T N/A Pre-designed 
rs11829586  101344517 intron 2 A, G N/A Pre-designed 
rs4764884  101343729 intron 2 C, T N/A Pre-designed 
rs5742683  101337847 intron 2 A, G N/A Pre-designed 
rs17884626 Ala115Thr 101337476 exon 3 C, T Alanine to 
Threonine 
Validated 
rs5009837  101334399 intron 3 C, T N/A Pre-designed 
rs17727841  101333760 intron 3 C, G N/A Pre-designed 
rs4764883  101330435 intron 3 C, T N/A Pre-designed 
rs9308315  101328023 intron 3  N/A Pre-designed 
rs978458  101326369 intron 3 C, T N/A Validated 
rs12316064†  101324933 intron 3 C, T N/A Custom† 
rs5742692  101323728 intron 3 A, G N/A Pre-designed 
rs11111262  101322307 intron 3 A, G N/A Custom 
rs1520220  101320652 intron 3 C, G N/A Validated 
rs3730204  101319644 exon 4;            
3’ untranslated 
C, T N/A Custom 
rs6214  101317699 exon 4;            
3’ untranslated  
C, T N/A Validated 
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rs6219  101314322 exon 4;            
3’ untranslated  
C, T N/A Validated 
rs2946834  101311944 downstream of 
IGF-I 
A, G N/A Validated 
* Alleles represent DNA strand from TaqMan assays.  rs9308315 was genotyped as an alternate SNP to replace rs4764883, which appeared  
 inconsistent with Hardy Weinberg Equilibrium (α = 0.01) among African Americans. 
† SNPs dropped from analyses due to TaqMan assay failure with design. 
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Table 3.3. IGFBP-3 single nucleotide polymorphisms (SNPs) selected for genotyping in the NIEHS Uterine Fibroid Study* 
 
Reference SNP 
ID 
Alternate Name Chromosome 
Position 
Location Alleles Amino Acid 
Change 
TaqMan 
Assay 
rs903889  45931520 promoter G, T N/A Pre-designed 
rs924140  45929639 promoter C, T N/A Pre-designed 
rs2854744 -202 A/C 45927600 promoter G, T N/A Pre-designed 
rs2854746 G2133C 
(Ala32Gly) 
45927170 exon 1 C, G Alanine to 
Glycine 
Pre-designed 
rs2471551  45923580 intron 1 C, G N/A Pre-designed 
rs9282734 His158Pro 45923494 exon 2 A, C Histidine to 
Proline 
Custom 
rs2453837  45922575 intron 3 A, G N/A Pre-designed 
rs6953668  45922400 intron 3 A, G N/A Pre-designed 
rs3110697  45921554 intron 3 A, G N/A Pre-designed 
rs2453840†  45920337 intron 4 A, C N/A Custom 
rs2453839  45920098 intron 4 C, T N/A Pre-designed 
rs6670  45918779 exon 5;           
 3’ untranslated 
A, T N/A Pre-designed 
rs13223993  45917755 downstream of 
IGFBP-3 
A, G N/A Pre-designed 
rs2270628  45916095 downstream of 
IGFBP-3 
C, T N/A Pre-designed 
rs12671457  45913451 downstream of 
IGFBP-3 
A, C N/A Pre-designed 
* Alleles represent DNA strand from TaqMan assays, except alleles on opposite DNA strand shown for rs2854744 (-202 A/C). 
† Possible triallelic polymorphism but has not been confirmed by sequencing groups.  
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Table 3.4. Genotype distribution of IGF-I single nucleotide polymorphisms (SNPs) among premenopausal Caucasian and 
African American women in the NIEHS Uterine Fibroid Study  
 
Caucasians* African Americans* SNP 
Reference 
ID 
 MAF (%) Genotypes N 
HWE  
 p value† 
 MAF (%) Genotypes N 
HWE  
 p value†  
AA  10 AA  102 
AG 107 AG 266 
rs35767 16.0 
GG 280 
1.000 40.8 
GG 208 
0.322 
 
GG 1 GG 2 
AG 29 AG 34 
rs5742612 3.9 
AA 369 
0.909 3.3 
AA 543 
0.240 
 
CC 0 CC 8 
CG 14 CG 117 
rs5742614 1.8 
GG 386 
1.000 11.5 
GG 451 
1.000 
 
CT 0 CT 9 rs3729846 0 
CC 400 
-- 0.8 
CC 565 
1.000 
 
AA 21 AA 3 
AG 139 AG 61 
rs12821878 22.7 
GG 238 
0.986 5.8 
GG 513 
0.598 
 
TT 31 TT 61 
AT 170 AT 251 
rs10860869 29.1 
AA 197 
0.596 32.3 
AA 266 
0.931 
 
AA 5 AA 0 
AC  88 AC 39 
rs1019731 12.3 
CC 305 
0.858 3.4 
 
CC 536 
1.000 
 
CC 29 CC 44 
CT 160 CT 213 
rs7956547 27.3 
TT 210 
0.971 26.2 
TT 318 
0.363 
 
CC 0 CC 4 
CT 4 CT 75 
rs5742626 0.5 
TT 395 
1.000 7.2 
TT 498 
0.680 
 
AG 1 AG 26 rs17880975 0.1 
GG 396 
1.000 2.3 
GG 548 
1.000 
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AA  1 AA  4 
AG 47 AG 46 
rs2033178 6.2 
GG 349 
1.000 4.7 
GG 521 
0.062 
 
rs17884646 0 TT 398 -- 0 TT 578 -- 
GG 1 GG 10 
AG 16 AG 119 
rs5742657 2.2 
AA 384 
0.354 12.1 
AA 447 
0.625 
 
GG 0 GG 9 
GT 1 GT 115 
rs5742663 0.1 
TT 397 
1.000 11.6 
TT 451 
0.699 
 
AA 0 AA 10 
AG 18 AG 112 
rs11829586 2.3 
GG 381 
1.000 11.5 
GG 452 
0.411 
 
TT 25 TT 35 
CT 154 CT 202 
rs4764884 25.7 
CC 218 
0.880 
 
23.7 
CC 338 
0.570 
 
GG 0 GG 8 
AG 1 AG 106 
rs5742683 0.1 
AA 397 
1.000 10.6 
AA 461 
0.610 
 
CT 0 CT 11 rs17884626 0 
CC 400 
-- 1.0 
CC 567 
1.000 
 
TT 36 TT 107 
CT 168 CT 262 
rs5009837 30.3 
CC 192 
1.000 41.3 
CC 207 
0.155 
 
CC 15 CC 3 
CG 123 CG 48 
rs17727841 19.1 
GG 262 
0.997 4.7 
GG 526 
0.242 
 
CC 37 TT 135 
CT 168 CT 249 
rs4764883 30.9 
TT 186 
1.000 
 
45.8 
CC 183 
0.007‡ 
 
AA 28 TT 154 
AT 167 AT 262 
rs9308315 28.2 
TT 201 
0.490 
 
49.8 
AA 156 
0.052 
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TT 28 TT 85 
CT 165 CT 260 
rs978458 28.0 
CC 202 
0.567 
 
37.5 
CC 229 
0.466 
 
GG 0 GG 11 
AG 17 AG 112 
rs5742692 2.1 
AA 383 
1.000 
 
11.7 
AA 451 
0.270 
 
AA 3 AA 2 
AG 73 AG 27 
rs11111262 9.9 
GG 322 
0.881 
 
2.7 
GG 542 
0.118 
 
GG 13 GG 74 
CG 125 CG 252 
rs1520220 19.1 
CC 258 
0.805 
 
34.7 
CC 250 
0.443 
 
CT 18 CT 3 rs3730204 2.3 
TT 379 
1.000 
 
0.3 
TT 570 
1.000 
 
TT 67 CC 127 
CT 184 CT 264 
rs6214 39.8 
CC 148 
0.495 
 
45.2 
TT 182 
0.107 
 
TT 2 TT 9 
CT 76 CT 87 
rs6219 10.0 
CC 322 
0.429 
 
9.1 
CC 481 
0.072 
 
AA 40 AA 143 
AG 181 AG 282 
rs2946834 33.0 
GG 175 
0.588 
 
49.3 
GG 151 
0.665 
 
NOTE: MAF, minor allele frequency; HWE, Hardy Weinberg Equilibrium. 
* Caucasians: N = 402; African Americans: N = 582. 
† Based on exact test statistic (α = 0.01). 
‡ Appears inconsistent with HWE (α = 0.01). 
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Table 3.5. Genotype distribution of IGFBP-3 single nucleotide polymorphisms (SNPs) among premenopausal Caucasian and 
African American women in the NIEHS Uterine Fibroid Study  
 
Caucasians* African Americans* SNP 
Reference 
ID 
 MAF (%) Genotypes N 
HWE  
 p value†  
 MAF (%) Genotypes N 
HWE  
 p value†   
GG 22 GG 10 
GT 132 GT 88 
rs903889 22.0 
TT 246 
0.510 
 
9.4 
TT 478 
0.040 
 
TT 82 CC 95 
CT 210 CT 258 
rs924140 46.8 
CC 108 
0.335 
 
38.9 
TT 223 
0.188 
 
AA 79 CC 107 
AC 204 AC 265 
rs2854744 46.3 
CC 108 
0.397 
 
42.2 
AA 196 
0.332 
 
CC 65 CC 53 
CG 203 CG 263 
rs2854746 41.7 
GG 131 
0.427 
 
32.1 
GG 259 
0.284 
 
CC 17 CC 27 
CG 120 CG 178 
rs2471551 19.4 
GG 260 
0.587 
 
20.3 
GG 367 
0.425 
 
CC 0 CC 2 
AC 3 AC 34 
rs9282734 0.4 
AA 394 
1.000 
 
3.3 
AA 540 
0.242 
 
rs2453837 0 GG 398 -- 0 GG 576 -- 
AA 0 AA 3 
AG 5 AG 52 
rs6953668 0.6 
GG 395 
1.000 
 
5.0 
GG 521 
0.335 
 
AA 63 AA 80 
AG 203 AG 255 
rs3110697 41.4 
GG 131 
0.347 
 
36.1 
GG 240 
0.391 
 
AA 12 AA 7 
AC 121 AC 92 
rs2453840 18.3 
CC 264 
0.840 
 
9.2 
CC 477 
0.394 
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CC 14 CC 94 
CT 131 CT 282 
rs2453839 20.1 
TT 251 
0.677 
 
40.9 
TT 198 
0.784 
 
AA 12 AA 9 
AT 145 AT 127 
rs6670 21.2 
TT 241 
0.101 
 
12.6 
TT 439 
1.000 
 
AA 19 AA 117 
AG 131 AG 265 
rs13223993 21.4 
GG 245 
0.867 
 
43.6 
GG 190 
0.185 
 
TT 15 TT 84 
CT 138 CT 248 
rs2270628 21.0 
CC 247 
0.542 
 
36.2 
CC 242 
0.137 
 
CC 8 CC 3 
AC 111 AC 52 
rs12671457 16.5 
AA 267 
0.495 
 
5.1 
AA 518 
0.339 
 
NOTE: MAF, minor allele frequency; HWE, Hardy Weinberg Equilibrium. 
* Caucasians: N = 402; African Americans: N = 582. 
† Based on exact test statistic (α = 0.01). 
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Table 3.6. Estimated power to detect main effects prevalence differences (PD) by 
race with SNPs or diplotypes (α = 0.05) 
 
 Frequency of Genetic Variant* 
PD 0.05 0.10 0.20 0.30 0.40 0.50 
 African Americans (n=582)† 
0.10 19.7 31.8 49.9 60.8 66.3 68.0 
0.15 37.2 60.0 83.3 91.7 94.6 95.4 
0.20 58.3 84.1 97.5 99.4 99.8 99.8 
0.30 91.6 99.6 >99.9 >99.9 >99.9 >99.9 
 Caucasians (n=402)† 
0.10 17.8 27.0 41.0 49.8 54.4 55.7 
0.15 31.8 50.0 71.9 82.1 86.5 87.7 
0.20 48.8 72.7 91.7 96.7 98.2 98.5 
0.30 80.9 96.8 99.9 >99.9 >99.9 >99.9 
*Refers to combined frequency of heterozygous and homozygous variant genotypes.   
†Given baseline prevalence of 0.40 (African Americans), 0.30 (Caucasians). 
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Figure 3.1. Depiction of IGF-I single nucleotide polymorphisms (SNPs) evaluated among premenopausal African American and Caucasian 
participants from the National Institute of Environmental Health Sciences (NIEHS) Uterine Fibroid Study.  Relative distances of SNPs were 
based on mapping information from the Entrez Gene database sponsored by the National Center for Biotechnology Information (NCBI), National 
Library of Medicine (NLM).  SNPs selected a priori include: rs3729846, synonymous SNP; rs17884626, nonsynonymous SNP.  Race-specific 
diplotype groups and linkage disequilibrium (LD) blocks are listed for each SNP.  Group refers to combination of SNPs for diplotype estimation.  LD 
blocks consist of SNPs with minor allele frequency (MAF) ≥ 5% in strong LD (95% of pairwise SNP comparisons with one-sided 95% confidence 
intervals for the D prime statistic within 0.7-0.98).  Values for diplotype group and position (--) were not listed for SNPs excluded from diplotype 
estimation based on either: 1) Tagger algorithm (pairwise r
2
 ≥ 0.8);  2) MAF < 5% (excluded from LD blocks (--)) or MAF < 3% for SNPs selected a 
priori.   
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Figure 3.2. Depiction of IGFBP-3 single nucleotide polymorphisms (SNPs) evaluated among premenopausal African American and Caucasian 
participants from the National Institute of Environmental Health Sciences (NIEHS) Uterine Fibroid Study.  Relative distances of SNPs were 
based on mapping information from the Entrez Gene database sponsored by the National Center for Biotechnology Information (NCBI), National 
Library of Medicine (NLM).  SNPs selected a priori include: rs2854744 (-202 A/C); rs2854746 and rs9282734, nonsynonymous SNPs.  Race-specific 
diplotype groups and linkage disequilibrium (LD) blocks are listed for each SNP.  Group refers to combination of SNPs for diplotype estimation.  LD 
blocks consist of SNPs with minor allele frequency (MAF) ≥ 5% in strong LD (95% of pairwise SNP comparisons with one-sided 95% confidence 
intervals for the D prime statistic within 0.7-0.98).  Values for diplotype group and position (--) were not listed for SNPs excluded from diplotype 
estimation based on either: 1) Tagger algorithm (pairwise r
2
 ≥ 0.8);  2) MAF < 5% (excluded from LD blocks (--)) or MAF < 3% for SNPs selected a 
priori.   
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Figure 3.3.  Hypothetical causal diagram.   
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CHAPTER IV 
 
PAPER 1: IGF-I AND IGFBP-3 POLYMORPHISMS IN RELATION TO 
CIRCULATING LEVELS AMONG AFRICAN AMERICAN AND CAUCASIAN 
WOMEN 
 
 
 
Abstract 
Circulating insulin-like growth factor-one (IGF-I) and IGF binding protein-3 
(IGFBP-3) have been studied in relation to common diseases.  Although twin- and 
family-based studies suggest that genetic variation contributes to circulating IGF-I and 
IGFBP-3 levels, prior analyses of associations with multiple IGF-I and IGFBP-3 
polymorphisms have been limited, especially among African Americans.  We evaluated 
30 IGF-I and 15 IGFBP-3 single nucleotide polymorphisms (SNPs) and estimated 
diplotypes in association with plasma IGF-I and IGFBP-3 levels among 984 
premenopausal African American and Caucasian women.  We noted associations 
between IGF-I and IGFBP-3 SNPs and plasma IGF-I and IGFBP-3 among both races.  In 
both racial groups, IGFBP-3 rs2854746 (Ala32Gly) was positively associated with 
plasma IGFBP-3, (CC versus GG: Caucasians: 631 ng/ml, 95% CI: 398, 864; African 
Americans: 897 ng/ml, 95% CI: 656, 1138).  In comparison to referent diplotypes with 
the rs2854746 CG genotype, IGFBP-3 diplotypes with the GG genotype had lower mean 
plasma IGFBP-3 levels while IGFBP-3 diplotypes with the CC genotype had higher 
mean plasma IGFBP-3 levels among both races.  The nearby IGFBP-3 promoter SNP, 
rs2854744, which was in strong LD (r
2  
> 0.8) with rs2854746 in Caucasians but not 
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African Americans, was also associated with plasma IGFBP-3 in both races.  Eight other 
IGFBP-3 SNPs were associated with plasma IGFBP-3, and associations were generally 
consistent between races.  Twelve IGF-I SNPs were associated with plasma IGF-I, but 
these associations were generally discordant between races.  There was no consistent 
pattern between IGF-I SNP and diplotype associations with plasma IGF-I.  Associations 
were also noted between IGFBP-3 SNPs and plasma IGF-I and between IGF-I SNPs and 
plasma IGFBP-3 although many were relatively imprecise, and there was no consistent 
pattern with their respective diplotype associations.   
 
Introduction 
 Insulin-like growth factor-one (IGF-I), a peptide with structural similarities to 
insulin, has been the focus of prior research because of its potential role in disease.  
Specifically, IGF-I has been implicated in many biologic processes, including cell cycle 
regulation, differentiation, proliferation, hormone secretion, and apoptosis.  IGF-binding 
proteins (IGFBPs)  help regulate the activity of IGFs by influencing their bioavailablity 
and degradation  (1, 2).  IGFBPs may also have independent effects through interactions 
with cell surface molecules (1, 2).  IGFBP-3, which binds approximately 90% of 
circulating IGF-I, has been the most studied of the IGFBPs (3).  Independent of effects on 
IGFs, IGFBP-3 may inhibit growth and increase apoptosis in breast cancer cells (4, 5), 
but these findings have not been confirmed.   
Circulating IGF-I levels, and to a lesser extent circulating IGFBP-3 levels, have been 
studied in association with cardiovascular disease, diabetes, and cancer (6-9).   Prior 
studies have reported positive associations between circulating IGF-I and premenopausal 
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breast cancer (10), but two recent studies reported positive IGF-I associations with 
postmenopausal breast cancer only (11, 12).  Associations between pre- or post-
menopausal breast cancer and circulating IGFBP3 associations have been inconsistent 
(10).    
 Estimates from twin- or family-based studies suggest that genetic factors may 
account for up to 50% of the inter-individual variation in plasma IGF-I levels (13, 14) 
and up to 60% of the variation in plasma IGFBP-3 levels (13, 15).  In adults, age is the 
most consistently reported nongenetic factor associated with IGF-I blood levels (3, 16-
25), with lower circulating IGF-I levels (3, 16-25) associated with increasing age.  
Women have lower circulating IGF-I (17, 20, 21, 23, 25, 26) but higher IGFBP-3 levels 
(17, 20, 21, 25, 26) than men, and  two studies have suggested that African American 
women have higher circulating IGF-I levels than Caucasian women (21, 27).   
Our research goal was to investigate relations between IGF-I and IGFBP-3 
polymorphisms and circulating IGF-I and IGFBP-3 levels among African American and 
Caucasian women.  Prior analysis of dense single nucleotide polymorphisms (SNP) and 
IGF-I and IGFBP-3 levels among African Americans has been limited to the Multiethnic 
Cohort Study, which included only about 150 African Americans (28).  We selected 45 
SNPs in IGF-I and IGFBP-3 and examined whether these SNPs and their estimated 
diplotypes (paired haplotypes) were associated with IGF-I and IGFBP-3 plasma levels in 
premenopausal African American and Caucasian women that participated in the National 
Institute for Environmental Health Sciences (NIEHS) Uterine Fibroid Study. 
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Methods 
 
Study population 
The study population consisted of 984 premenopausal women (582 African 
Americans and 402 Caucasians) with available DNA samples for genotyping from the 
National Institute for Environmental Health Sciences (NIEHS) Uterine Fibroid Study 
(UFS).  The parent study was designed to estimate the prevalence of uterine leiomyomata 
(fibroids) among African American and Caucasian women and evaluate potential 
etiologic factors for fibroids.  Details of the parent study were previously described (29, 
30).  Briefly, a random sample of 2,384 George Washington University female health 
plan members, aged 35 to 49, was obtained for potential enrollment into the parent study 
(29, 30).  The study was approved by Institutional Review Boards at NIEHS and George 
Washington University, and the consent form specified use of specimens for genetic 
polymorphism analyses.    
UFS eligibility criteria were met by 1,786 of the 2,102 women that consented to 
eligibility screening.  Most ineligible women were excluded because they no longer 
attended the health plan clinic where the parent study was based (71%) or they had been 
misidentified as a 35-49 year-old female (16%).  Enrollment occurred from 1996 through 
1999. Approximately 20% of eligible women refused participation, resulting in a total of 
1,430 participants in the parent study (30).  Demographic characteristics, reproductive 
history, smoking status, and alcohol use were assessed from telephone interviews and 
self-administered questionnaires.  Body weight was measured at the clinic visit.   
We restricted the current study population to women that self-identified as African 
American or Caucasian (n = 1,323) to facilitate race-specific analyses, and excluded 
  
 78
postmenopausal women because they did not attend the UFS clinic visit for ultrasound 
screening and blood collection (n = 178).  Race and menopausal status criteria for the 
current study were met by 1,145 women, and DNA was extracted for 984 of the 1,003 
women with collected blood samples. 
Sample collection and assays 
Fasting blood samples were collected through venipuncture and processed for 
plasma, which was stored at -80°C.  Plasma IGF-I was measured in nanograms per 
milliliter (ng/mL) at NIEHS using a double-antibody radioimmunoassay by extraction 
method (Nichols Institute Diagnostics, San Juan Capistrano, CA), with a reported 
detection limit of 0.06 ng/mL.   Plasma IGFBP-3 was measured in ng/mL at NIEHS by a 
double-antibody immunoradiometric assay from Diagnostic Systems Laboratories, Inc. 
(Webster, TX), with a  reported detection limit of 0.05 ng/mL  The mean inter-assay 
coefficients of variation on replicate quality control samples was 8.8% for IGF-I and 
4.2% for IGFBP-3. 
Genomic DNA was extracted from whole blood using a phenol:chloroform 
procedure, but a safer and more efficient modified salt precipitation protocol was adopted 
when it became available (GenQuik Protocol). 
Genetic polymorphisms 
 
Race-specific haplotype-tagging SNPs in IGF-I and IGFBP-3 were selected using 
Genome Variation Server (GVS) software (sponsored by the Seattle SNPs Program for 
Genomic Applications (PGA)) (31).  We used the Seattle SNPs database as the reference 
population for IGF-I, while for IGFBP-3, which had not been evaluated by Seattle SNPs,  
we used the HapMap database (31). We expanded coverage to include 5 kilobases (kb) 
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outside the 5’ and 3’ ends of each gene, and specified a value of 0.8 for the pairwise 
correlation coefficient (r
2
) to identify haplotype-tagging SNPs to capture variation across 
the gene.  Haplotype-tagging SNPs with a minor allele frequency (MAF) greater than 5% 
among women in African American or Caucasian reference populations were selected for 
genotyping.  Overall, the GVS software identified 29 haplotype-tagging SNPs for IGF-I 
and 12 haplotype-tagging SNPs for IGFBP-3.  In addition, we selected four SNPs a 
priori based on functional significance, including one nonsynonymous IGF-I SNP 
(rs17884626), one synonymous IGF-I SNP (rs3729846), and two nonsynonymous 
IGFBP-3 SNPs (rs2854746, rs9282734) and an IGFBP-3 promoter SNP (-202 A/C, 
rs2854744) a priori based on previous studies of associations with circulating IGF-I and 
IGFBP-3 levels and health outcomes (28, 32-38). 
Genotyping was performed using the TaqMan genotyping approach (39-41) at an 
outside laboratory (Mammalian Genotyping Core, Lineberger Comprehensive Cancer 
Center; Chapel Hill, NC).  Allele-specific oligonucleotide probes for 39 selected SNPs 
were purchased from Applied Biosystems (ABI; Foster City, CA) “TaqMan® Validated 
and Coding SNP or Pre-Designed SNP Genotyping Assays”.  ABI attempted to develop 
custom assays for the 6 remaining SNPs through their “Custom TaqMan® SNP 
Genotyping Assays” service.  Two IGF-I haplotype tagging SNPs were dropped from 
analyses, including one for which a custom assay could not be developed, and one with a 
pre-designed assay that did not meet ABI technical specifications.  In addition, we 
genotyped an alternate IGF-I haplotype-tagging SNP to substitute one that appeared 
inconsistent with Hardy-Weinberg equilibrium among our African American study 
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population.  Thus, we genotyped 30 IGF-I and 15 IGFBP-3 SNPs, including 40 
haplotype-tagging SNPs and 5 SNPs selected a priori. 
PCR amplification was performed on an ABI GeneAmp® PCR System 9700 thermal 
cycler with dual 384-well-blocks, and endpoint plates were read using the ABI 7900HT 
system.  Fluorescent VIC and 6-FAM reporter dyes were used to distinguish wild type 
and variant alleles.  Alleles were called automatically through Sequence Detection 
System (SDS) 2.3 software, but output also was reviewed by experienced operators.  The 
DNA concentration of all samples was validated using a NanoDrop® ND-1000 
Spectrophotometer prior to dilution to 5 ng/ul (using DNA grade sterile water).  All 
samples were placed into eleven 96-well microtiter plates, with each plate containing two 
blank samples and two known DNA standard (Control DNA CEPH Individual 1347-02, 
ABI) samples.  Samples were subsequently aliquoted into three 384-well PCR plates for 
analysis.  Quality control measures also included blinded genotyping of 28 duplicate 
samples representing 22 women, which produced concordant results for all samples.  The 
overall call rate was 98.8%, and only 5 women had less than 50% of complete allele calls 
for the 45 SNPs assayed.  We confirmed that SNP genotype frequencies were consistent 
with Hardy-Weinberg equilibrium (HWE) within each racial group using the exact test 
statistic with one degree of freedom (alpha = 0.01) (42).   
Diplotype estimation 
We estimated associations with race-specific diplotypes (paired haplotypes), that 
were imputed for groups of related SNPs within each gene, as described below.  SNPs 
were excluded from race-specific diplotype analyses if their MAF in our study population 
was below 5% for haplotype-tagging SNPs or below 3% for a priori SNPs within the 
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racial group being evaluated.  Women missing genotype data for more than 50% of the 
SNPs considered for diplotype analyses within a gene were excluded from diplotype 
estimation for that gene (1 Caucasian and 3 African Americans for IGFBP-3 analyses, 3 
Caucasians and 2 African Americans for IGF-I analyses).  We examined race-specific 
linkage disequilibrium (LD) patterns using Haploview software (43) to identify SNPs in 
each gene that could be combined for estimating diplotypes.  First, we identified blocks 
consisting of individual SNPs (with MAF at least 5%) in strong LD (95% of pairwise 
SNP comparisons with one-sided 95% confidence intervals for the D prime statistic 
within 0.7 to 0.98) (44).  Next, we used the Tagger approach (45) in Haploview to 
identify pairs of redundant SNPs in strong LD (pairwise r
2
 values of at least 0.8), and 
excluded one member of each redundant pair from diplotype estimation unless both SNPs 
were selected a priori.  Race-specific pairwise r
2
 values are available for IGFBP-3 and 
IGF-I SNPs in Tables A.1-A.4.   
  Race-specific diplotypes representing defined groups of SNPs in each gene were 
then estimated using PHASE version 2.1 (46, 47), which allocates the most likely 
diplotypes for each person, with the prior assumption that frequently observed haplotypes 
with less ambiguity due to homozygosity are more probable.  PHASE also provides a 
posterior probability estimate that expresses the uncertainty associated with each 
diplotype assignment.  To reduce the number of race-specific diplotype groups evaluated 
for each gene, we combined individual SNPs that were not included in a block with an 
adjacent block, and combined adjacent blocks with each other, when doing so resulted in 
diplotypes that were estimated with at least 90% certainty (posterior probability) for at 
least 90% of observations.  Otherwise, diplotype groups encompassed individual SNPs 
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not included in a block, or SNPs within a single block only.  Women were assigned their 
most probable diplotype for each group, or were classified as missing for the diplotype 
group if their most probable diplotype had a posterior probability below 90%.   
Statistical analysis 
All statistical analyses were stratified by race and conducted using SAS V9.1 (SAS 
Institute Inc., Cary, NC).  We used ordinary linear regression to estimate associations 
between IGF-I and IGFBP-3 gene variants (individual SNPs and race-specific 
diplotypes) and IGF-I and IGFBP-3 plasma levels.  Because of biological interrelations 
between IGF-I and IGFBP-3, variants in each gene were analyzed for associations with 
circulating levels of both proteins.  Estimated associations are unadjusted since there are 
no known factors other than race that would predict both plasma levels and gene variants.  
For individual SNP analyses, we first considered a codominant model of inheritance 
in which heterozygous and homozygous variant genotypes were separately evaluated 
relative to the homozygous wildtype (referent) genotype (most common for specific 
race).  Codominant models make the fewest assumptions with regard to inheritance 
pattern, but were feasible only for common variants. Therefore, when there were 10 or 
fewer women with the homozygous variant genotype, we assumed a dominant model that 
compared a single index category, including homozygous variant and heterozygous 
genotypes, to the homozygous wildtype genotype.  To compare race-specific associations 
with plasma IGF-I or IGFBP-3 levels, we combined data from both racial groups and 
estimated racial differences in mean plasma levels (i.e., differences of mean differences) 
associated with variant vs. referent genotypes.  Specifically, we fit linear regression 
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models that included multiplicative gene by race interaction terms along with separate 
parameters for race and genotypes (Tables A.5-A.6).   
To estimate diplotype associations with IGF-I or IGFBP-3 plasma levels, we used 
separate race-specific models for each diplotype group, with the most common diplotype 
as the reference category.  Diplotypes assigned to 5 or fewer women were combined into 
one “rare diplotype” category.  To enhance the validity and precision of regression 
estimates, we used an empirical-Bayes method of information-weighted averaging (48).  
Specifically, we assumed a prior mean of 0, since we did not have prior information to 
group diplotypes according to the anticipated direction or strength of potential 
associations with plasma levels. We specified a prior variance corresponding to +/- one 
standard deviation (2*standard deviation /3.92)
2
 of the mean plasma level of IGF-I (prior 
variances: African Americans, 1,419; Caucasians, 901) and IGFBP-3 (prior variances: 
African Americans, 186,819; Caucasians, 174,161) in the study population.  This method 
shrinks regression estimates toward the prior mean such that imprecise estimates based 
on smaller numbers of observations move further toward the prior mean than more 
precise regression estimates.  We applied the shrinkage estimator for each diplotype and 
report posterior medians (50
th
 percentile of the posterior probability distribution) and 
95% posterior limits (2.5
th
 and 97.5
th
 percentiles of the posterior probability distribution).  
Regression estimates and 95% confidence limits estimated directly by linear regression 
are available in Tables A.7-A.14.  
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Results 
Participant characteristics 
Mean plasma IGF-I and IGFBP-3 levels, as well as characteristics of the study 
population are displayed in Table 4.1 by race.  African Americans were less likely than 
Caucasians to have a college or graduate degree (33% vs. 87%), to report regular alcohol 
consumption (at least 0.5 drinks per week in the past year, 42% vs. 78%), or to report 
being nulliparous at UFS enrollment (21% vs. 59%).  African Americans were more 
likely than Caucasians to be overweight or obese (75% vs. 41%) and to report current 
smoking (30% vs. 8%).  Few women in either racial group were currently taking oral 
contraceptives.   
IGFBP-3 SNPs  
For plasma IGFBP-3, we emphasize associations where mean plasma levels 
estimated for the index genotypes are approximately 200 ng/mL higher or lower than the 
mean level estimated for the referent genotype (i.e., roughly +/- 5% of the estimated 
mean level for the referent group, which ranged from about 3798 to 4693 ng/mL).  
However, we do not consider imprecise associations with SNPs having ten or fewer 
observations with heterozygous and homozygous variant genotypes combined.   
Ten IGFBP-3 SNP variants (rs903889, rs924140, rs2854744, rs2854746, rs2471551, 
rs3110697, rs2453840, rs2453839, rs2270628, rs12671457) were associated with plasma 
IGFBP-3 levels in at least one racial group when compared with homozygous wildtype 
genotypes.   Among Caucasians, plasma IGFBP-3 levels were elevated in association 
with variant genotypes for three SNPs (rs924140, rs2854744, rs2854746) relative to 
reference genotypes (approximately 600 ng/mL higher for homozygous variants, almost 
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400 ng/mL higher for heterozygotes) (Table 4.2).  Pairwise r
2
 values for all three SNPs 
were at least 0.8, indicating strong LD.  These three SNPs were also associated with 
plasma IGFBP-3 levels among African Americans.  Specifically, plasma levels were 
about 900 ng/mL higher in association with the CC genotype for the nonsynonymous 
rs2854746 SNP compared to the GG genotype, and about 460 ng/mL higher in 
association with the CG genotype (Table 4.3).  Plasma IGFBP-3 levels in African 
Americans were higher in association with the rs924140 TT and rs2854744 AA 
genotypes corresponding to the homozygous variant genotypes in Caucasians, though 
estimated associations were inverse because these genotypes were the homozygous 
wildtype (referent) genotypes among African Americans.  As in Caucasians, rs924140 
and rs2854744 were in strong LD (r
2
 = 0.82); however, rs2854746 was not in strong LD 
with either of these SNPs (r
2
 range 0.30 to 0.34) among African Americans.   
In both racial groups, rs3110697 variant genotypes were inversely associated with 
plasma IGFBP-3 relative to the referent genotypes (about 430 ng/mL lower in Caucasians 
and 550 ng/mL lower in African Americans for the AA genotype, with smaller 
differences associated with the AG genotype).  Among both racial groups, r
2 
values for 
rs3110697 with rs924140 and rs2854744 ranged from 0.55 to 0.65, indicating moderate 
LD, but rs3110697 was not in LD with rs2854746 (r
2 
< 0.5).  Plasma IGFBP-3 was also 
inversely associated with rs2471551 variants among African Americans (460 ng/mL 
lower for the CC genotype and 260 ng/mL lower for the CG genotype relative to the GG 
genotype). 
Relatively imprecise estimates based on fewer than 25 women suggest inverse 
associations between plasma IGFBP-3 and homozygous variant genotypes for five SNPs 
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(rs903889, rs2471551, rs2453840, rs2453839, rs2270628) among Caucasians.  Among 
African Americans, homozygous and heterozygous variants combined for two less 
common SNPs were positively (rs2453840) and inversely (rs12671457) associated with 
plasma IGFBP-3, with differences of about 200 ng/mL relative to homozygous wildtype 
genotypes. None of the other IGFBP-3 SNPs with plasma IGFBP-3 associations were in 
LD with each other, except for rs2453840 and rs2453839, which were in strong LD 
among Caucasians (r
2
 = 0.87). 
 Based on combined race models with interaction terms, race-specific SNP 
associations with plasma IGFBP-3 showed little evidence of discordance by race (Table 
A.5).  Two possible exceptions were rs2854746, which was more strongly associated 
with plasma IGFBP-3 among African Americans than Caucasians, and rs2270628, which 
had estimated race-specific associations with the homozygous variant that were imprecise 
and in opposite direction.  However, estimated differences of mean differences between 
racial groups, especially for homozygous variant genotypes, were relatively imprecise. 
For plasma IGF-I, we emphasize associations where mean plasma levels estimated 
for the index genotypes are approximately 16-18 ng/mL higher or lower than the mean 
level estimated for the referent genotype (i.e., about +/- 10% of the estimated mean level 
for the referent group, which ranged from 158 to 176 ng/mL).  Homozygous variants for 
two IGFBP-3 SNPs (rs903889, rs6670) among Caucasians and four IGFBP-3 SNPs 
(rs924140, rs2471551, rs3110697, rs2270628) among African Americans were associated 
with plasma IGF-I relative to the homozygous wildtype genotypes.  However, three of 
the six SNP associations (rs903889, rs6670, rs2475551) with plasma IGF-I were 
relatively imprecise due to fewer than 30 homozygous variant observations.   
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IGFBP-3 Diplotypes 
Among Caucasians, there were three LD blocks representing 10 of 12 IGFBP-3 
SNPs for diplotype analyses, with two SNPs outside LD blocks.  After excluding two 
redundant IGFBP-3 SNPs (r
2
 ≥ 0.8), two groups were created for diplotype estimation by 
combining LD blocks or SNPs outside LD blocks as described previously.  Among the 
two Caucasian IGFBP-3 groups, there were 48 unique diplotypes, with 20 of these 
diplotypes classified as rare (5 or fewer women).  Diplotypes for each group were 
estimated for 93% to 98% of the 401 Caucasians for IGFBP-3 diplotype analyses.   
Among African Americans, there were four LD blocks representing 11 of 14 IGFBP-
3 SNPs for diplotype analyses, with three SNPs outside LD blocks.  After excluding one 
redundant IGFBP-3 SNP (r
2
 ≥ 0.8), three groups were created for diplotype estimation.  
Among the three African American IGFBP-3 groups, there were 71 unique diplotypes, 
which included 33 rare diplotypes.  Diplotypes for each group were estimated for 94% to 
99% of the 579 African Americans for IGFBP-3 diplotype analyses.     
Similar to individual SNP analyses, we emphasized associations where the index 
diplotypes were associated with plasma IGFBP-3 differences of at least 200 ng/mL from 
the mean IGFBP-3 level for the referent diplotype.  Six Caucasian IGFBP-3 group 1 
diplotypes (GCGGAC/GCGGAC, TAGGGC/GCGGAC, TCGCAC/GCGGAC, 
TCGCAC/TCGCAC, TCGGGA/GCGGAC, TCGGGA/TCGCAC) were inversely 
associated with plasma IGFBP-3 relative to the TACGGC/GCGGAC (referent) diplotype 
(Figure 4.1).  All six diplotypes included the GG genotype for rs2854746 (3
rd
 diplotype 
position), and five of the diplotypes included the CC genotype for rs2854744 (2
nd
 
diplotype position).  The only two Caucasian IGFBP-3 group 1 diplotypes 
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(TACGGA/TACGGC, TACGGC/TACGGC) having the CC genotype for rs2854746 
were positively associated with plasma IGFBP-3.       
Eight of the ten African American IGFBP-3 group 1 diplotypes 
(TACGAGG/GCGGAGA, TAGGAGA/TAGGAGG, TAGGAGG/GCGGAGA,  
TAGGAGG/TAGGAGG, TCGCAGA/GCGGCAA, TCGCAGA/TAGGAGA, 
TCGCAGA/TAGGAGG, TCGCAGA/TCGCAGA, TCGCAGA/TCGGAGG, 
TCGGAGA/TACGAGG) that were inversely associated with plasma IGFBP-3 relative to 
the TAGGAGG/TACGAGG diplotype (Figure 4.2) included the GG genotype for 
rs2854746 (3
rd
 diplotype position). Three of the ten diplotypes also included the CC 
genotype for rs2854744 (2
nd
 position), and one was the only diplotype that included the 
CC genotype for rs2471551 (4
th
 diplotype position).  The African American IGFBP-3 
group 1 diplotype TACGAGG/TACGAGG, the only diplotype with the CC genotype for 
rs2854746, was positively associated with plasma IGFBP-3.  The African American 
IGFBP-3 group 2 diplotype CC/CC was inversely associated with plasma IGFBP-3 
compared to the CT/CC (referent) diplotype.  
Similar to individual SNP analyses, we generally emphasized associations where the 
index diplotypes were associated with plasma IGF-I differences of at least 10% (16-18 
ng/mL) from the mean IGF-I level for the referent diplotype.  One Caucasian IGFBP-3 
group 1 diplotype (TCGGGA/TCGCAC) was inversely associated with plasma IGF-I 
compared to the TACGGC/GCGGAC diplotype.  Among African Americans, eight 
IGFBP-3 Group 1 diplotypes (TAGGAGA/TACGAGG, TAGGAGA/TAGGAGG, 
TAGGAGG/GCGGAGA, TCGCAGA/GCGGCAA, TCGCAGA/TACGAGG, 
TCGCAGA/TCGCAGA, TCGCAGA/TCGGAGG, TCGGAGG/TACGAGG) were 
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inversely associated with plasma IGF-I, and two IGFBP-3 Group 1 diplotypes 
(TACGAGG/GCGGAGA, TCGGAGG/TCGGAGG) were positively associated with 
plasma IGF-I relative to the TAGGAGG/TACGAGG diplotype.  Seven of the eight 
African American IGFBP-3 Group 1 diplotypes that were inversely associated with 
plasma IGF-I included AG or AA genotypes for rs3110697 (7
th
 diplotype position), 
which were inversely associated with plasma IGF-I in SNP analyses.  Both African 
American IGFBP-3 group 3 diplotypes (TATA/TGTC, TATA/TATA) that included the 
rs2270628 TT genotype (3
rd
 diplotype position) were positively associated with plasma 
IGF-I relative to the TATA/TGCA diplotype. 
IGF-I SNPs 
Among Caucasians, homozygous variants for two common IGF-I SNPs (rs1520220, 
rs6214) and variants for five rare (MAF < 5%) IGF-I SNPs (rs5742612, rs5742614, 
rs5742657, rs5742692, rs3730204) were associated with plasma IGF-I, with estimated 
mean differences of at least 10% (17 ng/mL) relative to the homozygous wildtype 
genotypes (Table 4.4).  However, with the exception of the positive association between 
rs6214 and plasma IGF-I, associations were rather imprecise due to 30 or fewer 
observations with variant genotypes.  None of the IGF-I SNPs noted above were in LD 
(r
2
 < 0.4) except for strong LD between rs5742657 and rs5742692 (r
2
 = 0.94). 
Among Caucasians, nine IGF-I SNP variants were inversely associated (rs4764884, 
rs5009837, rs4764883, rs9308315, rs978458, rs1520220, rs3730204, rs6219, rs2946834) 
with plasma IGFBP-3, while one rare (MAF < 5%) IGF-I SNP variant (rs5742612) was 
positively associated with plasma IGFBP-3 (estimated differences of at least 200 ng/mL 
for variant genotypes relative to homozygous wildtype genotypes), although five SNP 
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associations (rs5742612, rs4764884, rs9308315, rs978458, rs1520220) were relatively 
imprecise due to 30 or fewer observations with variant genotypes.  Five (rs4764884, 
rs5009837, rs4764883, rs9308315, rs978458) of the ten IGF-I SNPs associated with 
plasma IGFBP-3 were in strong LD with each other (r
2 
≥ 0.8), and rs1520220 was in 
moderate LD with rs978458 and rs9308315 (r
2 
approximately 0.60) but had slightly 
smaller r
2 
values of about 0.50 with rs4764884, rs5009837, and rs4764883. 
Among African Americans, three rare (MAF < 5%) IGF-I (rs2033178, rs17727841, 
rs11111262) variants were associated with plasma IGF-I relative to the homozygous 
wildtype genotypes, although the rs11111262 association was relatively imprecise due to 
fewer than 30 variant observations (Table 4.5).  In addition, variants for two more 
common IGF-I SNPs (rs6219, rs2946834) were positively associated with plasma IGF-I.  
Of the five IGF-I SNPs noted above, only rs17727841 and rs11111262 were in moderate 
LD with each other (r
2 
= 0.56).  The rs1086869 TT genotype was positively associated 
with plasma IGFBP-3 relative to the AA genotype, but there were no other IGF-I SNP 
variants associated with meaningful differences (≥ 200 ng/mL) in plasma IGFBP-3. 
Based on models that included an interaction term with race, mean plasma IGF-I 
levels estimated for several of the IGF-I homozygous variants varied between racial 
groups by at least 16-18 ng/ml, which may indicate modification by race.  However, 
estimated differences of mean differences between African Americans and Caucasians 
were imprecise (Table A.6) 
IGF-I Diplotypes 
Among Caucasians, there were three LD blocks representing 15 of 17 IGF-I SNPs 
for diplotype analyses, with two SNPs outside LD blocks.  After excluding six redundant 
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IGF-I SNPs (r
2
 ≥ 0.8), four groups were created for diplotype estimation by combining 
LD blocks or SNPs outside LD blocks as described previously.  Among the four 
Caucasian IGF-I groups, there were 40 unique diplotypes, with 13 of these diplotypes 
considered rare (5 or fewer observations).  Diplotypes for each group were estimated for 
97% to 99% of the 399 Caucasians for IGF-I diplotype analyses.   
Among African Americans, there were four LD blocks representing 16 of 20 IGF-I 
SNPs for diplotype analyses, with four SNPs outside LD blocks.  After excluding six 
redundant IGF-I SNPs (r
2
 ≥ 0.8), four groups were created for diplotype estimation.  
Among the four African American IGF-I groups, there were 73 unique diplotypes, with 
25 of these diplotypes considered rare.  Diplotypes for each group were estimated for 
95% to 99% of the 580 African Americans for IGF-I diplotype analyses.     
Five Caucasian IGF-I group 3 diplotypes (GCTCT/GCTGC, GGCCC/AGTGC, 
GGCCT/AGTGC, GGCCT/GGCCT, GGCCT/GGTGT) were positively associated with 
plasma IGF-I, with differences of at least 10% (17 ng/mL) higher than estimated mean 
levels for the referent GGCCC/GGCCT diplotype (Figure 4.3).  However, the 
associations with the GCTCT/GCTGC and GGCCT/GGTGT diplotypes were relatively 
imprecise.  The IGF-I group 3 GGCCT/GGCCT diplotype was positively associated with 
plasma IGFBP-3 (mean difference of at least 200 ng/mL relative to referent diplotype).   
IGF-I group 4 diplotypes (CA/TA and rare (TA/TA), CA/CA) that included the AA 
genotype for rs2946834 (2
nd
 diplotype position) were inversely associated with plasma 
IGFBP-3 relative to the mean level for the referent CG/CG diplotype.  The IGF-I group 4 
diplotype category (CA/TA and TA/TA diplotypes) also was inversely associated with 
plasma IGF-I.   
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The African American IGF-I group 1 GGG/GCG diplotype was positively associated 
with plasma IGF-I relative to the AGG/GGG diplotype, and an imprecise inverse 
association based on fewer than ten observations was noted between the GCG/GCG 
diplotype and plasma IGF-I (Figure 4.4).  Four IGF-I group 2 diplotypes 
(ATCCC/TCTTT, ATTCC/TCTCC, ATTCC/TCTCT, TTTCT/TCTTT) and two IGF-I 
group 3 diplotypes (AAGC/AACT, TACC/TACC) were associated with plasma IGF-I 
relative to the referent diplotypes although estimates were imprecise since there were 15 
or fewer observations with index diplotypes.  In addition, the IGF-I group 4 CA/TA 
diplotype was positively associated with plasma IGF-I relative to the referent CA/CG 
diplotype.  Two IGF-I group 2 diplotypes (ATTCC/TCTCT, TTTCT/TCTTT) and four 
IGF-I group 3 diplotypes (AACC/AGGT, AACC/TACC, AAGC/AACT, TACC/TACC) 
were associated with plasma IGFBP-3, relative to the referent diplotypes, but estimates 
were imprecise due to 15 or fewer observations with index diplotypes.  None of the 
associations between plasma IGFBP-3 or IGF-I levels and African American IGF-I 
diplotypes were explained by patterns with SNP associations. 
 
Discussion 
 
Overall, we noted several associations between individual IGF-I and IGFBP-3 SNPs 
and their respective protein levels.  In addition, we detected associations between IGFBP-
3 SNPs and plasma IGF-I levels and associations between IGF-I SNPs and IGFBP-3 
plasma levels, predominantly among Caucasians.  The strongest evidence of association 
between genetic variation and circulating protein levels was between the nonsynonymous 
IGFBP-3 SNP, rs2854746, and plasma IGFBP-3.  In both races, the CC genotype was 
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associated with higher estimated mean plasma levels than the GG genotype, with 
intermediate mean levels for those with the CG genotype.  In addition, IGFBP-3 
diplotypes with the rs2854746 GG genotype had lower mean plasma IGFBP-3 levels, and 
IGFBP-3 diplotypes with the CC genotype had higher mean plasma IGFBP-3 levels 
relative to referent diplotypes with the CG genotype in both racial groups.   
Among both racial groups, estimated increases in plasma IGFBP-3 levels were 
similar in association with AA versus CC genotypes for s2854744, though estimated 
associations with diplotypes that included this variant were not as consistent as for 
rs2854746.  Associations between rs2854744 and plasma IGFBP-3 in Caucasians might 
be explained by strong LD between rs2854744 and rs2854746 (r
2  
= 0.82); however, these 
two SNPs were not in LD among African Americans (r
2  
= 0.34).  Alternatively, estimated 
plasma IGFBP-3 associations with rs2854744 might be explained by effects of rs924140, 
which was excluded from Caucasian and African American diplotypes, but was in LD 
with rs2854744 among women in both racial groups (Caucasians: r
2  
= 0.99; African 
Americans: r
2  
= 0.82).  However, no functional effects of rs924140 have been reported in 
the literature. 
Biologic evidence supports a causal relation of rs2854746 with plasma IGFBP-3 
levels, since this SNP results in an amino acid change from alanine to glycine.  Evidence 
from protein sequence analysis reported in the UniProtKB/Swiss-Prot database (49) 
suggests that the amino acid coded by the rs2854746 SNP is within the region responsible 
for IGF binding.  The Multiethnic Cohort Study (28) and a small study of controls from a 
population-based cancer case-control study (50) both reported associations between 
rs2854746 and plasma IGFBP-3 in the same direction to our study findings.   
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Other epidemiologic studies have not evaluated rs2854746, but several have 
examined rs2854744 and plasma IGFBP-3 predominantly among Caucasians.  Seven 
studies reported higher circulating IGFBP-3 among women with two copies of the A 
allele compared with women who had no A alleles, and intermediate levels among those 
with AC genotype (32-38), including a study of Physicians’ Health Study participants by 
Deal et al. (33), who noted that rs2854744 (-202 A/C SNP) had the strongest correlation 
with plasma IGFBP-3 of the five evaluated IGFBP-3 promoter SNPs.  In addition, Deal 
et al. reported that  promoter activity was increased in vitro in association with the 
rs2854744 A allele (33), indicating greater IGFBP-3 protein production.  However, 
strong LD with rs2854746 may be a possible causal explanation for associations between 
rs2854744 and plasma IGFBP-3 among Caucasians.  As in our study population, the 
Multiethnic Cohort Study reported strong LD (r
2
 value ≥ 0.8) for rs2854744 and 
rs2854746 among Caucasians but not African Americans (28).  In addition, they noted 
that only rs2854746 was associated with plasma IGFBP-3 levels after accounting for both 
SNPs in their analytic model (142)(28), though sparse data limited inferences across the 
five race/ethnicity groups included in the cohort.  Similar to our study, the Multiethnic 
Cohort Study also reported decreased plasma IGFBP-3 levels in association with 
rs3110697 AA vs. GG genotypes among both races, and that rs3110697 was not in strong 
LD with rs2854744 or rs2854746 (28).  
We also reported consistent inverse associations between IGFBP-3 rs2471551 
variants and plasma IGFBP-3 among both racial groups.  This SNP has potential 
functional relevance as it is located at a splice site (intron 1 within less than 20 kb of exon 
2).  In addition, Canzian et al. (22) reported that rs2471551 (homozygous variant versus 
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homozygous wildtype genotypes) was inversely associated with circulating IGFBP-3 for 
a predominantly Caucasian case-control study nested within the European Prospective 
Investigation into Cancer and Nutrition. 
The focus of many prior epidemiologic studies of IGF-I has been the dinucleotide 
CA repeat polymorphism (position -969) located in the promoter approximately one kb 
upstream of the transcription site; however, relations between CA repeat polymorphisms 
and circulating IGF-I levels have been inconsistent (27, 35-36, 51-58).  Methodological 
differences in the categorization of repeat genotypes and the potential for substantial 
misclassification during genotyping (59) make it difficult to compare results across 
studies.  Although we did not evaluate this repeat polymorphism, we evaluated IGF-I 
SNPs within five kb of the 5’ and 3’ ends of the gene.   
Our study estimated higher mean plasma IGF-I levels in association with the rs6214 
TT genotype relative to the CC genotype among Caucasians and found no clear 
associations between rs35767 and plasma IGF-I or IGFBP-3 among either racial group.  
In contrast, Canzian, et al. measured five IGF-I SNPs in a predominantly Caucasian study 
population and reported associations for rs35767 with circulating IGF-I and IGFBP-3 but 
no associations with rs6214 (32).   
We also estimated an inverse association between plasma IGF-I and the rs1520220 
homozygous variant relative to the homozygous wildtype genotype among Caucasians, 
but noted only a weak positive association among African Americans. We also noted a 
positive association between rs2946834 AA versus GG genotypes and plasma IGF-I 
among African Americans, but a weak inverse association among Caucasians although 
race-specific associations may not be meaningfully different based on imprecision with 
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estimated difference of mean differences.  Al-Zahrani et al. also reported no association 
between rs6214 and plasma IGF-I, but in contrast with our study, they noted a positive 
association with homozygous variant genotypes relative to homozygous wildtype 
genotypes for rs2946834 and rs1520220 (34).  Although both SNPs were tightly 
correlated in this predominantly Caucasian study population, a positive association 
remained with rs1520220 only after adjustment for rs2946834 (34).   
Our study had a very high call rate for genotyping.  We evaluated IGF-I or IGFBP-3 
variants in association with plasma levels of both proteins due to biological interrelations 
between IGF-I and IGFBP-3. Previous studies have evaluated IGF-I or IGFBP-3 variants 
in association with their respective protein levels only, except two studies examined 
associations with both proteins including the Canzian et al. evaluation of several IGF-I 
and IGFBP-3 variants within a Caucasian study population (32) and one study that only 
evaluated the IGF-I dinucleotide CA repeat polymorphism and IGFBP-3 rs2854746 (50). 
Diplotype estimation may have been biased by the removal of women that had a 
lower degree of certainty (posterior probability < 90%) for assigned diplotypes, though 
this bias should be negligible given that 1% to 7% of women were excluded for race-
specific analyses of each diplotype group.  Rare diplotypes were assigned with lower 
certainty, as the PHASE software assumes that frequently observed haplotypes with less 
ambiguity are more probable.  We did not attempt to estimate associations with rare 
diplotypes (5 or fewer observations in our study population) within each group 
individually, but instead combined them into a single category.  Rare diplotype categories 
were associated with plasma IGF-I and IGFBP-3 levels in some instances, but these 
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associations could not be interpreted due to the heterogeneity of the diplotypes included 
in these categories. 
We used a method of information-weighted averaging that intentionally biased 
estimates towards the null, since we assumed a null value for our prior mean; however, 
this approach increased the precision of estimates, particularly diplotypes assigned to 
small numbers of women.  We selected a prior mean of zero since we had no prior 
information to indicate functional similarities between diplotypes and direction of 
associations with plasma IGF-I and IGFBP-3 levels relative to referent diplotypes.  
Despite the increase in bias for posterior medians using this approach, a reduction in the 
overall mean square error based on a greater decrease in variance of estimates has been 
shown with simulation studies and an occupational cohort study (60).   
Possible selection bias exists if women excluded from the study because they lacked 
DNA for genotyping (161 total, 14% of the eligible study population) differed from the 
remaining study population with respect to their genotypes or plasma IGF-I or IGFBP-3 
levels.  A slightly greater proportion of the African Americans (108 total, 16%) in the 
eligible study population were excluded than Caucasians (53 total, 12%).  The parent 
study obtained only one measurement of plasma IGF-I and IGFBP-3 from study 
participants, which may not reflect intra-individual variation; however, the Nurses’ 
Health Study reported high correlations (> 0.8) for plasma IGF-I and IGFBP-3 
measurements across premenopausal women over time (61).  Age and sex are strong 
predictors of circulating IGF-I and IGFBP-3, but these factors were unlikely to influence 
our results since our study population was restricted to women within a narrow 15-year 
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age range (35 to 49 years) and adjusting for age did not affect our results (data not 
shown).   
We restricted our study to Caucasians and African Americans and stratified all 
analyses by race; however, population stratification within each racial group is still a 
potential limitation of our study (62-65).  Several of the reported associations may reflect 
random error or bias; however, at least one (between the nonsynonymous IGFBP-3 SNP 
(rs2854746) and plasma IGFBP-3) showed evidence of a dose-response effect that was 
consistent for the individual SNP and diplotype analyses among both racial groups.  It 
will be important to validate this finding, as well as other results, in additional study 
populations. 
A major strength of our study was the large number of African American 
participants, which allowed us to expand beyond previous research that has focused 
almost exclusively on relations between IGF-I and IGFBP-3 SNPs and their respective 
protein levels in Caucasians. Because African Americans have more genetic 
heterogeneity than Caucasians, the frequency of etiologically relevant SNPs may differ, 
and may at least partly explain racial disparities in the burden of cancer and 
cardiovascular disease.  Therefore, assessing IGF-I and IGFBP-3 variants that predict 
circulating IGF-I and IGFBP-3 is important to improve our understanding of the potential 
biologic role of IGF-I and IGFBP-3 in the etiology of common diseases. 
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Table 4.1. Characteristics of premenopausal women with genotype information by 
race from NIEHS Uterine Fibroid Study  
 
Characteristic 
African Americans 
 (N=582) 
N (%) 
 Caucasians  
(N=402) 
N (%) 
Age (years)    
35-39 219 (37.6)  137 (34.1) 
40-44 205 (35.2)  135 (33.6) 
45+ 158 (27.1)  130 (32.3) 
Education    
High school 121 (20.8)*  12 (3.0) 
Some postsecondary 265 (45.5)  33 (8.2) 
College degree 123 (21.1)  133 (33.1) 
Graduate degree 68 (11.7)  217 (54.0) 
Missing 5 (0.9)  7 (1.7) 
Current oral contraceptives use†  
 
28 (4.8)  37 (9.2) 
Parity    
0 120 (20.6)  236 (58.7) 
1 134 (23.0)  54 (13.4) 
2 194 (33.3)  91 (22.6) 
3+ 134 (23.0)  21 (5.2) 
Body mass index     
Under- normal weight (<25) 147 (25.3)  236 (58.7) 
Overweight (25-<30) 178 (30.6)  95 (23.6) 
Obese (30+) 257 (44.2)  71 (17.7) 
Smoking status    
Current smoker 172 (29.6)  31 (7.7) 
Former smoker 133 (22.9)  139 (34.6) 
Never smoked 277 (47.6)  232 (57.7) 
Alcohol intake (past year)    
<0.5 drinks/week 300 (51.5)  60 (14.9) 
≥0.5 drinks/week   245 (42.1)  314 (78.1) 
Missing 37 (6.4)  28 (7.0) 
 Mean (SD)  Mean (SD) 
Plasma IGF-I (ng/mL)† 165 (74.0)  172 (58.7) 
Plasma IGFBP-3 (ng/mL)† 4085 (859.7)  4524 (822.3) 
* Includes 11 women with less than high school education. 
† N missing: oral contraceptives: 4 African Americans, 3 Caucasians; IGF-I and IGFBP-3:          
   8 African Americans, 1 Caucasian. 
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Table 4.2. Unadjusted linear regression of IGFBP-3 single nucleotide polymorphisms (SNPs) on plasma IGFBP-3 and IGF-I 
levels among Caucasians 
 
Plasma IGFBP-3 (ng/mL)   Plasma IGF-I (ng/mL) 
Block* 
Diplotype 
Group* 
Diplotype 
Position* 
SNP Reference 
ID 
 MAF 
(%)† 
Genotype N‡ 
β§ 95% CI§   β§ 95% CI§ 
GG 22 -398 -754, -42  21 -4, 47 
GT 131 -67 -240, 106  3 -10, 15 
1 1 1 rs903889 22.0 
TT 246 4572 4470, 4674  170 163, 178 
TT 82 581 352, 810  5 -12, 22 
CT 210 375 190, 560  6 -7, 20 
1 -- -- rs924140 46.8 
CC 107 4210 4059, 4361  168 157, 179 
AA 79 592 364, 819  4 -13, 21 
AC 204 353 170, 536  6 -8, 19 
1 1 2 rs2854744|| 46.3 
CC 107 4221 4073, 4370  169 158, 180 
CC 65 631 398, 864  7 -10, 24 
CG 203 379 206, 551  5 -8, 18 
1 1 3 rs2854746|| 41.7 
GG 130 4226 4091, 4360  169 158, 179 
CC 17 -345 -745, 55  -9 -37, 20 
CG 119 -119 -296, 57  -4 -17, 8 
1 1 4 rs2471551 19.4 
GG 260 4583 4484, 4682  174 167, 182 
AC 3 698 -233, 1629  46 -20, 113 -- -- -- rs9282734|| 0.4 
AA 393 4520 4439, 4601  172 166, 178 
-- -- -- rs2453837 0 GG 397 4524 4444, 4605  172 167, 178 
AG 5 394 -330, 1119  33 -18, 85 -- -- -- rs6953668 0.6 
GG 394 4522 4441, 4603  172 166, 178 
AA 62 -425 -670, -181  6 -11, 24 
AG 203 -188 -366, -10  -2 -15, 11 
1 1 5 rs3110697 41.4 
GG 131 4693 4554, 4832  172 162, 182 
AA 12 -535 -1008, -62  -3 -37, 31 
AC 121 -45 -221, 131  -6 -18, 7 
2 1 6 rs2453840 18.3 
CC 263 4560 4461, 4658  174 167, 182 
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CC 14 -325 -760, 111  -5 -36, 26 
CT 131 -114 -285, 57  -10 -22, 2 
2 -- -- rs2453839 20.1 
TT 250 4574 4474, 4675  176 169, 183 
AA 12 74 -402, 551  -22 -56, 12 
AT 145 79 -90, 249  -2 -14, 10 
Outside 2 1 rs6670 21.2 
TT 240 4494 4390, 4598  174 166, 181 
AA 19 39 -343, 421  -4 -31, 24 
AG 131 42 -131, 216  4 -8, 16 
Outside 2 2 rs13223993 21.4 
GG 244 4522 4419, 4624  171 164, 179 
TT 15 -316 -743, 112  -15 -45, 16 
CT 137 -15 -186, 156  3 -9, 15 
3 2 3 rs2270628 21.0 
CC 247 4544 4441, 4646  172 165, 179 
 AC, CC 118 -119 -296, 59  -5 -17, 8 3 2 4 rs12671457 16.5 
AA 267 4558 4460, 4657   174 167, 181 
  NOTE: MAF, minor allele frequency. 
   *  Blocks consist of SNPs with MAF ≥ 5% in strong linkage disequilibrium (LD) (95% of pairwise SNP comparisons with one-sided 95% confidence  
intervals for the D prime statistic within 0.7-0.98).  Group refers to SNP combination for diplotype estimation.  Position refers to SNP order in each group for 
diplotype estimation; the position for each group begins with “1”.  Values for diplotype group and position (--) were not listed for SNPs excluded from 
diplotype estimation based on either: 1) Tagger algorithm (r
2
 ≥ 0.8);  2) MAF < 5% (excluded from blocks (--)).  rs2453840 (block 2) was combined with 
block 1 SNPs for diplotype estimation.  rs6670 and rs13223993 were combined with block 3 SNPs for diplotype estimation. 
  †  Based on total N = 402. 
  ‡  Total N = 401, excluded 1 woman missing plasma IGFBP-3 and IGF-I levels. 
  §  β’s (95% CIs) in last row of each SNP represent the mean plasma IGFBP-3 or IGF-I levels for homozygous wildtype genotypes (reference) estimated  
from linear regression intercepts.  β’s for heterozygous and homozygous variant genotypes represent differences in the mean plasma IGFBP-3 or IGF-I levels 
for the reference genotypes estimated from linear regression.     
  ||  SNPs selected a priori.  rs2854744 is also known as -202 A/C; rs2854746 and rs9282734, nonsynonymous SNPs. 
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Table 4.3. Unadjusted linear regression of IGFBP-3 single nucleotide polymorphisms (SNPs) on plasma IGFBP-3 and IGF-I 
levels among African Americans 
 
Plasma IGFBP-3 (ng/mL)   Plasma IGF-I (ng/mL) 
Block* 
Diplotype 
Group* 
Diplotype 
Position* 
SNP Reference 
ID 
 MAF 
(%)† 
Genotype N‡ 
β§ 95% CI§   β§ 95% CI§ 
GT, GG 97 -131 -318, 55  5 -12, 21 Outside 1 1 rs903889 9.4 
TT 471 4108 4031, 4185  164 157, 171 
CC 95 -560 -761, -360  -17 -35, 1 
CT 251 -276 -427, -125  -8 -21, 5 
1 -- -- rs924140 38.9 
TT 222 4304 4194, 4414  171 161, 181 
CC 107 -534 -728, -339  -13 -31, 4 
AC 258 -258 -412, -105  -8 -21, 6 
1 1 2 rs2854744|| 42.2 
AA 195 4305 4190, 4421  171 161, 181 
CC 52 897 656, 1138  8 -14, 30 
CG 259 458 318, 598  7 -6, 20 
1 1 3 rs2854746|| 32.1 
GG 256 3798 3699, 3897  161 152, 170 
CC 27 -465 -796, -133  -24 -53, 5 
CG 173 -258 -412, -105  -8 -21, 5 
1 1 4 rs2471551 20.3 
GG 364 4193 4106, 4280  169 161, 176 
AC, CC 36 24 -263, 311  -13 -38, 12 -- 1 5 rs9282734|| 3.3 
AA 532 4079 4007, 4151  166 159, 172 
-- -- -- rs2453837 0 GG 568 4083 4012, 4154  165 159, 171 
AG, AA 55 -124 -362, 115  -16 -37, 4 1 1 6 rs6953668 5.0 
GG 513 4094 4020, 4169  166 160, 173 
AA 78 -551 -764, -338  -19 -37, 0 
AG 251 -365 -513, -217  -13 -26, 0 
Outside 1 7 rs3110697 36.1 
GG 238 4325 4219, 4431  173 164, 182 
AC, AA 98 209 24, 394  6 -10, 22 2 2 1 rs2453840 9.2 
CC 470 4045 3969, 4122  164 157, 170 
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CC 93 -167 -380, 45  2 -16, 20 
CT 279 -28 -186, 129  -3 -17, 11 
2 2 2 rs2453839 40.9 
TT 194 4130 4009, 4251  166 156, 176 
AT, AA 133 -44 -210, 121  -9 -23, 6 3 3 1 rs6670 12.6 
TT 434 4100 4020, 4180  167 160, 174 
AA 116 -17 -216, 182  -7 -24, 10 
AG 264 -147 -308, 14  -6 -20, 8 
3 3 2 rs13223993 43.6 
GG 184 4163 4039, 4286  169 158, 180 
TT 83 84 -131, 300  17 -2, 35 
CT 247 -64 -218, 90  -6 -19, 8 
4 3 3 rs2270628 36.2 
CC 236 4101 3991, 4211  165 155, 174 
 AC, CC 55 -218 -456, 21  12 -9, 32 4 3 4 rs12671457 5.1 
AA 510 4106 4032, 4181   163 157, 170 
  NOTE: MAF, minor allele frequency. 
  *  Blocks consist of SNPs with MAF ≥ 5% in strong linkage disequilibrium (LD) (95% of pairwise SNP comparisons with one-sided 95% confidence  
intervals for the D prime statistic within 0.7-0.98).  Group refers to SNP combination for diplotype estimation.  Position refers to SNP order in each group for 
diplotype estimation; the position for each group begins with “1”.  Values for diplotype group and position (--) were not listed for SNPs excluded from 
diplotype estimation based on either: 1) Tagger algorithm (r
2
 ≥ 0.8);  2) MAF < 5% (excluded from blocks (--)) or MAF < 3% for SNPs selected a priori.  
rs903889 and rs3110697 were combined with block 1 SNPs for diplotype estimation.  SNPs in blocks 3 and 4 were combined together for diplotype 
estimation.       
  † Based on total N = 582. 
  ‡ Total N = 574, excluded 8 women missing plasma IGFBP-3 and IGF-I levels. 
  §  β’s (95% CIs) in last row of each SNP represent the mean plasma IGFBP-3 or IGF-I levels for homozygous wildtype genotypes (reference) estimated  
from linear regression intercepts.  β’s for heterozygous and homozygous variant genotypes represent differences in the mean plasma IGFBP-3 or IGF-I  
levels for the reference genotypes estimated from linear regression.     
  ||  SNPs selected a priori.  rs2854744 is also known as -202 A/C; rs2854746 and rs9282734, nonsynonymous SNPs. 
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Table 4.4. Unadjusted linear regression of IGF-I single nucleotide polymorphisms (SNPs) on plasma IGFBP-3 and IGF-I levels 
among Caucasians 
 
Plasma IGFBP-3 (ng/mL)   Plasma IGF-I (ng/mL) 
Block* 
Diplotype 
Group* 
Diplotype 
Position* 
SNP 
Reference ID 
 MAF 
(%)† 
Genotype N‡ 
β§ 95% CI §   β§ 95% CI§  
AG, AA  116 -20 -197, 157  5 -7, 18 Outside 1 1 rs35767 16.0 
GG 280 4525 4429, 4620  171 164, 177 
AG, GG 30 240 -65, 546  21 -1, 42 -- -- -- rs5742612 3.9 
AA 368 4506 4422, 4590  171 165, 177 
CG 14 227 -211, 665  18 -14, 49 -- -- -- rs5742614 1.8 
GG 385 4518 4436, 4600  172 166, 178 
-- -- -- rs3729846|| 0 CC 399 4528 4447, 4608  172 166, 178 
AA 21 235 -130, 601  0 -26, 27 
AG 139 52 -119, 223  5 -8, 17 
1 2 1 rs12821878 22.7 
GG 237 4494 4390, 4598  171 163, 178 
TT 31 -188 -499, 123  -5 -28, 17 
AT 170 29 -140, 198  6 -6, 18 
1 -- -- rs10860869 29.1 
AA 196 4532 4417, 4647  170 162, 179 
 AC, AA 93 98 -93, 288  10 -4, 23 1 2 2 rs1019731 12.3 
CC 304 4509 4417, 4601  170 164, 177 
CC 29 -167 -486, 152  -5 -28, 18 
CT 160 -3 -173, 166  2 -10, 14 
1 2 3 rs7956547 27.3 
TT 209 4541 4429, 4652  172 164, 180 
CT 4 -255 -1058, 548  -3 -61, 54 -- -- -- rs5742626 0.5 
TT 394 4522 4442, 4603  172 166, 178 
AG 1 -607 -2223, 1008  -78 -193, 37 -- -- -- rs17880975 0.1 
GG 395 4531 4450, 4613  173 167, 178 
AG, AA  47 -139 -389, 111  5 -13, 22 2 3 1 rs2033178 6.2 
GG 349 4537 4451, 4623  172 166, 178 
-- -- -- rs17884646 0 TT 397 4523 4443, 4603  172 166, 178 
AG, GG 17 29 -370, 428  18 -11, 46 -- -- -- rs5742657 2.2 
AA 383 4524 4442, 4607  171 166, 177 
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GT 1 -519 -2131, 1093  12 -103, 127 -- -- -- rs5742663 0.1 
TT 396 4532 4451, 4613  172 167, 178 
AG 18 107 -282, 496  16 -12, 43 -- -- -- rs11829586 2.3 
GG 380 4524 4441, 4606  172  166, 178 
TT 25 -251 -587, 85  -16 -40, 8 
CT 153 -128 -296, 40  0 -12, 12 
2 -- -- rs4764884 25.7 
CC 218 4588 4481, 4696  173 165, 181 
AG 1 -512 -2116, 1092  12 -102, 127 -- -- -- rs5742683 0.1 
AA 396 4525 4445, 4606  172 166, 178 
-- -- -- rs17884626|| 0 CC 399 4526 4445, 4607  172 167, 178 
TT 36 -223 -513, 67  -6 -27, 15 
CT 167 -52 -221, 117  6 -6, 18 
2 -- -- rs5009837 30.3 
CC 192 4564 4449, 4680  170 162, 178 
CC 15 -273 -700, 155  -4 -35, 27 
CG 123 -78 -254, 98  -4 -17, 8 
2 3 2 rs17727841 19.1 
GG 261 4559 4459, 4658  174 167, 181 
CC 37 -237 -525, 50  -8 -29, 12 
CT 167 -60 -230, 110  4 -8, 17 
2 -- -- rs4764883 30.9 
TT 186 4577 4460, 4694  171 163, 179 
AA 28 -315 -636, 5  -16 -39, 7 
AT 166 -107 -274, 60  3 -9, 15 
2 -- -- rs9308315 28.2 
TT 201 4590 4478, 4703  172 164, 180 
TT 28 -313 -634, 8  -13 -37, 10 
CT 164 -114 -281, 53  4 -8, 16 
2 3 3 rs978458 28.0 
CC 202 4590 4478, 4702  172 163, 180 
AG 17 27 -373, 426  18 -11, 46 -- -- -- rs5742692 2.1 
AA 382 4526 4444, 4609  171 166, 177 
AG, AA  76 -181 -385, 23  -4 -19, 10 2 -- -- rs11111262 9.9 
GG 321 4567 4478, 4657  173 167, 180 
GG 13 -539 -989, -88  -33 -65, 0 
CG 124 -164 -337, 9  7 -6, 19 
2 3 4 rs1520220 19.1 
CC 258 4590 4491, 4688  171 164, 178 
  
 
1
1
3
 
CT 18 -206 -595, 183  -24 -52, 3 -- -- -- rs3730204 2.3 
TT 378 4538 4455, 4621  173 168, 179 
TT 67 178 -59, 414  17 0, 34 
CT 183 -59 -236, 119  -2 -14, 11 
Outside 3 5 rs6214 39.8 
CC 148 4524 4392, 4656  170 161, 180 
CT, TT 78 -200 -402, 3  -6 -20, 9 3 4 1 rs6219 10.0 
CC 321 4565 4476, 4655  174  167, 180 
AA 39 -287 -571, -3  -7 -28, 13 
AG 181 -78 -248, 92  1 -11, 13 
3 4 2 rs2946834 33.0 
GG 175 4585 4463, 4706   172 164, 181 
 NOTE: MAF, minor allele frequency. 
  *  Blocks consist of SNPs with MAF ≥ 5% in strong linkage disequilibrium (LD) (95% of pairwise SNP comparisons with one-sided 95% confidence  
intervals for the D prime statistic within 0.7-0.98).  Group refers to SNP combination for diplotype estimation.  Position refers to SNP order in each group for 
diplotype estimation; the position for each group begins with “1”.  Values for diplotype group and position (--) were not listed for SNPs excluded from 
diplotype estimation based on either: 1) Tagger algorithm (r
2
 ≥ 0.8);  2) MAF < 5% (excluded from blocks (--)).  rs6214 was combined with block 2 SNPs for 
diplotype estimation. 
  †  Based on total N = 402. 
  ‡  N = 401, excluded 1 woman missing plasma IGFBP-3 and IGF-I levels. 
  §  β’s (95% CIs) in last row of each SNP represent the mean plasma IGFBP-3 or IGF-I levels for homozygous wildtype genotypes (reference) estimated  
from linear regression intercepts.  β’s for heterozygous and homozygous variant genotypes represent differences in the mean plasma IGFBP-3 or IGF-I levels 
for the reference genotypes estimated from linear regression.     
  ||  SNPs selected a priori.  rs3729846, synonymous SNP; rs17884626, nonsynonymous SNP. 
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Table 4.5. Unadjusted linear regression of IGF-I single nucleotide polymorphisms (SNPs) on plasma IGFBP-3 and IGF-I levels 
among African Americans 
 
Plasma IGFBP-3 (ng/mL)   Plasma IGF-I (ng/mL) 
Block* 
Diplotype 
Group* 
Diplotype 
Position* 
SNP Reference 
ID 
 MAF 
(%)†  
Genotype N‡ 
β§  95% CI§    β§ 95% CI§ 
AA 99 40 -166, 245  -1 -19, 17 
AG 264 -68 -224, 89  -2 -16, 11 
1 1 1 
 
rs35767 40.8 
GG 205 4109 3992, 4227  166 156, 176 
 AG, GG 35 154 -139, 448  5 -20, 31 -- -- -- rs5742612 3.3 
AA 536 4079 4006, 4152  164 158, 171 
CG, CC 124 -48 -219, 123  8 -6, 23 1 1 2 rs5742614 11.5 
GG 444 4097 4017, 4177  163 156, 170 
CT 9 291 -266, 848  33 -16, 82 -- -- -- rs3729846|| 0.8 
CC 557 4070 3999, 4140  164 158, 170 
AG, AA  64 -180 -404, 43  -15 -34, 5 Outside 1 3 rs12821878 5.8 
GG 505 4106 4031, 4181  167 160, 173 
TT 59 265 23, 507  11 -10, 32 
AT 249 54 -95, 202  12 -1, 25 
Outside 2 1 rs10860869 32.3 
AA 262 4034 3930, 4137  158 149, 167 
AC 39 -140 -420, 140  -10 -34, 14 -- -- -- rs1019731 3.4 
CC 528 4096 4023, 4170  165 159, 172 
CC 43 152 -118, 422  8 -16, 32 
CT 210 73 -75, 221  10 -3, 23 
2 2 2 rs7956547 26.2 
TT 314 4042 3949, 4136  160 152, 168 
CT, CC 78 27 -178, 233  -8 -26, 9 2 2 3 rs5742626 7.2 
TT 491 4084 4007, 4160  166 159, 173 
AG 26 319 -19, 657  8 -21, 38 -- -- -- rs17880975 2.3 
GG 540 4075 4002, 4147  165 158, 171 
AG, AA  50 -135 -385, 115  -24 -46, -3 -- -- -- rs2033178 4.7 
GG 513 4099 4025, 4174  167 161, 174 
-- -- -- rs17884646 0 TT 570 4084 4014, 4155  165 159, 171 
  
 
1
1
5
 
AG, GG 128 75 -94, 243  3 -11, 18 2 -- -- rs5742657 12.1 
AA 440 4063 3984, 4143  164 157, 170 
GT, GG 123 102 -69, 274  8 -6, 23 2 -- -- rs5742663 11.6 
TT 444 4063 3983, 4143  163 156, 170 
AG, AA 121 116 -56, 288  7 -8, 22 2 -- -- rs11829586 11.5 
GG 445 4054 3974, 4133  163 156, 170 
TT 34 102 -202, 405  10 -16, 36 
CT 200 11 -140, 162  5 -8, 18 
2 2 4 rs4764884 23.7 
CC 333 4073 3981, 4165  162 154, 170 
AG, GG 113 112 -65, 289  5 -11, 20 2 -- -- rs5742683 10.6 
AA 454 4061 3982, 4140  164 157, 171 
CT 11 104 -408, 617  13 -31, 57 -- -- -- rs17884626|| 1.0 
CC 559 4085 4014, 4156  164 158, 171 
TT 105 135 -67, 337  8 -9, 26 
CT 260 96 -61, 254  10 -3, 24 
Outside 2 5 rs5009837 41.3 
CC 203 4014 3896, 4132  158 148, 168 
CG, CC 49 74 -178, 326  23 1, 44 -- -- -- rs17727841 4.7 
GG 520 4079 4005, 4153  163 156, 169 
TT 132 -128 -321, 66  -12 -29, 5 
CT 248 -105 -270, 60  -11 -25, 3 
3 -- -- rs4764883 45.8 
CC 180 4169 4043, 4295  173 162, 183 
TT 150 -85 -277, 107  -12 -28, 5 
AT 262 -94 -264, 76  -11 -26, 4 
3 3 1 rs9308315 49.8 
AA 152 4145 4009, 4280  173 161, 185 
TT 83 113 -104, 329  9 -10, 28 
CT 259 72 -82, 226  7 -6, 20 
3 -- -- rs978458 37.5 
CC 224 4039 3926, 4151  160 151, 170 
GG 11 69 -443, 581  14 -31, 58 
AG 111 120 -58, 299  4 -12, 19 
3 3 2 rs5742692 11.7 
AA 444 4054 3974, 4134  164 157, 170 
AG, AA 27 81 -252, 413  40 11, 68 -- -- -- rs11111262 2.7 
GG 536 4083 4010, 4155  163 157, 169 
  
 
1
1
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GG 73 112 -113, 336  10 -9, 29 
CG 250 111 -40, 263  6 -7, 19 
3 3 3 rs1520220 34.7 
CC 245 4024 3917, 4132  161 151, 170 
CT 3 -736 -1711, 239  6 -79, 90 -- -- -- rs3730204 0.3 
TT 562 4097 4026, 4168  165 159, 171 
CC 124 -63 -259, 133  -3 -20, 14 
CT 263 61 -102, 223  -4 -18, 10 
Outside 3 4 rs6214 45.2 
TT 178 4068 3942, 4193  167 156, 178 
 CT, TT 94 60 -130, 251  16 -1, 32 4 4 1 rs6219 9.1 
CC 475 4074 3996, 4151  162 155, 169 
AA 142 149 -49, 346  16 0, 33 
AG 279 52 -119, 223  2 -12, 17 
4 4 2 rs2946834 49.3 
GG 147 4026 3888, 4165   159 147, 171 
  NOTE: MAF, minor allele frequency. 
  *  Blocks consist of SNPs with MAF ≥ 5% in strong linkage disequilibrium (LD) (95% of pairwise SNP comparisons with one-sided 95% confidence intervals 
for the D prime statistic within 0.7-0.98).  Group refers to SNP combination for diplotype estimation.  Position refers to SNP order in each group for 
diplotype estimation; the position for each group begins with “1”.  Values for diplotype group and position (--) were not listed for SNPs excluded from 
diplotype estimation based on either: 1) Tagger algorithm (r
2
 ≥ 0.8);  2) MAF < 5% (excluded from blocks (--)).  rs12821878 was combined with block 1 
SNPs for diplotype estimation.  rs10860869 and rs5009837 were combined with block 2 SNPs for diplotype estimation.  rs9308315 was substituted for  
rs4764883 (Hardy-Weinberg p value <0.01).  rs6214 was combined with block 3 SNPs for diplotype estimation. 
  †  Based on total N = 582. 
  ‡  Total N = 574, excluded 8 women missing plasma IGFBP-3 and IGF-I levels. 
  §  β’s (95% CIs) in last row of each SNP represent the mean plasma IGFBP-3 or IGF-I levels for homozygous wildtype genotypes (reference) estimated  
from linear regression intercepts.  β’s for heterozygous and homozygous variant genotypes represent differences in the mean plasma IGFBP-3 or IGF-I levels 
for the reference genotypes estimated from linear regression.     
  ||  SNPs selected a priori.  rs3729846, synonymous SNP; rs17884626, nonsynonymous SNP.  
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CHAPTER V 
PAPER 2: ASSOCIATION OF IGF-I AND IGFBP-3 POLYMORPHISMS WITH 
UTERINE LEIOMYOMATA AMONG AFRICAN AMERICAN AND 
CAUCASIAN WOMEN 
 
 
Abstract 
Uterine leiomyomata (fibroids) are responsible for substantial morbidity, especially 
among African Americans.  Insulin-like growth factor-I (IGF-I), a potent mitogen, is 
hypothesized to be involved in fibroid pathogenesis based on gene expression studies, 
and IGFBP-3 may be involved in IGF-I mediated mechanisms based on influencing 
bioavailability of IGF-I.  We evaluated 30 IGF-I and 15 IGFBP-3 SNPs and estimated 
diplotypes in relation to fibroid prevalence (any and 2+ cm) among 984 premenopausal 
African American and Caucasian women.  We noted associations between IGF-I and 
IGFBP-3 variants and fibroids, but findings with diplotypes generally did not support 
SNP associations.  Relatively precise IGF-I and IGFBP-3 SNP variant associations with 
magnitudes of at least 10% were predominantly reported among African Americans, 
including functionally relevant IGFBP-3 SNPs of rs9282734 (nonsynonymous) (overall: 
PD = -0.130, 95% CI: -0.294, 0.034) and rs2475551 (splice site) (overall: PD = 0.208, 
95% CI: 0.095, 0.320) and IGF-I SNP rs35767 (promoter) (overall: PD = 0.208, 95% CI: 
0.095, 0.320).  Associations with larger fibroids were generally consistent or slightly 
weaker than associations with any fibroids, and did not provide stronger evidence for
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IGF-I involvement in promoting growth rather than tumorigenesis.  This is the first 
epidemiologic study to evaluate IGF-I and IGFBP-3 variants in relation to fibroids.  In 
conclusion, this study provides support for hypothesis of IGF-I involvement with 
fibroids.  Future research should validate findings in other populations represented by 
African Americans and examine other genes involved in the IGF-I pathway.    
 
Introduction 
Uterine leiomyomata (fibroids) are hormonally-dependent benign tumors of smooth 
muscle origin that are the principal indication for hysterectomies in the United States (1, 
2).  Age and ethnicity have been the most consistently reported risk factors for uterine 
fibroids, with advancing age until menopause and African American versus Caucasian 
race associated with an increased incidence of fibroids and related morbidity (3-7).  The 
National Institute of Environmental Health Sciences (NIEHS) Uterine Fibroid Study, 
which used ultrasound screening to detect fibroids in cohort participants, estimated that 
the risk of fibroids by age 50 is over 80% among African Americans and over 60% 
among Caucasians (3).      
Estrogens and progesterones are hypothesized to promote fibroid development and 
growth by accelerating the activity of cytokines and growth factors (8).  In particular, 
insulin-like growth factor-I (IGF-I), a polypeptide with structural similarities to insulin, 
has been implicated in fibroid etiology based on in vitro promotion of fibroid cell growth 
(9) and evidence of increased IGF-I mRNA or peptides (10-16) in fibroids relative to 
normal myometrium.  A recent study reported elevated IGF-I mRNA and protein after 
estrogen treatment in fibroids relative to normal myometrium, in addition to relative 
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changes in levels of two IGF-I pathway factors (17).  IGF Binding Protein-3 (IGFBP-3) 
binds approximately 90% of circulating IGF-I (18), and may contribute to IGF-I 
mediated pathogenic mechanisms. Although biologic evidence supporting IGFBP-3 
involvement with uterine fibroids is limited, one gene expression study found elevated 
IGFBP-3 mRNA in fibroids compared to normal myometrium (16).    
We examined whether IGF-I and IGFBP-3 were associated with uterine fibroid 
development and growth by evaluating relations between IGF-I and IGFBP-3 
polymorphisms and the prevalence of uterine fibroids.  Specifically, we evaluated 45 
single nucleotide polymorphisms (SNPs) in IGF-I and IGFBP-3 and estimated diplotypes 
(paired haplotypes) in association with the prevalence of  1) all fibroids versus no fibroids 
and 2) larger (>2cm) fibroids versus small fibroids or no fibroids among premenopausal 
African American and Caucasian participants in the National Institute for Environmental 
Health Sciences (NIEHS) Uterine Fibroid Study. 
 
Methods 
 
Study population 
The study population consisted of 984 premenopausal women (582 African 
Americans and 402 Caucasians) with available DNA samples for genotyping from the 
NIEHS Uterine Fibroid Study (UFS).  The parent study was designed to estimate the 
prevalence of uterine leiomyomata (fibroids) among African American and Caucasian 
women, and to evaluate potential etiologic factors for fibroids.  The consent form 
specified use of biological samples for genetic polymorphism analyses.  Details of the 
parent study, which was approved by the NIEHS and George Washington University 
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Human Subject’s Review Boards, were previously described (3, 19, 20).  Briefly, 
participants in the parent study were recruited from a random sample of 35 to 49-year old 
George Washington University health plan members.  Approximately 20% of eligible 
women refused participation, resulting in a total of 1,430 participants enrolled between 
1996 through 1999 (19).   
We restricted the current study population to women who self-reported their race as 
African American or Caucasian (n = 1,323) to facilitate race-specific analyses, and 
excluded women who were postmenopausal at enrollment since they were not asked to 
participate in ultrasound screening and blood collection (n = 178).  Race and menopausal 
status criteria were met by 1,145 women, and DNA was extracted for 984 of the 1,003 
women with collected blood samples.   
Uterine fibroid assessment 
Many women have asymptomatic fibroids; therefore, the parent study conducted 
ultrasound screening of premenopausal participants to provide a better estimate of fibroid 
prevalence than previous studies based on clinical diagnosis or treatment by 
hysterectomy only.  Both transabdominal and transvaginal ultrasound procedures were 
performed by trained sonographers certified by the American Registry of Diagnostic 
Medical Sonographers under the supervision of a radiologist who verified their 
assessments.  Information collected by sonographers included the size and location of the 
two largest fibroids and the number of tumors within the uterus (3).  Study sonograms 
were not performed for women who had a recent ultrasound at the clinic that conducted 
UFS study sonograms; instead, medical records were abstracted to obtain fibroid 
information for these women (N = 204, approximately 20% of the current study sample).  
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In addition, 19 women in our study sample were classified with regard to the size and 
presence of fibroids based on self-reported previous diagnoses only.  Fibroid status could 
not be assessed in seven African Americans and eight Caucasians in our study sample; 
however, these women were genotyped based on analyses with other outcomes including 
circulating IGF-I and IGFBP-3 levels (not shown in current paper).   
Selection of genetic polymorphisms 
 
Race-specific haplotype-tagging SNPs in IGF-I and IGFBP-3 were selected using 
Genome Variation Server (GVS) software (sponsored by the Seattle SNPs Program for 
Genomic Applications (PGA)) (21).  We used the Seattle SNPs database as the reference 
population for IGF-I, and the HapMap database for IGFBP-3, which has not been 
evaluated by Seattle SNPs (21).  In addition to SNPs within each gene, we included SNPs 
within 5 kilobases (kb) of the 5’ and 3’ ends of IGF-I and IGFBP-3, and used a value of 
0.8 as the pairwise correlation coefficient (r
2
) for identifying haplotype-tagging SNPs.  
We selected only haplotype-tagging SNPs with a minor allele frequency (MAF) greater 
than 5% among women in at least one racial group.  There were 29 haplotype-tagging 
SNPs for IGF-I and 12 haplotype-tagging SNPs for IGFBP-3 overall.  In addition, we 
selected four SNPs a priori based on functional significance, including one 
nonsynonymous IGF-I SNP (rs17884626), one synonymous IGF-I SNP (rs3729846), and 
two nonsynonymous IGFBP-3 SNPs (rs2854746, rs9282734) and an IGFBP-3 promoter 
SNP (-202 A/C, rs2854744) a priori based on previous studies of associations with 
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Sample collection and genotyping 
Blood specimens were collected through venipuncture after an 8-hour fast.  Genomic 
DNA was initially extracted from whole blood using a phenol:chloroform procedure, but 
was later replaced by a safer and more efficient modified salt precipitation procedure 
(GenQuik Protocol).  Genotyping was performed using the TaqMan genotyping approach 
(30-32) at an outside laboratory (Mammalian Genotyping Core, Lineberger 
Comprehensive Cancer Center; Chapel Hill, NC).  Allele-specific oligonucleotide probes 
for 39 selected SNPs were purchased from Applied Biosystems (ABI; Foster City, CA) 
“TaqMan® Validated and Coding SNP or Pre-Designed SNP Genotyping Assays”.  In 
addition, ABI attempted to develop custom assays for the 6 remaining SNPs through their 
“Custom TaqMan® SNP Genotyping Assays” service.  Two of the initially selected IGF-
I haplotype tagging SNPs were removed from analyses, including one for which a custom 
assay could not be developed and one with a pre-designed assay that did not meet ABI 
technical specifications.  We also genotyped an alternate IGF-I haplotype-tagging SNP 
after one seemed inconsistent with Hardy-Weinberg equilibrium among African 
Americans.  Thus, 30 IGF-I and 15 IGFBP-3 SNPs were genotyped, including 40 
haplotype-tagging SNPs and 5 SNPs selected a priori. 
PCR amplification was performed on an ABI GeneAmp® PCR System 9700 thermal 
cycler with dual 384-well-blocks, and endpoint plates were read using the ABI 7900HT 
system.  VIC and 6-FAM reporter dyes were used as the fluorescent signals to distinguish 
wild type and variant alleles.  Alleles were called automatically through Sequence 
Detection System (SDS) 2.3 software, and confirmed through a review of all output by 
experienced operators.  The DNA concentration of each sample was validated using a 
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NanoDrop® ND-1000 Spectrophotometer prior to dilution to 5 ng/ul (using DNA grade 
sterile water).  Samples were placed into eleven 96-well microtiter plates and aliquoted 
into three 384-well PCR plates for analysis.  Each of the eleven microtiter plates 
contained four randomly assigned controls, including two blank samples and two with a 
known DNA standard (Control DNA CEPH Individual 1347-02, ABI).  Quality control 
measures also included blinded genotyping of 28 duplicate samples representing 22 
women, which produced concordant results for all samples.  The overall call rate was 
98.8%, and only 5 women had less than 50% of complete allele calls for the 45 SNPs 
assayed.  We confirmed that SNP genotype frequencies were consistent with Hardy-
Weinberg equilibrium (HWE) within each racial group using the exact test statistic with 
one degree of freedom (α = 0.01) (33).   
Diplotype estimation 
In addition to estimating associations with individual SNPs, we estimated 
associations with race-specific diplotypes (paired haplotypes) imputed for groups of 
related SNPs within each gene, as described below.  We excluded SNPs from race-
specific diplotype analyses if their MAF was below 5% (for haplotype-tagging SNPs) or 
3% (for a priori SNPs) within the racial category being evaluated.  In addition, women 
missing genotype data for more than 50% of the SNPs relevant for diplotype estimation 
within a gene were excluded from diplotype analyses for that gene (one Caucasian and 
three African Americans for IGFBP-3, three Caucasians and two African Americans for 
IGF-I).  We then evaluated race-specific linkage disequilibrium (LD) patterns using 
Haploview software (34) to identify SNPs in each gene that could be grouped together to 
estimate diplotypes.  First, we identified blocks consisting of individual SNPs (with MAF 
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at least 5%) in LD based on 95% of pairwise SNP comparisons with one-sided 95% 
confidence intervals for the D prime statistic within 0.7 to 0.98 (35).  Next, we used the 
Tagger approach (36) in Haploview to identify pairs of redundant SNPs in strong LD 
(pairwise r
2
 values ≥ 0.8), and excluded one member of each redundant pair from 
diplotype estimation unless both SNPs had been selected a priori.  Race-specific pairwise 
r
2
 values are available for IGFBP-3 and IGF-I SNPs in Tables A.1-A.4.  
Race-specific diplotypes for defined groups of SNPs were then estimated using 
PHASE version 2.1 (37, 38), which uses a Markov chain-Monte Carlo (MCMC) 
algorithm to allocate the most likely diplotypes for each person, with the prior 
assumption that frequently observed haplotypes with less ambiguity are more probable.  
PHASE also provides a posterior probability estimate that expresses the uncertainty 
associated with each diplotype assignment.  To simplify diplotype analyses, we created 
race-specific groups for diplotype estimation by combining individual SNPs that were not 
included in a block with adjacent blocks, and combined adjacent blocks with each other, 
if doing so resulted in diplotypes that were estimated with at least 90% certainty 
(posterior probability) for at least 90% of individuals within the racial category.  
Otherwise, diplotype groups represented SNPs within a single block, or individual SNPs 
that were not included in a block.  We assigned women to their most probable diplotype 
for each group; however, if their most probable diplotype had a posterior probablility 
below 90%, we classified women as missing for that diplotype group. 
Statistical analysis 
All statistical analyses were stratified by race and conducted using SAS V9.1 (SAS 
Institute Inc., Cary, NC).  We estimated race-specific prevalence differences (PDs) for 
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associations between IGF-I and IGFBP-3 gene variants and prevalent fibroids, including 
associations with individual SNPs and associations with race-specific diplotypes.  We 
performed separate analyses to 1) estimate associations between gene variants and any 
uterine fibroids versus no uterine fibroids, and 2) estimate associations with fibroids at 
least 2 cm in diameter versus no fibroids and fibroids < 2cm.  The latter analysis focuses 
on women with moderate to larger fibroids to explore the hypothesis that IGF-I 
stimulates fibroid growth rather than incidence.  We reported unadjusted associations 
since there are no known factors other than race that would predict both fibroids and gene 
variants.  We estimated 95% confidence intervals for crude prevalence differences (PD) 
in SAS V9.1, which calculates standard errors from the square root of the sum of the 
fibroid prevalence variances based on formula for independent proportions.  For 
diplotype analyses, we used Poisson regression with the robust variance option in PROC 
GENMOD to estimate prevalence differences with 95% confidence intervals (39).   
For the analysis of individual SNPs, we first considered a codominant (general) 
model of inheritance in which heterozygous and homozygous variant genotypes were 
separately evaluated relative to the homozygous wildtype genotype.  Codominant models 
make the fewest assumptions with regard to the inheritance pattern but could be used 
only for common variants.  Therefore, for less common variants, we used a dominant 
model in which we combined homozygous variant and heterozygous genotypes and 
compared to those with the homozygous wildtype genotype.  Associations with 
individual SNPs were not estimated if there were 5 or fewer women in a racial group with 
heterozygous and homozygous variant genoypes combined. 
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We estimated associations between IGF-I or IGFBP-3 diplotypes and fibroids using 
separate race-specific models for each diplotype group, with the most common diplotype 
as the reference category.  Diplotypes assigned to 5 or fewer women were combined into 
a “rare diplotype” category.  We used a Bayesian method of information-weighted 
averaging (40) to improve the validity and precision of estimates.  This method shrinks 
imprecise estimates based on smaller numbers of observations further toward the prior 
mean than more precise regression estimates.  Since we did not have information to 
group diplotypes according to the direction or strength of their potential associations with 
fibroids, we assumed a prior mean of 0, and specified a prior variance, (0.5/3.92)
2
 ≈ 
0.016, that assumed with 95% probability that regression estimates would vary within a 
range of ± 0.25.  For each diplotype, we applied the shrinkage estimator and report 
posterior medians (50
th
 percentile of the posterior probability distribution) and 95% 
posterior limits (2.5
th
 and 97.5
th
 percentiles of the posterior probability distribution).  
Regression estimates and 95% confidence intervals estimated directly by Poisson 
regression with robust variances are available in Tables A.15-A.22. 
 
Results 
 
Participant characteristics 
The study population included 582 African American women and 402 Caucasian 
women that were similar with regard to age (35 to 49 years) based on the study design.  
The overall prevalence of fibroids was 72% among African Americans and 50% among 
Caucasians, with 56% of African Americans having at least one fibroid that was 2 cm 
diameter or larger, compared with 33% of Caucasians (Table 5.1).   
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IGFBP-3 SNPs  
We emphasize SNP associations where fibroid prevalence is increased or decreased 
by at least 10% with variant genotypes relative to homozygous wildtype genotypes, and 
we consider less support for imprecise associations based on small numbers with variant 
genotypes under comparison.  Among Caucasians, the homozygous variant versus the 
homozygous wildtype genotypes for two SNPs (rs2453840, rs2453839) in strong LD 
(pairwise r
2
 value = 0.87) were inversely associated with any fibroids (rs2453840: PD = -
0.105; 95% CI: -0.390, 0.181; rs2453839: PD = -0.088; 95% CI: -0.354, 0.179), but were 
positively associated with larger fibroids (at least 2 cm in diameter) (rs2453840: PD = 
0.077, 95% CI: -0.208, 0.362; rs2453839: PD = 0.091, 95% CI: -0.175, 0.357) (Table 
5.2).  In addition, the homozygous variant versus the homoyzygous wildtype genotypes 
for two SNPs (rs903889, rs2270628) were positively associated with any fibroids 
(rs903889: PD = 0.095, 95% CI: -0.120, 0.310; rs2270628: PD = 0.104, 95% CI: -0.152, 
0.360), but only rs2270628 variants were associated with larger fibroids (PD = 0.149; 
95% CI: -0.111, 0.408).  These two SNPs (rs903889, rs2270628) were not in LD with 
each other nor with any SNPs associated with fibroids (pairwise r
2
 values < 0.2).  
Associations with all four SNPs noted above were imprecise based on fewer than 25 
observations with homozygous variant genotypes.   
Among African Americans, there was an association in the opposite direction to 
Caucasians between rs903889 (combined GT and GG versus TT genotypes) and any 
fibroids (PD = -0.113; 95% CI: -0.216, -0.010), but no association with larger fibroids 
(Table 5.3).  In addition, there were fibroid associations with three additional SNPs 
(rs2471551, rs9282734, rs12671457) among African Americans that were not reported 
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for Caucasians.  The homozygous variant genotype (CC) for rs2471551 was positively 
associated with any fibroids (PD = 0.208; 95% CI: 0.095, 0.320) and larger fibroids (PD 
= 0.167; 95% CI: -0.011, 0.345) relative to the homozygous wildtype genotype (GG), 
with little difference in the prevalence of either fibroid outcome in association with the 
CG genotype.  The combined AC and CC genotypes for the rare rs9283734 
(nonsynonymous, MAF ≈ 3%) and the rs12671457 (MAF ≈ 5%) SNPs were inversely 
associated with prevalence of any fibroids (rs9282734: PD = -0.130; 95%CI: -0.294, 
0.034; rs12671457: PD = -0.081, 95% CI: -0.213, 0.050) and larger fibroids (rs9282734: 
PD = -0.135, 95%CI: -0.303, 0.032; rs12671457: 0.121; 95% CI: -0.259, 0.018) relative 
to the AA genotype.  None of the SNPs with reported fibroid associations among African 
Americans were in LD with each other (pairwise r
2
 values < 0.4). 
IGFBP-3 diplotypes 
We generally emphasize associations between diplotypes and fibroid prevalence 
based on posterior medians with magnitudes of at least 10%, and we focus on more 
precise associations where diplotypes represent at least 10 women.  Patterns of IGFBP-3 
diplotype associations among either Caucasians or African Americans could not be 
explained by associations with individual IGFBP-3 SNPs.  Among Caucasians, IGFBP-3 
group 1 diplotypes (TACGGA/TACGGC, TCGCAC/TCGCAC) relative to the referent 
diplotype (TACGGC/GCGGAC) were inversely associated with prevalence of any 
fibroids (TACGGA/TACGGC: -0.102, 95% posterior limits: -0.274, 0.070;  
TCGCAC/TCGCAC: -0.111, 95% posterior limits: -0.297, 0.076) and larger fibroids (at 
least 2 cm in diameter) (TACGGA/TACGGC: -0.105, 95% posterior limits: -0.268, 
0.057; TCGCAC/TCGCAC:  -0.138, 95% posterior limits: -0.308, 0.032) (Figure 5.1).  
  
 133
The IGFBP-3 group 2 diplotype of TACA/TGCA, was inversely associated with 
prevalence of any fibroids (-0.078, 95% posterior limits: -0.225, 0.069) and larger 
fibroids (-0.069, 95% posterior limits: -0.203, 0.066).   Despite representing a weaker 
association with fibroid prevalence (<10%), it was a relatively precise estimate based on 
greater than 10% (n = 51) of Caucasians with the TACA/TGCA diplotype.    
Among African Americans, two IGFBP-3 group 1 diplotypes 
(TCGCAGA/GCGGAGA, TCGCAGA/TCGCAGA) were positively associated with 
prevalence of any fibroids (TCGCAGA/GCGGAGA: 0.112, 95% posterior limits: -0.048, 
0.272; TCGCAGA/TCGCAGA: 0.158; 95% posterior limits: 0.035, 0.281) and larger 
fibroids (TCGCAGA/GCGGAGA: 0.187, 95% posterior limits: 0.026, 0.349; 
TCGCAGA/TCGCAGA: 0.086, 95% posterior limits: -0.072, 0.243) relative to the 
referent diplotype (TAGGAGG/TACGAGG) (Figure 5.2).  Three IGFBP-3 group 3 
diplotypes (TACA/AGCA, TGCA/TGCA, TGTC/TGCA) were inversely associated with 
prevalence of larger fibroids (TACA/AGCA: -0.158, 95% posterior limits: -0.336, 0.020; 
TGCA/TGCA: -0.137, 95% posterior limits: -0.250, -0.023; TGTC/TGCA: -0.120; 95% 
posterior limits: -0.306, 0.065) relative to the referent diplotype (TATA/TGCA), with 
slightly smaller associations with any fibroids.  Of the three IGFBP-3 group 3 diplotypes 
noted above, only the TGCA/TGCA diplotype represented a considerable proportion of 
African American women in our study population (18%, n = 104).   
IGF-I SNPs  
We focus on SNPs where fibroid prevalence is increased or decreased by at least 
10% with variant genotypes relative to homozygous wildtype genotypes, and we place 
less emphasis on imprecise associations based on small numbers with variant genotypes 
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under comparison.  Among Caucasians, prevalence of any fibroids was decreased in 
association with homozygous variant genotypes of rs12821878 (PD = -0.111, 95% CI: -
0.335, 0.113) and rs2946834 (PD = -0.119, 95% CI: -0.289, 0.052) and increased in 
association with homozygous variant genotypes of rs10860869 (PD = 0.133, 95% CI: -
0.053, 0.320) and rs7956547 (PD = 0.114, 95% CI: -0.079, 0.308) relative to 
homozygous wildtype genotypes, with weaker associations estimated in the same 
direction with larger fibroids (Table 5.4).  The pairwise r
2
 value for rs10860869 and 
rs7956547 was 0.91, indicating strong LD among Caucasians, but neither rs12821878 nor 
rs2946834 were in strong LD with each other or with either of the two former IGF-I 
SNPs.  Imprecise associations based on fewer than 20 women with variants were 
estimated between the prevalence of any fibroids and the heterozygous genotypes (no 
homozygous variants) for the rare rs5742614 (MAF ≈ 2%) (PD = -0.159; 95% CI: -0.415, 
0.097) and rs3730204 (MAF ≈ 2%) (PD = 0.116; 95% CI: -0.127, 0.358) SNPs relative to 
homozygous wildtype genotypes, but no associations were evident for larger fibroids.   
Among African Americans, there were three common SNPs (rs35767, rs5742614, 
rs4764884) with fibroid associations.  Specifically, rs35767 AA versus GG genotypes 
and rs4764884 TT versus CC genotypes were positively associated with prevalence of 
any fibroids (rs35767: PD = 0.116, 95% CI: 0.015, 0.216; rs4764884: PD = 0.094, 95% 
CI: -0.040, 0.227) and larger fibroids (rs35767: PD = 0.104, 95% CI: -0.012, 0.221; 
rs4764884: 0.097, 95% CI: -0.069, 0.263), which no fibroid associations with either SNP 
were noted among Caucasians (Table 5.5).  The combined CG and CC genotypes versus 
the GG genotype for rs5742614 were inversely associated with prevalence of any fibroids 
(PD = -0.120; 95% CI: -0.215, -0.026 and larger fibroids (PD = -0.144; 95% CI: -0.243, -
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0.044).  Neither of these three SNPs (rs35767, rs5742614, rs4764884) were in LD with 
each other (pairwise r
2
 values < 0.1) among African Americans.  Positive associations 
between two rare (MAF < 5%) SNP variants and prevalence of overall (rs17880975: PD 
= 0.113, 95% CI: -0.036, 0.262; rs11111262: PD = 0.135, 95% CI: 0.004, 0.266) and 
larger fibroids (rs17880975: PD = 0.157, 95% CI: -0.024, 0.338; rs11111262: PD = 
0.163, 95% CI: -0.005, 0.331) were noted relative to homozygous wildtype genotypes.  
IGF-I diplotypes 
We highlighted diplotype associations with fibroid prevalence based on posterior 
medians with magnitudes of at least 10% and more precise associations where diplotypes 
represent at least 10 women.  Among Caucasians, four IGF-I group 3 diplotypes 
(GGCCC/GCTGC: -0.139, 95% posterior limits: -0.290, 0.012; GGCCC/GGCCC: -
0.107, 95% posterior limits: -0.236, 0.021; GGCCT/AGTGC: -0.119, 95% posterior 
limits: -0.298, 0.060; GGCCT/GGCCT: -0.161, 95% posterior limits: -0.313, -0.009) 
versus referent diplotype (GGCCC/GGCCT) were inversely associated with prevalence 
of any fibroids (Figure 5.3).  Weaker inverse associations with larger fibroids were noted 
for the GGCCC/GCTGC and GGCCT/GGCCT diplotypes, with a stronger inverse 
association for the GGCCT/AGTGC diplotype (-0.162; 95% posterior limits: -0.313, -
0.011).  However, there was no association with larger fibroids for the common 
GGCCC/GGCCC diplotype representing almost 20% of Caucasians (n = 76).  Two IGF-I 
group 4 diplotypes (versus the referent diplotype CG/CG) were inversely associated with 
prevalence of any fibroids (CA/CA: -0.104, 95% posterior limits: -0.267, 0.059; CG/TA: 
-0.077, 95% posterior limits: -0.203, 0.050) and larger fibroids (CA/CA: -0.128, 95% 
posterior limits: -0.273, 0.016; CG/TA: -0.080, 95% posterior limits: -0.198, 0.039).  The 
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latter diplotype (CG/TA) has a weaker association with fibroids (<10%), but estimates 
are relatively precise based on approximately 15% (n = 59) of Caucasians with CG/TA 
diplotype.  There were no patterns in individual SNP associations to explain any of the 
estimated Caucasian IGF-I diplotype associations. 
Among African Americans, the IGF-I group 1 GGG/GCG diplotype, which 
represented approximately 10% of women (n = 55), was inversely associated with 
prevalence of any fibroids (-0.132, 95% posterior limits: -0.257, -0.007) and larger 
fibroids (-0.134, 95% posterior limits: -0.261, -0.006) compared to the referent diplotype 
(AGG/GGG) (Figure 5.4).  The IGF-I group 2 TTTCT/TCTTT diplotype was inversely 
associated with any fibroids (-0.131, 95% posterior limits: -0.314, 0.052), while there was 
a positive association between the TCTTT/TCTTT diplotype and fibroids of any size 
(0.122, 95% posterior limits: 0.001, 0.243) relative to the referent diplotype 
(ATTCC/ATTCC), with weaker associations for both diplotypes estimated with larger 
fibroids.  The latter diplotype (TCTTT/TCTTT) was the only common diplotype that 
included the TT genotype for rs4764884, which was positively associated with fibroids.  
Three IGF-I group 3 diplotypes (versus the referent TACT/TACT diplotype) were 
inversely associated with any fibroids, including AACC/AGGT (-0.156, 95% posterior 
limits: -0.340, 0.028), AACT/TACT (-0.101, 95% posterior limits: -0.289, 0.086), and 
AAGC/AACC (-0.087, 95% posterior limits: -0.232, 0.057), but only the AACC/AGGT 
(-0.124, 95% posterior limits: -0.303, 0.055) diplotype was associated with larger 
fibroids.  There were no consistent patterns in estimated associations with individual 
IGF-I SNPs and any of the African American diplotypes, with the exception of the IGF-I 
group 3 TCTTT/TCTTT diplotype.   
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Discussion 
This is the first study to evaluate IGF-I and IGFBP-3 polymorphisms in association 
with the prevalence of fibroids.  In summary, we noted fibroid prevalence among African 
Americans was associated with five IGF-I (rs35767, rs5742614, rs17880975, rs4764884, 
rs11111262) and four IGFBP-3 (rs903889, rs2471551, rs9282734, rs12671457) SNPs, 
which included two IGF-I (rs17880975, rs11111262) and two IGFBP-3 SNPs 
(rs9282734, rs12671457) with MAF 5% or less.  However, among Caucasians, fibroid 
prevalence was associated with six IGF-I SNPs (rs5742614, rs12821878, rs10860869, 
rs7956547, rs3730204, rs2946834) and four IGFBP-3 SNPs (rs903889, rs2453840, 
rs2453839, rs2270628); however, the majority of associations, including three IGF-I 
SNPs (rs5742614, rs12821878, rs3730204) and four IGFBP-3 SNPs, were relatively 
imprecise due to fewer than 25 observations with variant genotypes.   
Only one of the fibroid associations involved an a priori selected SNP, the rare 
(MAF ≈ 3%) nonsynonymous IGFBP-3 rs9282734 SNP (His158Pro), in which variants 
were inversely associated with fibroids of any size and at least 2 cm in diameter among 
African Americans.  This SNP could not be evaluated among Caucasians, since less than 
five women had the variant genotypes.  Based on protein sequencing analysis reported in 
the UniProtKB/Swiss-Prot database (41), the amino acid coded by rs9282734 is not 
within the protein region affiliated with IGF binding but instead is within a 
compositionally biased region of the IGFBP-3 protein, which is predominantly rich with 
serine and threonine.  Associations with other health outcomes or circulating IGFBP-3 
protein levels have not been reported with this SNP.    
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We reported strong positive associations between another functionally relevant 
IGFBP-3 SNP (rs2471551 CC versus GG genotypes) and fibroid prevalence among 
African Americans.  Specifically, rs2471551 is located at a splice site (intron 1 within 
less than 20 kb of exon 2).  Inverse associations with CC versus GG variants were also 
estimated with circulating IGFBP levels among Caucasians and African Americans in our 
study (not published).  In addition, Canzian et al.(22) reported that rs2471551 
(homozygous variant versus homozygous wildtype genotypes) was inversely associated 
with circulating IGFBP-3 but not with circulating IGF-I or with breast cancer for a 
predominantly Caucasian case-control study nested within the European Prospective 
Investigation into Cancer and Nutrition.  Inverse associations were also reported among 
African Americans between fibroids and two IGFBP-3 SNPs, with possible functional 
effects based on their location outside the 5’ (rs903889) and 3’ (rs12671457) ends of the 
gene; however, other studies have not reported associations with health outcomes or 
circulating levels with these SNPs.  Our study estimated associations between rs903889 
and plasma IGFBP-3 and IGF-I among Caucasians, and associations with plasma IGFBP-
3 only among African Americans (unpublished).  
Relatively imprecise associations between IGFBP-3 SNPs (rs903889, rs2453840, 
rs2453839, rs2270628) and fibroids among Caucasians are likely to be spurious findings, 
especially given that the association with rs2453830 and rs2453839 are in the opposite 
direction with larger fibroids.  Canzian et al. reported that rs2453839 was not associated 
with circulating IGF-I or IGFBP-3 levels or with breast cancer (22).  Also, Tamimi et al. 
estimated no association between IGFBP-3 SNPs, including rs2453839 and rs2270628, 
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and mammographic density among Nurses’ Heath Study controls nested within a breast 
cancer case-control study (42).  
We estimated a positive association between a common IGF-I SNP (rs35767 AA 
versus GG genotypes), which is located within the promoter region, and fibroids among 
African Americans.  Canzian et al. reported inverse associations for rs35767 homozygous 
variant versus homozygous wildtype genotypes with circulating IGFBP-3 and breast 
cancer among a predominantly Caucasian study population (22).  In addition, a common 
IGF-I SNP (rs2946834 AA versus GG genotypes), which is located downstream of IGF-I 
at the 3’ end, was inversely associated with fibroids among Caucasians.  Tamimi et al. 
reported an inverse association for rs2946834 AA versus GG genotypes and percentage 
mammographic density within the Nurses’ Health Study (42).    
Current biological evidence supports a role of IGF-I in fibroid pathogenesis, but is 
lacking for IGFBP-3; however, we hypothesized that IGFBP-3 may indirectly affect 
fibroid pathogenesis by influencing levels of bioavailable IGF-I.  Studies have found 
increased IGF-I mRNA and peptides in fibroids versus normal myometrium (10-16) and 
in fibroids versus normal myometrium in response to estrogen treatment, as well as 
decreases in IGF-I mRNA and protein in response to progesterone (43).  Overall, these 
findings support the hypothesis that fibroid tumorigenesis or growth may be promoted by 
hormonally-mediated alteration of cytokines or growth factors (8).  However, since IGF-I 
is a strong mitogen, we would expect that IGF-I or IGFBP-3 variant associations with 
larger fibroids would be stronger than those with fibroids of any size. 
From previous unpublished analyses in the NIEHS UFS, plasma IGF-I levels were 
inversely associated with fibroid prevalence among Caucasians but not African 
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Americans, while plasma IGFBP-3 levels were not associated with fibroids.  We did not 
find support for fibroid associations with the common nonsynonymous IGFBP-3 SNP of 
rs2854746 or with the rs2854744 (-202 A/C) SNP, both of which were associated with 
plasma IGFBP-3 levels among both Caucasians and African Americans in NIEHS 
Uterine Fibroid Study (cite 1
st
 paper).  However, lack of fibroid associations with 
circulating IGF-I or IGFBP-3 levels or with SNPs strongly predicting circulating levels 
does not negate involvement of IGF-I or IGFBP-3 in fibroid etiology since biological 
evidence for IGF-I in fibroid pathogenesis emphasizes IGF-I levels in the uterine tissue 
rather than the circulation.  In addition, IGF-I or IGFBP-3 variants associated with 
circulating IGF-I or IGFBP-3 may not predict levels within uterine tissue. 
A major strength of our study was the high proportion of African Americans, who 
have consistently been reported to have a greater prevalence of fibroids and fibroid-
related morbidity than Caucasians (3, 4, 6, 7).  Etiologically relevant SNPs between races 
may differ based on differences in race-specific distributions of respective genotypes.  
Given racial differences in fibroid prevalence, it was not surprising that we noted more 
evidence for associations with IGF-I and IGFBP-3 variants among African Americans 
based on relative precision of estimates within racial groups.  We were able to examine 
associations with not only overall fibroid prevalence, but also with larger fibroids (at least 
2 cm in diameter) to assess whether IGF-I and IGFBP-3 variants might influence tumor 
growth versus incidence.  Associations with two fibroid outcomes were generally in the 
same direction, but typically there were slightly stronger associations with any fibroids 
rather than larger fibroids, which was not expected since IGF-I is known for its growth-
promoting actions.  However, differences between analyses were not consistent and large 
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enough to suggest that genetic variants may be more relevant for incidence rather than 
growth of fibroids.  Our study based fibroid status predominantly on ultrasound screening 
rather than clinical diagnosis or treatment by hysterectomy alone, which reduced the 
potential for misclassification bias if IGF-I or IGFBP-3 variants were associated with the 
incidence of all fibroid tumors, regardless of size.   
We restricted our study to Caucasians and African Americans and stratified all 
analyses by race; however, population stratification within each racial group may still be 
a potential bias with our study (44-47).  In addition, we did not have statistical power to 
explore whether gene-environmental interactions could further explain findings.  Race-
specific diplotype associations with fibroids generally did not support patterns with SNP 
associations, suggesting that diplotype associations may be either due to spurious 
findings or if etiologically relevant may be due to interactions between the SNPs within 
the particular diplotype group.  We attempted to reduce spurious findings for less 
common diplotypes by using a Bayesian method of information-weighted averaging that 
increased the precision of estimates, particularly for diplotypes with small numbers of 
women; however, these methods were not applied to individual SNP associations.  
Despite the increase in bias for posterior medians from this method, simulation studies 
indicate that there is a reduction in the overall mean square error based on the greater 
decrease in variance of estimates (48).     
Since fibroids represent a common health outcome related to substantial morbidity, 
even IGF-I or IGFBP-3 variant associations with magnitudes of less than 20% as 
reported in our study could be important.  Some of the reported SNP or diplotype 
associations may reflect random error or bias, especially associations based on small 
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numbers with SNP variant or diplotype.  Validation of findings with other study 
populations well-represented by African Americans would be important for assessing 
whether any of the IGF-I and IGFBP-3 SNPs are relevant with fibroid etiology.  Future 
research should also consider other genes besides IGF-I and IGFBP-3 that are involved 
with the IGF-I pathway based on support for IGF-I involvement with fibroid 
pathogenesis.   
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Table 5.1. Uterine fibroid status of premenopausal women with genotype 
information by race from NIEHS Uterine Fibroid Study  
 
Uterine fibroids African American (N=582) 
N (%) 
 Caucasian (N=402) 
N (%) 
None 154 (26.5)  194 (48.3) 
Any 421 (72.3)  200 (49.8) 
<2 cm 94 (16.2)  69 (17.2) 
2 - <4 cm 187 (32.1)  87 (21.6) 
≥4 cm 140 (24.1)  44 (10.9) 
Missing 7 (1.2)  8 (2.0) 
  
 
1
4
9
 
Table 5.2. Unadjusted prevalence differences (PD) and 95% confidence intervals (CI) for uterine fibroids in association with 
IGFBP-3 single nucleotide polymorphisms (SNPs) among Caucasians 
 
Uterine Fibroids (any) Uterine Fibroids (2+ cm) 
Block* 
Diplotype 
Group* 
Diplotype 
Position* 
SNP Reference 
ID 
 
MAF 
(%)† 
Genotype 
N(any 
fibroids):  
total N‡ PD§ 95% CI 
 
N(2+ cm 
fibroids): 
total N‡ 
 
PD§ 95% CI 
GG 13:22 0.095 -0.120, 0.310 7:22 -0.008 -0.212, 0.195 
GT 67:128 0.028 -0.080, 0.135 45:128 0.025 -0.077, 0.127 
1 1 1 rs903889 22.0 
TT 120:242 0  79:242 0  
TT 38:80 -0.039 -0.184, 0.106 23:80 -0.012 -0.143, 0.120 
CT 106:205 0.003 -0.114, 0.120 76:205 0.072 -0.037, 0.181 
1 -- -- rs924140 46.8 
CC 55:107 0  32:107 0  
AA 36:77 -0.047 -0.193, 0.100 22:77 -0.013 -0.146, 0.120 
AC 104:199 0.009 -0.109, 0.126 75:199 0.078 -0.032, 0.188 
1 1 2 rs2854744|| 46.3 
CC 55:107 0  32:107 0  
CC 32:63 -0.019 -0.170, 0.131 18:63 -0.040 -0.178, 0.098 
CG 99:199 -0.030 -0.140, 0.081 71:199 0.031 -0.074, 0.136 
1 1 3 rs2854746|| 41.7 
GG 68:129 0  42:129 0  
CC 7:16 -0.063 -0.313, 0.188 5:16 -0.026 -0.261, 0.208 
CG 64:119 0.038 -0.071, 0.147 39:119 -0.011 -0.113, 0.092 
1 1 4 rs2471551 19.4 
GG 127:254 0  86:254 0  
AC 1:3 --   1:3 --   -- -- -- rs9282734|| 0.4 
AA 199:386 0  130:386 0  
-- -- -- rs2453837 0 GG 199:390 --  130:390 --  
AG 1:5 --   1:5 --   -- -- -- rs6953668 0.6 
GG 199:387 0  130:387 0  
AA 32:62 0.036 -0.116, 0.187 18:62 -0.043 -0.182, 0.096 
AG 106:198 0.055 -0.056, 0.166 70:198 0.020 -0.085, 0.125 
1 1 5 rs3110697 41.4 
GG 62:129 0  43:129 0  
  
 
1
5
0
 
AA 5:12 -0.105 -0.390, 0.181 5:12 0.077 -0.208, 0.362 
AC 59:118 -0.021 -0.130, 0.088 38:118 -0.018 -0.120, 0.084 
2 1 6 rs2453840 18.3 
CC 135:259 0  88:259 0  
CC 6:14 -0.088 -0.354, 0.179 6:14 0.091 -0.175, 0.357 
CT 64:128 -0.016 -0.123, 0.091 42:128 -0.009 -0.110, 0.091 
2 -- -- rs2453839 20.1 
TT 127:246 0  83:246 0  
AT, AA 85:155 0.068 -0.034, 0.169 57:155 0.053 -0.044, 0.149 Outside 2 1 rs6670 21.2 
TT 113:235 0  74:235 0  
AA 9:19 -0.041 -0.274, 0.192 5:19 -0.069 -0.276, 0.138 
AG 65:127 -0.003 -0.110, 0.105 45:127 0.022 -0.080, 0.125 
Outside 2 2 rs13223993 21.4 
GG 124:241 0  80:241 0  
TT 9:15 0.104 -0.152, 0.360 7:15 0.149 -0.111, 0.408 
CT 71:135 0.030 -0.075, 0.135 47:135 0.030 -0.070, 0.130 
3 2 3 rs2270628 21.0 
CC 120:242 0  77:242 0  
 AC, CC 61:117 0.020 -0.090, 0.128 40:117 0.009 -0.095, 0.112 3 2 4 rs12671457 16.5 
AA 131:261 0  87:261 0  
  NOTE: MAF, minor allele frequency. 
  * Blocks consist of SNPs with MAF ≥ 5% in strong linkage disequilibrium (LD) (95% of pairwise SNP comparisons with one-sided 95% confidence intervals 
for the D prime statistic within 0.7-0.98).  Group refers to combination of SNPs for diplotype estimation.  Position refers to SNP order in each group for 
diplotype estimation.; the position for each group begins with “1”.  Values for diplotype group and position (--) were not listed for SNPs excluded from 
diplotype estimation based on either: 1) Tagger algorithm (r
2
 ≥ 0.8);  2) MAF < 5% (excluded from blocks (--)).  rs2453840 (block 2) was combined with 
block 1 SNPs for diplotype estimation.  rs6670 and rs13223993 were combined with block 3 SNPs for diplotype estimation. 
  † Based on total N = 402. 
  ‡ Total N = 394, excluded 8 women missing uterine fibroid status. 
  § PDs were not estimated for SNPs with 5 or fewer women with combined heterozygous and homozygous variant genotypes. 
  || SNPs selected a priori.  rs2854744 is also known as -202 A/C; rs2854746 and rs9282734, nonsynonymous SNPs. 
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Table 5.3. Unadjusted prevalence differences (PD) and 95% confidence intervals (CI) for uterine fibroids in association with 
IGFBP-3 single nucleotide polymorphisms (SNPs) among African Americans 
 
Uterine Fibroids (any) Uterine Fibroids (2+ cm) 
Block* 
Diplotype 
Group* 
Diplotype 
Position* 
SNP 
Reference ID 
 MAF 
(%)† 
Genotypes 
N(any 
fibroids):  
total N‡ PD 95% CI 
  
N(2+ cm 
fibroids): 
total N‡ 
 
PD 95% CI 
GT, GG 62:97 -0.113 -0.216, -0.010 53:97 -0.030 -0.139, 0.079 Outside 1 1 rs903889 9.4 
TT 355:472 0  272:472 0  
CC 71:93 0.021 -0.083, 0.125 59:93 0.060 -0.058, 0.177 
CT 181:255 -0.032 -0.113, 0.048 137:255 -0.037 -0.127, 0.052 
1 -- -- rs924140 38.9 
TT 164:221 0  127:221 0  
CC 77:105 -0.004 -0.109, 0.101 64:105 0.006 -0.110, 0.122 
AC 189:262 -0.016 -0.098, 0.067 138:262 -0.076 -0.168, 0.015 
1 1 2 rs2854744§ 42.2 
AA 143:194 0  117:194 0  
CC 39:52 0.004 -0.125, 0.133 31:52 0.002 -0.144, 0.149 
CG 185:260 -0.035 -0.111, 0.042 141:260 -0.051 -0.137, 0.034 
1 1 3 rs2854746§ 32.1 
GG 191:256 0  152:256 0  
CC 24:26 0.208 0.095, 0.320 19:26 0.167 -0.011, 0.345 
CG 130:177 0.019 -0.061, 0.099 98:177 -0.010 -0.099, 0.079 
1 1 4 rs2471551 20.3 
GG 259:362 0  204:362 0  
AC, CC 22:36 -0.130 -0.294, 0.034 16:36 -0.135 -0.303, 0.032 -- 1 5 rs9282734§ 3.3 
AA 395:533 0  309:533 0  
-- -- -- rs2453837 0 GG 417:569 --  323:569 --  
AG, AA 36:54 -0.069 -0.201, 0.062 29:54 -0.036 -0.176, 0.104 1 1 6 rs6953668 5.0 
GG 379:515 0  295:515 0  
AA 59:78 0.021 -0.089, 0.132 47:78 0.044 -0.082, 0.169 
AG 181:252 -0.017 -0.096, 0.062 142:252 0.005 -0.083, 0.093 
Outside 1 7 rs3110697 36.1 
GG 175:238 0  133:238 0  
AC, AA 68:98 -0.047 -0.147, 0.052 54:98 -0.022 -0.130, 0.086 2 2 1 rs2453840 9.2 
CC 349:471 0  270:471 0  
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CC 69:94 -0.004 -0.113, 0.104 55:94 0.036 -0.085, 0.158 
CT 200:278 -0.019 -0.100, 0.062 158:278 0.020 -0.071, 0.111 
2 2 2 rs2453839 40.9 
TT 144:195 0  107:195 0  
AT, AA 102:135 0.033 -0.051, 0.117 79:135 0.019 -0.076, 0.115 3 3 1 rs6670 12.6 
TT 313:433 0  245:433 0  
AA 87:114 0.044 -0.057, 0.145 68:114 0.067 -0.047, 0.182 
AG 192:262 0.013 -0.070, 0.097 155:262 0.063 -0.030, 0.155 
3 3 2 rs13223993 43.6 
GG 136:189 0  100:189 0  
TT 62:81 0.056 -0.053, 0.165 45:81 0.012 -0.113, 0.137 
CT 183:245 0.037 -0.042, 0.116 148:245 0.061 -0.027, 0.148 
4 3 3 rs2270628 36.2 
CC 171:241 0  131:241 0  
 AC, CC 36:55 -0.081 -0.213, 0.050 25:55 -0.121 -0.259, 0.018 4 3 4 rs12671457 5.1 
AA 376:511 0  294:511 0  
  NOTE: MAF, minor allele frequency. 
 * Blocks consist of SNPs with MAF ≥ 5% in strong linkage disequilibrium (LD) (95% of pairwise SNP comparisons with one-sided 95% confidence intervals 
for the D prime statistic within 0.7-0.98).  Group refers to combination of SNPs for diplotype estimation.  Position refers to SNP order in each group for 
diplotype estimation; the position for each group begins with “1”.  Values for diplotype group and position (--) were not listed for SNPs excluded from 
diplotype estimation based on either: 1) Tagger algorithm (r
2
 ≥ 0.8);  2) MAF < 5% (excluded from blocks (--)) or MAF < 3% for SNPs selected a priori.  
rs903889 and rs3110697 were combined with block 1 SNPs for diplotype estimation.  SNPs in blocks 3 and 4 were combined together for diplotype 
estimation.       
  † Based on total N = 582. 
  ‡ Total N = 575, excluded 7 women missing uterine fibroid status. 
  § SNPs selected a priori.  rs2854744 is also known as -202 A/C; rs2854746 and rs9282734, nonsynonymous SNPs. 
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Table 5.4. Unadjusted prevalence differences (PD) and 95% confidence intervals (CI) for uterine fibroids in association with 
IGF-I single nucleotide polymorphisms (SNPs) among Caucasians 
 
Uterine Fibroids (any) Uterine Fibroids (2+ cm) 
Block* 
Diplotype 
Group* 
Diplotype 
Position* 
SNP 
Reference ID 
 MAF 
(%)† 
Genotypes 
N(any 
fibroids):  
total N‡ PD§ 95% CI  
  
N(2+ cm 
fibroids): 
total N‡ 
  
PD§ 95% CI  
AG, AA  59:116 -0.001 -0.109, 0.108 40:116 0.012 -0.092, 0.115 Outside 1 1 rs35767 16.0 
GG 139:273 0  91:273 0  
AG, GG 14:30 -0.046 -0.232, 0.140 8:30 -0.074 -0.240, 0.092 -- -- -- rs5742612 3.9 
AA 185:361 0  123:361 0  
CG 5:14 -0.159 -0.415, 0.097 4:14 -0.050 -0.292, 0.191 -- -- -- rs5742614 1.8 
GG 195:378 0  127:378 0  
-- -- -- rs3729846|| 0 CC 200:392 --  131:392 --  
AA 8:20 -0.111 -0.335, 0.113 5:20 -0.082 -0.281, 0.117 
AG 70:135 0.008 -0.098, 0.114 47:135 0.016 -0.084, 0.117 
1 2 1 rs12821878 22.7 
GG 120:235 0  78:235 0  
TT 19:30 0.133 -0.053, 0.320 13:30 0.098 -0.091, 0.288 
AT 83:166 0.000 -0.104, 0.104 52:166 -0.022 -0.119, 0.075 
1 -- -- rs10860869 29.1 
AA 97:194 0  65:194 0  
 AC, AA 41:89 -0.064 -0.182, 0.054 28:89 -0.028 -0.138, 0.083 1 2 2 rs1019731 12.3 
CC 158:301 0  103:301 0  
CC 17:28 0.114 -0.079, 0.308 11:28 0.069 -0.123, 0.261 
CT 81:156 0.027 -0.077, 0.130 53:156 0.016 -0.082, 0.114 
1 2 3 rs7956547 27.3 
TT 102:207 0  67:207 0  
CT 3:4 --  2:4 --  -- -- -- rs5742626 0.5 
TT 196:387  0  129:387  0  
AG 1:1 --  1:1 --  -- -- -- rs17880975 0.1 
GG 199:388 0  130:388 0  
AG, AA  22:48 -0.056 -0.207, 0.094 16:48 0.000 -0.142, 0.142 2 3 1 rs2033178 6.2 
GG 176:342 0  114:342 0  
-- -- -- rs17884646 0 TT 199:390 --  131:390 --  
  
 
1
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AG, GG 8:17 -0.040 -0.283, 0.203 5:17 -0.041 -0.263, 0.181 -- -- -- rs5742657 2.2 
AA 192:376 0  126:376 0  
GT 0:1 --  0:1 --  -- -- -- rs5742663 0.1 
TT 200:389 0  131:389 0  
AG 9:18 -0.009 -0.246, 0.227 6:18 -0.002 -0.225, 0.221 -- -- -- rs11829586 2.3 
GG 190:373 0  125:373 0  
TT 11:24 -0.053 -0.264, 0.157 8:24 -0.002 -0.200, 0.197 
CT 77:150 0.002 -0.103, 0.106 50:150 -0.002 -0.100, 0.097 
2 -- -- rs4764884 25.7 
CC 110:215 0  72:215 0  
AG 0:1 --  0:1 --  -- -- -- rs5742683 0.1 
AA 198:389 0  129:389 0  
-- -- -- rs17884626|| 0 CC 200:392 --  131:392 --  
TT 20:35 0.048 -0.131, 0.226 14:35 0.051 -0.125, 0.227 
CT 80:164 -0.036 -0.141, 0.069 51:164 -0.038 -0.136, 0.060 
2 -- -- rs5009837 30.3 
CC 99:189 0  66:189 0  
CC 6:14 -0.081 -0.347, 0.185 4:14 -0.050 -0.294, 0.193 
CG 61:119 0.003 -0.106, 0.112 39:119 -0.008 -0.110, 0.094 
2 3 2 rs17727841 19.1 
GG 132:259 0  87:259 0  
CC 20:36 0.020 -0.158, 0.198 14:36 0.034 -0.140, 0.207 
CT 78:164 -0.060 -0.165, 0.045 50:164 -0.050 -0.149, 0.049 
2 -- -- rs4764883 30.9 
TT 98:183 0  65:183 0  
AA 13:27 -0.044 -0.245, 0.157 10:27 0.022 -0.172, 0.216 
AT 80:163 -0.035 -0.138, 0.069 52:163 -0.030 -0.127, 0.068 
2 -- -- rs9308315 28.2 
TT 104:198 0  69:198 0  
TT 13:27 -0.041 -0.242, 0.160 10:27 0.024 -0.170, 0.217 
CT 80:161 -0.026 -0.130, 0.078 52:161 -0.024 -0.122, 0.074 
2 3 3 rs978458 28.0 
CC 104:199 0  69:199 0  
AG 8:17 -0.041 -0.284, 0.201 5:17 -0.042 -0.264, 0.180 -- -- -- rs5742692 2.1 
AA 192:375 0  126:375 0  
AG, AA  33:73 -0.068 -0.195, 0.058 24:73 -0.006 -0.125, 0.114 2 -- -- rs11111262 9.9 
GG 165:317 0  106:317 0  
  
 
1
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GG 7:13 0.005 -0.273, 0.283 7:13 0.195 -0.083, 0.472 
CG 55:122 -0.083 -0.190, 0.025 36:122 -0.049 -0.149, 0.051 
2 3 4 rs1520220 19.1 
CC 135:253 0  87:253 0  
CT 10:16 0.116 -0.127, 0.358 5:16 -0.025 -0.257, 0.207 -- -- -- rs3730204 2.3 
TT 190:373 0  126:373 0  
TT 30:66 -0.014 -0.159, 0.131 18:66 -0.086 -0.219, 0.047 
CT 102:180 0.098 -0.011, 0.207 61:180 -0.020 -0.124, 0.085 
Outside 3 5 rs6214 39.8 
CC 68:145 0  52:145 0  
CT, TT 35:75 -0.054 -0.179, 0.072 24:75 -0.018 -0.135, 0.100 3 4 1 rs6219 10.0 
CC 165:317 0  107:317 0  
AA 17:40 -0.119 -0.289, 0.052 12:40 -0.074 -0.234, 0.085 
AG 88:177 -0.047 -0.152, 0.058 55:177 -0.064 -0.163, 0.036 
3 4 2 rs2946834 33.0 
GG 93:171 0  64:171 0  
  NOTE: MAF, minor allele frequency. 
 * Blocks consist of SNPs with MAF ≥ 5% in strong linkage disequilibrium (LD) (95% of pairwise SNP comparisons with one-sided 95% confidence intervals 
for the D prime statistic within 0.7-0.98).  Group refers to SNP combination for diplotype estimation.  Position refers to SNP order in each group for diplotype 
estimation; the position for each group begins with “1”.  Values for diplotype group and position (--) were not listed for SNPs excluded from diplotype 
estimation based on either: 1) Tagger algorithm (r
2
 ≥ 0.8);  2) MAF < 5% (excluded from blocks (--)).  rs6214 was combined with block 2 SNPs for diplotype 
estimation. 
 † Based on total N = 402. 
 ‡ Total N = 394, excluded 8 women missing uterine fibroid status. 
 § PDs were not estimated for SNPs with 5 or fewer women with combined heterozygous and homozygous variant genotypes. 
 || SNPs selected a priori.  rs3729846, synonymous SNP; rs17884626, nonsynonymous SNP.  
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Table 5.5. Unadjusted prevalence differences (PD) and 95% confidence intervals (CI) for uterine fibroids in association with 
IGF-I single nucleotide polymorphisms (SNPs) among African Americans 
 
Uterine Fibroids (any) Uterine Fibroids (2+ cm) 
Block* 
Diplotype 
Group* 
Diplotype 
Position* 
SNP 
Reference ID 
 MAF 
(%)†  
Genotypes 
N(any 
fibroids):  
total N‡ PD§ 95% CI 
 
N(2+ cm 
fibroids): 
total N‡ 
   
PD§ 95% CI 
AA 81:101 0.116 0.015, 0.216 64:101 0.104 -0.012, 0.221 
AG 195:264 0.052 -0.031, 0.135 151:264 0.043 -0.048, 0.133 
1 1 1 
 
rs35767 40.8 
GG 140:204 0  108:204 0  
 AG, GG 27:36 0.021 -0.126, 0.167 22:36 0.048 -0.117, 0.212 -- -- -- rs5742612 3.3 
AA 391:536 0  302:536 0  
CG, CC 77:121 -0.120 -0.215, -0.026 55:121 -0.144 -0.243, -0.044 1 1 2 rs5742614 11.5 
GG 339:448 0  268:448 0  
CT 6:9 -0.066 -0.377, 0.244 4:9 -0.125 -0.453, 0.202 -- -- -- rs3729846|| 0.8 
CC 409:558 0  318:558 0  
AG, AA  47:63 0.014 -0.100, 0.129 37:63 0.021 -0.108, 0.150 Outside 1 3 rs12821878 5.8 
GG 371:507 0  287:507 0  
TT 42:61 -0.038 -0.167,  0.090 34:61 0.015 -0.124, 0.154 
AT 186:250 0.017 -0.060, 0.094 149:250 0.054 -0.032, 0.140 
Outside 2 1 rs10860869 32.3 
AA 189:260 0  141:260 0  
AC 26:38 -0.050 -0.202, 0.103 20:38 -0.045 -0.210, 0.119 -- -- -- rs1019731 3.4 
CC 389:530 0  303:530 0  
CC 35:44 0.071 -0.058, 0.200 27:44 0.066 -0.089, 0.220 
CT 154:212 0.002 -0.076, 0.080 123:212 0.032 -0.054, 0.119 
2 2 2 rs7956547 26.2 
TT 226:312 0  171:312 0  
CT, CC 60:78 0.046 -0.056, 0.147 43:78 -0.016 -0.135, 0.103 2 2 3 rs5742626 7.2 
TT 356:492 0  279:492 0  
AG 21:25 0.113 -0.036, 0.262 18:25 0.157 -0.024, 0.338 -- -- -- rs17880975 2.3 
GG 394:542 0  305:542 0  
AG, AA  33:50 -0.079 -0.216, 0.057 27:50 -0.030 -0.175, 0.115 -- -- -- rs2033178 4.7 
GG 380:514 0  293:514 0  
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-- -- -- rs17884646 0 TT 417:571 --  324:571 --  
AG, GG 91:128 -0.024 -0.112, 0.065 73:128 0.006 -0.092, 0.103 2 -- -- rs5742657 12.1 
AA 324:441 0  249:441 0  
GT, GG 88:123 -0.019 -0.109, 0.070 70:123 0.003 -0.096, 0.102 2 -- -- rs5742663 11.6 
TT 327:445 0  252:445 0  
AG, AA 87:122 -0.022 -0.112, 0.068 71:122 0.018 -0.081, 0.117 2 -- -- rs11829586 11.5 
GG 327:445 0  251:445 0  
TT 29:35 0.094 -0.040, 0.227 23:35 0.097 -0.069, 0.263 
CT 142:201 -0.029 -0.107, 0.050 113:201 0.002 -0.085, 0.089 
2 2 4 rs4764884 23.7 
CC 244:332 0  186:332 0  
AG, GG 80:113 -0.028 -0.121, 0.065 63:113 -0.012 -0.114, 0.091 2 -- -- rs5742683 10.6 
AA 335:455 0  259:455 0  
CT 9:11 0.088 -0.143, 0.319 8:11 0.163 -0.103, 0.429 -- -- -- rs17884626|| 1.0 
CC 409:560 0  316:560 0  
TT 77:107 0.007 -0.099, 0.112 62:107 0.050 -0.066, 0.166 
CT 195:260 0.037 -0.045, 0.119 153:260 0.059 -0.032, 0.150 
Outside 2 5 rs5009837 41.3 
CC 144:202 0  107:202 0  
CG, CC 37:51 -0.005 -0.133, 0.124 29:51 0.004 -0.138, 0.147 -- -- -- rs17727841 4.7 
GG 379:519 0  293:519 0  
TT 97:133 0.026 -0.075, 0.127 70:133 -0.012 -0.124, 0.099 
CT 186:245 0.056 -0.029, 0.141 151:245 0.078 -0.017, 0.173 
3 -- -- rs4764883 45.8 
CC 128:182 0  98:182 0  
TT 112:152 0.047 -0.055, 0.148 80:152 0.004 -0.108, 0.116 
AT 195:258 0.066 -0.024, 0.155 161:258 0.102 0.003, 0.200 
3 3 1 rs9308315 49.8 
AA 107:155 0  81:155 0  
TT 64:85 0.016 -0.092, 0.125 52:85 0.058 -0.064, 0.181 
CT 187:258 -0.012 -0.091, 0.068 147:258 0.016 -0.073, 0.105 
3 -- -- rs978458 37.5 
CC 165:224 0  124:224 0  
AG, GG 89:122 -0.005 -0.094, 0.084 72:122 0.026 -0.073, 0.125 3 3 2 rs5742692 11.7 
AA 327:445 0  251:445 0  
AG, AA 25:29 0.135 0.004, 0.266 21:29 0.163 -0.005, 0.331 -- -- -- rs11111262 2.7 
GG 389:535 0  300:535 0  
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GG 57:74 0.044 -0.067, 0.155 46:74 0.083 -0.044, 0.210 
CG 180:250 -0.007 -0.085, 0.072 143:250 0.033 -0.054, 0.121 
3 3 3 rs1520220 34.7 
CC 178:245 0  132:245 0  
CT 1:3 --  1:3 --  -- -- -- rs3730204 0.3 
TT 414:563 0  322:563 0  
CC 93:125 -0.002 -0.101, 0.010 75:125 0.048 -0.065, 0.160 
CT 185:260 -0.034 -0.118, 0.050 147:260 0.013 -0.081, 0.107 
Outside 3 4 rs6214 45.2 
TT 135:181 0  100:181 0  
 CT, TT 75:96 0.062 -0.030, 0.154 58:96 0.045 -0.063, 0.153 4 4 1 rs6219 9.1 
CC 341:474 0  265:474 0  
AA 111:143 0.042 -0.057, 0.140 88:143 0.058 -0.056, 0.171 
AG 197:279 -0.029 -0.118, 0.061 152:279 -0.013 -0.112, 0.086 
4 4 2 rs2946834 49.3 
GG 108:147 0  82:147 0  
  NOTE: MAF, minor allele frequency. 
  * Blocks consist of SNPs with MAF ≥ 5% in strong linkage disequilibrium (LD) (95% of pairwise SNP       
comparisons with one-sided 95% confidence intervals for the D prime statistic within 0.7-0.98).  Group refers to SNP combination for diplotype estimation.  
Position refers to SNP order in each group for diplotype estimation; the position for each group begins with “1”.  Values for diplotype group and position (--) 
were not listed for SNPs excluded from diplotype estimation based on either: 1) Tagger algorithm (r
2
 ≥ 0.8);  2) MAF < 5% (excluded from blocks (--)).  
rs12821878 was combined with block 1 SNPs for diplotype estimation.  rs10860869 and rs5009837 were combined with block 2 SNPs for diplotype 
estimation.  rs9308315 was substituted for rs4764883 (Hardy-Weinberg p value <0.01).  rs6214 was combined with block 3 SNPs for diplotype estimation. 
  † Based on total N = 582. 
  ‡ Total N = 575, excluded 7 women missing uterine fibroid status. 
  § PDs were not estimated for SNPs with 5 or fewer women with combined heterozygous and homozygous variant genotypes. 
  ||  SNPs selected a priori.  rs3729846, synonymous SNP; rs17884626, nonsynonymous SNP.  
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CHAPTER VI 
 
CONCLUSIONS 
 
Introduction 
Insulin-like growth factor-one (IGF-I), a peptide with structural similarities to 
insulin, is important for many cellular functions including cell cycle regulation, 
differentiation, and inhibition of apoptosis (1).  IGF binding protein-3 (IGFBP-3) 
influences IGF-I bioavailability and degradation but may act independently from IGF-I 
such as inhibiting growth and promoting apoptosis.  Associations with circulating IGF-I 
and IGFBP-3 have been evaluated with cardiovascular disease, diabetes, and cancer.  
Genetic factors are important determinants of circulating IGF-I (2, 3) and IGFBP-3 levels 
(2, 4).   
The common theme with both studies is that we evaluated variation in IGF-I and 
IGFBP-3 through single nucleotide polymorphisms and estimated diplotypes among a 
premenopausal population well-represented by both Caucasians and African Americans.  
Dense evaluation IGF-I and IGFBP-3 SNPs in relation to their circulating levels among 
African Americans has been limited to the Multiethnic Cohort study, which included a 
small African American sample (N = 150) (5).  Based on biological interrelations 
between IGF-I and IGFBP-3, we evaluated whether IGF-I and IGFBP-3 variants were 
associated with circulating levels of both proteins in our first study, which had previously 
been done in only two studies (6, 7).     
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In our second study, we analyzed associations between IGF-I and IGFBP-3 variants 
and prevalence of uterine fibroids.  Uterine fibroids are hormonally dependent benign 
tumors, which are the primary indicator for hysterectomies in the United States, and 
occur disproportionately among African Americans.  However, much of their etiology 
has still not been characterized.  One hypothesis is that estrogens and progesterones 
increase cytokine and growth factor activity, which promotes fibroid development and 
growth.  Tissue-specific evidence supports involvement of IGF-I in fibroid pathogenesis 
including in vitro promotion of fibroid growth (8) and increased IGF-I mRNA or peptides 
(9-15) (16) in fibroids relative to normal myometrium.  In particular, one gene expression 
study measured elevated IGF-I mRNA and protein in addition to changes in two IGF-I 
pathway factors after estrogen treatment (16).  Although tissue-specific evidence 
supporting IGFBP-3 involvement with fibroid etiology is limited to one study with 
elevated IGFBP-3 mRNA in fibroids (15), IGFBP-3 may contribute to IGF-I mediated 
mechanisms based on influence of IGFBP-3 on IGF-I bioavailability and degradation.  
However, no epidemiological study has previously investigated associations between 
variants of either gene and fibroids.   
For both studies, the study population was 984 premenopausal African American and 
Caucasian participants with available DNA from the NIEHS Uterine Fibroid Study.  The 
parent study conducted ultrasound screening of premenopausal women for fibroids to 
estimate their prevalence and investigate etiologic factors (17). 
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Summary of results 
Among African Americans and Causasians, one of the most consistent findings was 
the association between IGFBP-3 rs2854746 (Ala32Gly) and plasma IGFBP-3.  In 
particular, this SNP results in an amino acid change from alanine to glycine, and protein 
sequencing tools suggest that it is located in the region responsible for IGF binding.  We 
reported a dose response relation in which the CC genotype is positively associated with 
plasma IGFBP-3 relative to the GG genotype, with intermediate plasma IGFBP-3 levels 
associated with the CG genotype, which two other studies including the Multiethnic 
Cohort Study reported similar findings (5, 7).  In addition, diplotypes for both racial 
groups support individual rs2854746 associations.  We also reported high plasma IGFBP-
3 levels in association with AA versus CC genotypes of an IGFBP-3 promoter SNP 
(rs2854744, -202 A/C), but consistencies with diplotype findings were not as strong as 
with rs2854746, especially for African Americans.  Seven studies also report similar 
associations between rs2854744 and plasma IGFBP-3 (6, 18-23).  However, previous 
studies of this promoter SNP have been predominantly among Caucasians and have not 
evaluated rs2854746.  We reported strong LD between rs2854744 and rs2854746 among 
Caucasians only (r
2
 = 0.82), which may explain Caucasian associations between 
rs2854744 and plasma IGFBP-3.  Strong LD between these two SNPs was not present 
among African Americans (r
2
 = 0.34).  We also estimated associations between IGF-I 
SNPs and plasma IGF-I although we did not find patterns between SNPs and diplotype 
associations with plasma IGF-I, and other studies evaluating IGF-I SNPs were 
inconsistent with our findings.  
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We found more precise associations for IGF-I and IGFBP-3 SNPs with prevalence 
of fibroids among African Americans than Causasians, which had primarily imprecise 
associations due to 25 or fewer observations with homozygous variants.  In particular, 
two IGFBP-3 SNPs associated with fibroids among African Americans have potential 
functional relevance including rs9282734 (His158Pro),  which results in an amino acid 
change from histidine to proline, and rs2475551, which is located at a splice site within 
less than 20 kilobases (kb) from exon 2.  However, rs9282734 and rs2475551 have not 
been reported to be associated with diseases.  Among a Caucasian study population, 
Canzian et al. reported no association for rs2475551 with breast cancer but an inverse 
association with plasma IGFBP-3 (6), which the latter is consistent with our study 
findings.  Other fibroid associations among African Americans included SNPs outside 
IGFBP-3 at the 5’ (rs903889) and 3’ ends (rs12671457) and a SNP outside IGF-I at the 
5’ end (rs35767), and there was an association with a SNP outside IGF-I at the 3’ end 
(rs2946834) among Caucasians.  For the two IGF-I SNPs noted above, associations with 
mammographic density (rs2946834) (24) and breast cancer (rs35767) (6) have been 
reported among predominantly Caucasian study populations.  Generally, we estimated 
slightly stronger associations in a similar direction with prevalence of any fibroids rather 
than larger fibroids for IGF-I and IGFBP-3 variants; however, differences in fibroid 
analyses were not consistent and substantial enough to conclude that variants 
preferentially affect fibroid incidence versus growth. 
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Strengths and limitations 
The study population was well-represented by African Americans (about 60%), 
which was a major strength for both studies.  In addition, we attempted to capture 
variation across both genes by selecting haplotype-tagging SNPs from race-specific 
reference populations using a pairwise r
2  
value of 0.8.  In particular, the first paper 
contributes information on distribution of SNPs as well as associations with circulating 
IGF-I and IGFBP-3 among African Americans, who have been evaluated with dense 
coverage of IGF-I or IGFBP-3 polymorphisms by only one previous study (5).  For the 
second study, the high proportion of African Americans is particularly relevant given that 
greater prevalence of fibroids and related morbidity has been consistently reported among 
this racial group (17, 25-28). 
We are the first epidemiologic study to evaluate IGF-I and IGFBP-3 variants in 
association with uterine fibroids.  A major strength of our study population is that women 
were screened for uterine fibroids using ultrasounds, which reduces misclassification of 
fibroids since many women with fibroids in the parent study were asymptomatic.  Our 
investigation of the hypothesis that IGF-I would preferentially affect fibroid growth 
versus incidence was limited because we did not have statistical power to evaluate each 
of the fibroid size categories in relation to women with no fibroids.  Instead, we were 
only able to evaluate women with larger fibroids compared to women with small fibroids 
and no fibroids combined.   
Our genotyping was very successful, with only five women having less than 50% of 
complete allele calls for the 45 SNPs in study.  In addition, exclusions from uncertain 
estimated diplotypes (posterior probability < 90%) were negligible since 93 to 99% of 
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women were included for race-specific analyses of each diplotype group.  Given the 
heterogeneity of diplotypes represented within race-specific diplotype groups, validity 
and precision of regression estimates was a potential limitation with analyses.  However, 
we utilized an empirical-Bayes method (information-weighted averaging) (29), which 
shrunk imprecise regression estimates based on smaller numbers of observations further 
toward the prior mean of 0 based than more precise estimates.  Overall mean square error 
is reduced with this method based on a greater reduction in precision than the gain in bias 
with estimates (30).   
Possible selection bias is a limitation for both studies if excluded women differed 
from the remaining study population with respect to their genotypes or study outcomes 
(i.e. circulating protein levels or fibroid status).  To evaluate selection bias, we would 
need to consider not only women who were excluded from both studies because there 
was no DNA available, but also women who were dropped earlier from the study 
population for other reasons including postmenopausal at enrollment and refusal to 
participate.  We restricted study population to only African Americans and Caucasians 
and stratified all analyses by race for both studies, but population stratification could still 
be a bias within racial groups of our study population (31-34).  We had limited power to 
evaluate rare SNPs with both studies.  Rare estimated diplotypes (5 or fewer 
observations) were combined into one category for all analyses, but heterogeneity of 
diplotypes within these categories made interpretation of their estimated associations 
impossible.   Finally, we did not have statistical power to explore gene-environmental or 
gene-gene interactions, which may be relevant to our estimated associations, especially 
with differences in associations across racial groups.      
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 Future research 
Findings from the first study reported associations between several IGF-I and 
IGFBP-3 SNPs and their circulating protein levels.  In particular, we had a highly 
consistent finding with evidence suggesting a causal association between IGFBP-3 
rs2854746 (Ala32Gly) and plasma IGFBP-3 among both Caucasians and African 
Americans.  Validation of this association with rs2854746 and with other SNPs in our 
study would be needed in other study populations.  Further study is needed to assess 
functional significance of the SNPs with reported associations in either of our studies.  
For SNPs that have no known functional relevance, some of their associations with 
circulating protein levels or fibroids may be based on spurious findings, but instead they 
may tag a functional variant or affect expression.  Investigation of SNPs having 
associations with circulating protein levels with risk of cancer and cardiovascular disease 
would further our understanding in whether IGF-I mediated mechanisms and IGFBP-3 
independent actions are involved in their etiology, since issue of confounding would be 
lessened for associations with gene variants, unlike with circulating levels of their 
proteins.   
Given that this is the first epidemiologic study to evaluate IGF-I and IGFBP-3 in 
relation to fibroids, estimated associations cannot be considered conclusive without 
replication in other study populations.  Findings from the second study estimated precise 
associations with fibroids predominantly among African Americans.  Therefore, it would 
be important to replicate our findings within a study population with a substantial 
proportion of African Americans.  Other issues that should be considered in future studies 
are gene-gene interactions and gene-environment since IGF-I and IGFBP-3 have strong 
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biological interrelations, and their tissue-specific and circulating levels may be affected 
by environmental factors.  Finally, other genes involved in the IGF-I pathway should be 
considered to further investigate whether IGF-I is involved with fibroid pathogenesis.   
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APPENDIX 
 
 
 
Table A.1. Pairwise r
2
 between IGFBP-3 single nucleotide polymorphisms (SNPs) among Caucasians* 
 
 SNP rs # 903889 924140 2854744 2854746 2471551 3110697 2453840 2453839 6670 13223993 2270628 12671457 
903889             
924140 0.24            
2854744 0.23 0.99           
2854746 0.19 0.81 0.82          
2471551 0.06 0.16 0.16 0.12         
3110697 0.39 0.55 0.55 0.44 0.32        
2453840 0.04 0.00 0.00 0.00 0.05 0.12       
2453839 0.04 0.00 0.00 0.00 0.04 0.11 0..87      
6670 0.04 0.01 0.01 0.01 0.08 0.00 0.01 0.00     
13223993 0.00 0.05 0.05 0.02 0.03 0.00 0.04 0.04 0.07    
2270628 0.11 0.03 0.03 0.08 0.00 0.06 0.03 0.04 0.07 0.00   
12671457 0.12 0.06 0.06 0.06 0.00 0.09 0.02 0.02 0.05 0.05 0.77   
* Based on N = 401, excludes 1 woman missing more than 50% of IGFBP-3 SNPs included in diplotype estimation.  Excludes SNPs with minor allele  
   frequencies < 1%.  Pairwise r
2
 values ≥ 0.80, which are in bold, indicate SNP pairs in strong linkage disequilibrium. 
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 Table A.2. Pairwise r
2
 between IGFBP-3 single nucleotide polymorphisms (SNPs) among African Americans* 
 
SNP rs # 903889 924140 2854744 2854746 2471551 9282734 6953668 3110697 2453840 2453839 
903889           
924140 0.16          
2854744 0.14 0.82         
2854746 0.04 0.30 0.34        
2471551 0.02 0.38 0.33 0.10       
9282734 0.33 0.05 0.04 0.01 0.00      
6953668 0.28 0.08 0.07 0.02 0.01 0.64     
3110697 0.17 0.65 0.57 0.25 0.45 0.05 0.08    
2453840 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.01   
2453839 0.04 0.02 0.03 0.09 0.00 0.02 0.02 0.04 0.14  
6670 0.00 0.01 0.04 0.01 0.05 0.00 0.00 0.02 0.00 0.03 
13223993 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.03 0.00 
2270628 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.02 0.00 
12671457 0.04 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
* Based on N = 579, excludes 3 women missing more than 50% of IGFBP-3 SNPs included in diplotype estimation.  Excludes SNPs with minor allele  
   frequencies < 1%.  Pairwise r
2
 values ≥ 0.80, which are in bold, indicate SNP pairs in strong linkage disequilibrium. 
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SNP rs # 6670 13223993 2270628 12671457 
903889     
924140     
2854744     
2854746     
2471551     
9282734     
6953668     
3110697     
2453840     
2453839     
6670     
13223993 0.09    
2270628 0.07 0.45   
12671457 0.00 0.00 0.09  
* Based on N = 579, excludes 3 women missing more than 50% of IGFBP-3 SNPs included in diplotype estimation.  Excludes SNPs with minor allele  
   frequencies < 1%.  Pairwise r
2
 values ≥ 0.80, which are in bold, indicate SNP pairs in strong linkage disequilibrium. 
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Table A.3. Pairwise r
2
 between IGF-I single nucleotide polymorphisms (SNPs) among Caucasians* 
 
SNP rs # 35767 5742612 5742614 12821878 10860869 1019731 7956547 2033178 5742657 11829586 4764884 
35767            
5742612 0.21           
5742614 0.00 0.00          
12821878 0.04 0.01 0.00         
10860869 0.00 0.09 0.03 0.12        
1019731 0.02 0.00 0.00 0.47 0.05       
7956547 0.01 0.00 0.03 0.11 0.91 0.05      
2033178 0.35 0.00 0.00 0.01 0.02 0.00 0.02     
5742657 0.07 0.33 0.00 0.00 0.02 0.00 0.00 0.00    
11829586 0.07 0.33 0.00 0.00 0.02 0.00 0.00 0.00 0.88   
4764884 0.03 0.01 0.00 0.10 0.32 0.04 0.38 0.19 0.00 0.00  
5009837 0.10 0.04 0.00 0.12 0.45 0.06 0.39 0.15 0.05 0.04 0.79 
17727841 0.04 0.00 0.00 0.06 0.55 0.03 0.60 0.01 0.00 0.00 0.67 
4764883 0.09 0.04 0.00 0.13 0.45 0.06 0.39 0.15 0.05 0.04 0.78 
9308315 0.06 0.00 0.00 0.11 0.38 0.05 0.32 0.17 0.04 0.04 0.89 
978458 0.06 0.00 0.00 0.10 0.38 0.05 0.32 0.17 0.04 0.04 0.88 
5742692 0.08 0.35 0.00 0.00 0.02 0.00 0.00 0.00 0.94 0.94 0.00 
11111262 0.02 0.00 0.00 0.03 0.25 0.01 0.28 0.00 0.00 0.00 0.32 
1520220 0.13 0.01 0.00 0.06 0.11 0.03 0.07 0.28 0.05 0.05 0.49 
3730204 0.00 0.00 0.00 0.00 0.05 0.00 0.06 0.00 0.00 0.00 0.06 
6214 0.01 0.03 0.01 0.10 0.00 0.03 0.00 0.04 0.01 0.01 0.00 
6219 0.02 0.00 0.00 0.03 0.26 0.01 0.28 0.00 0.00 0.00 0.32 
2946834 0.06 0.02 0.00 0.11 0.04 0.06 0.03 0.13 0.03 0.02 0.20 
* Based on N = 399, excludes 3 women missing more than 50% of IGF-I SNPs included in diplotype estimation.  Excludes SNPs with minor allele  
   frequencies < 1%.  Pairwise r
2
 values ≥ 0.80, which are in bold, indicate SNP pairs in strong linkage disequilibrium. 
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SNP rs # 5009837 17727841 4764883 9308315 978458 5742692 11111262 1520220 3730204 6214 6219 2946834 
35767             
5742612             
5742614             
12821878             
10860869             
1019731             
7956547             
2033178             
5742657             
11829586             
4764884             
5009837             
17727841 0.53            
4764883 0.99 0.53           
9308315 0.88 0.60 0.88          
978458 0.88 0.59 0.87 0.98         
5742692 0.05 0.00 0.05 0.05 0.05        
11111262 0.25 0.47 0.25 0.28 0.28 0.00       
1520220 0.54 0.17 0.53 0.59 0.60 0.06 0.48      
3730204 0.05 0.10 0.05 0.06 0.06 0.00 0.00 0.00     
6214 0.00 0.00 0.00 0.00 0.00 0.01 0.07 0.08 0.03    
6219 0.25 0.46 0.25 0.28 0.28 0.00 0.97 0.48 0.00 0.07   
2946834 0.31 0.05 0.31 0.25 0.26 0.02 0.22 0.47 0.01 0.02 0.23   
* Based on N = 399, excludes 3 women missing more than 50% of IGF-I SNPs included in diplotype estimation.  Excludes SNPs with minor allele  
   frequencies < 1%.  Pairwise r
2
 values ≥ 0.80, which are in bold, indicate SNP pairs in strong linkage disequilibrium. 
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Table A.4. Pairwise r
2
 between IGF-I single nucleotide polymorphisms (SNPs) among African Americans* 
 
SNP rs # 35767 5742612 5742614 12821878 10860869 1019731 7956547 5742626 17880975 2033178 5742657 
35767            
5742612 0.05           
5742614 0.09 0.00          
12821878 0.04 0.00 0.00         
10860869 0.07 0.07 0.02 0.02        
1019731 0.02 0.00 0.00 0.56 0.01       
7956547 0.04 0.06 0.03 0.02 0.75 0.01      
5742626 0.08 0.00 0.01 0.00 0.03 0.00 0.02     
17880975 0.02 0.00 0.00 0.00 0.01 0.00 0.00 0.00    
2033178 0.00 0.00 0.00 0.00 0.02 0.00 0.03 0.00 0.00   
5742657 0.02 0.00 0.00 0.00 0.00 0.00 0.04 0.01 0.00 0.00  
5742663 0.01 0.00 0.00 0.00 0.00 0.00 0.03 0.01 0.00 0.00 0.88 
11829586 0.01 0.00 0.00 0.00 0.01 0.00 0.03 0.01 0.00 0.00 0.88 
4764884 0.05 0.00 0.03 0.01 0.48 0.01 0.65 0.01 0.00 0.15 0.04 
5742683 0.01 0.00 0.00 0.00 0.00 0.00 0.04 0.00 0.00 0.00 0.86 
17884626 0.01 0.29 0.00 0.00 0.02 0.00 0.02 0.00 0.00 0.00 0.00 
5009837 0.00 0.03 0.04 0.03 0.57 0.01 0.42 0.04 0.01 0.06 0.17 
17727841 0.03 0.00 0.00 0.00 0.10 0.00 0.13 0.00 0.00 0.00 0.00 
4764883 0.01 0.02 0.06 0.06 0.34 0.03 0.25 0.04 0.02 0.04 0.11 
9308315 0.02 0.01 0.08 0.05 0.25 0.03 0.17 0.03 0.01 0.04 0.12 
978458 0.00 0.00 0.03 0.02 0.45 0.01 0.32 0.03 0.01 0.07 0.21 
5742692 0.02 0.00 0.00 0.00 0.00 0.00 0.03 0.01 0.00 0.00 0.87 
11111262 0.01 0.00 0.00 0.00 0.05 0.00 0.07 0.00 0.00 0.00 0.00 
1520220 0.00 0.00 0.03 0.03 0.36 0.01 0.26 0.03 0.01 0.08 0.21 
6214 0.13 0.01 0.04 0.02 0.08 0.01 0.14 0.02 0.01 0.06 0.09 
6219 0.04 0.00 0.01 0.00 0.18 0.00 0.24 0.00 0.00 0.01 0.00 
2946834 0.00 0.01 0.02 0.05 0.24 0.03 0.16 0.02 0.02 0.03 0.11 
* Based on N = 580, excludes 2 women missing more than 50% of IGF-I SNPs included in diplotype estimation.  Excludes SNPs with minor allele  
   frequencies < 1%.  Pairwise r
2
 values ≥ 0.80, which are in bold, indicate SNP pairs in strong linkage disequilibrium. 
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SNP rs # 5742663 11829586 4764884 5742683 17884626 5009837 17727841 4764883 9308315 978458 
35767           
5742612           
5742614           
12821878           
10860869           
1019731           
7956547           
5742626           
17880975           
2033178           
5742657           
5742663           
11829586 0.89          
4764884 0.04 0.04         
5742683 0.88 0.81 0.03        
17884626 0.00 0.00 0.00 0.00       
5009837 0.17 0.17 0.43 0.16 0.01      
17727841 0.00 0.00 0.15 0.00 0.00 0.06     
4764883 0.11 0.11 0.26 0.10 0.00 0.60 0.04    
9308315 0.13 0.13 0.31 0.11 0.01 0.46 0.04 0.84   
978458 0.21 0.21 0.52 0.20 0.00 0.83 0.08 0.50 0.59  
5742692 0.89 0.89 0.04 0.81 0.00 0.16 0.00 0.10 0.12 0.21 
11111262 0.00 0.00 0.08 0.00 0.00 0.03 0.56 0.02 0.02 0.04 
1520220 0.21 0.21 0.44 0.19 0.00 0.71 0.00 0.44 0.52 0.87 
6214 0.09 0.09 0.27 0.10 0.00 0.05 0.00 0.18 0.25 0.08 
6219 0.00 0.00 0.30 0.01 0.00 0.14 0.11 0.08 0.09 0.16 
2946834 0.11 0.11 0.18 0.10 0.01 0.46 0.00 0.23 0.17 0.39 
* Based on N = 580, excludes 2 women missing more than 50% of IGF-I SNPs included in diplotype estimation.  Excludes SNPs with minor allele  
   frequencies < 1%.  Pairwise r
2
 values ≥ 0.80, which are in bold, indicate SNP pairs in strong linkage disequilibrium. 
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SNP rs # 5742692 11111262 1520220 6214 6219 2946834 
35767       
5742612       
5742614       
12821878       
10860869       
1019731       
7956547       
5742626       
17880975       
2033178       
5742657       
5742663       
11829586       
4764884       
5742683       
17884626       
5009837       
17727841       
4764883       
9308315       
978458       
5742692       
11111262 0.00      
1520220 0.24 0.05     
6214 0.09 0.03 0.11    
6219 0.00 0.24 0.18 0.10   
2946834 0.12 0.02 0.48 0.00 0.10   
* Based on N = 580, excludes 2 women missing more than 50% of IGF-I SNPs included in diplotype estimation.  Excludes SNPs with minor allele  
   frequencies < 1%.  Pairwise r
2
 values ≥ 0.80, which are in bold, indicate SNP pairs in strong linkage disequilibrium. 
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Table A.5. Differences of mean differences comparing African American and 
Caucasian mean plasma IGFBP-3 differences associated with index genotypes for 
IGFBP-3 single nucleotide polymorphisms (SNPs)* 
 
SNP Reference 
ID 
Genotypes Difference of Mean 
Differences 
95% CI 
GT, GG -17 -267, 233 rs903889† 
TT 0  
TT -21 -328, 286 
CT -91 -362, 181 
rs924140‡ 
CC 0  
AA -58 -360, 244 
AC -78 -340, 184 
rs2854744‡ 
CC 0  
CC 266 -70, 602 
CG 79 -144, 303 
rs2854746 
GG 0  
CC -120 -643, 404 
CG -139 -375, 97 
rs2471551 
GG 0  
AA -126 -452, 201 
AG -177 -410, 56 
rs3110697 
GG 0  
AC, AA 298 45, 551 rs2453840† 
CC 0  
CC 157 -340, 654 
CT 86 -149, 320 
rs2453839 
TT 0  
AT, AA -123 -358, 112 rs6670† 
TT 0  
AA -56 -494, 383 
AG -190 -428, 49 
rs13223993 
GG 0  
TT 400 -88, 888 
CT -49 -281, 183 
rs2270628 
CC 0  
AC, CC -99 -397, 198 rs12671457 
AA 0  
*  Only compares SNPs with at least 2% for minor allele frequencies among both racial groups.     
Combined data from both racial groups and fit linear regression models that included multiplicative gene 
by race interaction terms along with separate parameters for race and genotypes.  Referent genotypes 
were homozygous wildtype genotypes among Caucasians.   
†  These SNPs had different models of inheritance (i.e. codominant, dominant) for each of the  
    race-specific linear regression models.  Dominant model was used for these SNPs in linear    
    regression models with combined racial groups to estimate differences of mean differences.  
‡  These SNPs had opposite homozygous wildtype genotypes for race-specific linear regression  
    models among African Americans.   
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Table A.6. Differences of mean differences comparing African American and 
Caucasian mean plasma IGF-I differences associated with index genotypes for  
IGF-I single nucleotide polymorphisms (SNPs)* 
 
SNP Reference 
ID 
Genotypes Difference of Mean 
Differences 
95% CI 
AG, AA -7 -26, 11 rs35767† 
GG 0  
AG, GG -15 -50, 19 rs5742612 
AA 0  
CG, CC -9 -48, 30 rs5742614 
GG 0  
AG, AA -19 -41, 4 rs12821878† 
GG 0  
TT 16 -16, 48 
AT 6 -12, 24 
rs1086869 
AA 0  
AC, AA -20 -47, 8 rs1019731 
CC 0  
CC 13 -21, 47 
CT 8 -10, 27 
rs7956547 
TT 0  
AG, GG -29 -58, 0 rs2033178 
AA 0  
AG, GG -14 -50, 21 rs5742657 
AA 0  
AG, AA -9 -44, 26 rs11829586 
GG 0  
TT 26 -11, 63 
CT 5 -13, 24 
rs4764884 
CC 0  
TT 14 -15, 43 
CT 4 -14, 23 
rs5009837 
CC 0  
CG, CC 27 2, 51 rs17727841† 
GG 0  
CC 20 -8, 49 
CT -3 -23, 17 
rs4764883‡ 
TT 0  
AA 28 -3, 59 
AT -2 -22, 17 
rs9308315‡ 
TT 0  
TT 22 -10, 54 
CT 3 -16, 21 
rs978458 
CC 0  
AG, GG -13 -49, 23 rs5742692† 
AA 0  
AG, AA 44 13, 75 rs11111262 
GG 0  
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GG 43 1, 85 
CG -1 -20, 18 
rs1520220 
CC 0  
TT -14 -39, 11 
CT 1 -19, 22 
rs6214‡ 
CC 0  
CT, TT 21 -1, 44 rs6219 
CC 0  
AA 24 -4, 52 
AG 1 -19, 21 
rs2946834 
GG 0  
*  Only compares SNPs with at least 2% for minor allele frequencies among both racial groups.     
Combined data from both racial groups and fit linear regression models that included multiplicative gene 
by race interaction terms along with separate parameters for race and genotypes.  Referent genotypes 
were homozygous wildtype genotypes among Caucasians.   
†  These SNPs had different models of inheritance (i.e. codominant, dominant) for each of the  
    race-specific linear regression models.  Dominant model was used for these SNPs in linear    
    regression models with combined racial groups to estimate differences of mean differences.  
‡  These SNPs had opposite homozygous wildtype genotypes for race-specific linear regression  
    models among African Americans.   
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Table A.7. Unadjusted linear regression of IGFBP-3 group-specific diplotypes on plasma IGFBP-3 levels among Caucasians* 
 
Group Diplotypes N† 
Maximum 
Likelihood 
Estimates‡ 
95% Confidence 
Interval‡ 
Posterior 
Medians‡ 
95% Posterior 
Limits‡ 
 Intercept  4661 4471, 4852   
1 Rare 40 -499 -804, -194 -438 -724, -152 
1 GCGGAC/GCGGAC 21 -508 -889, -128 -418 -763, -73 
1 TACGGA/TACGGC 23 299 -69, 666 249 -87, 584 
1 TACGGA/TCGCAC 10 141 -373, 655 101 -334, 536 
1 TACGGC/TACGGC 34 209 -112, 530 181 -118, 480 
1 TACGGC/TAGGGC 13 -78 -538, 381 -60 -460, 341 
1 TACGGC/TCGCAC 55 -29 -307, 250 -26 -290, 238 
1 TACGGC/TCGGGA 31 -37 -368, 294 -32 -339, 275 
1 TAGGGC/GCGGAC 6 -581 -1225, 64 -358 -864, 148 
1 TAGGGC/TCGCAC 6 -260 -905, 384 -161 -667, 346 
1 TCGCAC/GCGGAC 22 -245 -618, 129 -202 -542, 138 
1 TCGCAC/TCGCAC 14 -304 -750, 142 -235 -626, 157 
1 TCGGGA/GCGGAC 11 -386 -879, 107 -283 -705, 139 
1 TCGGGA/TCGCAC 15 -681 -1114, -247 -531 -914, -148 
1 TCGGGA/TCGGGA 6 -249 -893, 396 -153 -660, 353 
1 TACGGC/GCGGAC 63 REF  REF  
* N = 401, excludes 1 woman missing more than 50% of IGFBP-3 SNPs included in diplotype estimation. 
† N = 370, excludes 30 women with less than 90% posterior probability for best diplotype assignment in PHASE software and 1 woman missing  
   plasma IGFBP-3 level. 
‡ Units: ng/ml. 
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Group Diplotypes N† 
Maximum 
Likelihood 
Estimates‡ 
95% Confidence 
Interval‡ 
Posterior 
Medians‡ 
95% Posterior 
Limits‡ 
 Intercept  4587 4392, 4782   
2 Rare 5 -751 -1487, -16 -415 -962, 132 
2 AGCA/AGCA 12 -18 -516, 480 -13 -438, 412 
2 TACA/AGCA 34 12 -323, 347 10 -300, 320 
2 TACA/TACA 12 101 -397, 598 73 -352, 499 
2 TACA/TATA 6 -174 -851, 502 -104 -625, 418 
2 TACA/TGCA 53 -82 -375, 210 -73 -348, 203 
2 TACA/TGTC 18 -51 -473, 371 -40 -415, 334 
2 TATA/AGCA 9 254 -310, 817 172 -292, 636 
2 TATA/TGCA 10 -41 -579, 497 -29 -478, 421 
2 TGCA/TGCA 63 -80 -359, 200 -71 -336, 193 
2 TGCA/TGTC 61 -142 -423, 140 -127 -393, 140 
2 TGTC/AGCA 32 -68 -409, 274 -58 -373, 257 
2 TGTC/TGTC 10 -163 -701, 376 -113 -563, 336 
2 TGCA/AGCA 66 REF  REF  
* N = 401, excludes 1 woman missing more than 50% of IGFBP-3 SNPs included in diplotype estimation. 
† N = 391, excludes 9 women with less than 90% posterior probability for best diplotype assignment in PHASE software and 1 woman missing  
   plasma IGFBP-3 level. 
‡ Units: ng/ml. 
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Table A.8. Unadjusted linear regression of IGFBP-3 group-specific diplotypes on plasma IGF-I levels among Caucasians* 
 
Group Diplotypes N† 
Maximum 
Likelihood 
Estimates‡ 
95% Confidence 
Interval‡ 
Posterior 
Medians‡ 
95% Posterior 
Limits‡ 
 Intercept  177 163, 192   
1 Rare 40 -24 -47, 0 -20 -42, 1 
1 GCGGAC/GCGGAC 21 12 -17, 41 10 -16, 36 
1 TACGGA/TACGGC 23 0 -28, 28 0 -25, 25 
1 TACGGA/TCGCAC 10 -13 -52, 26 -9 -42, 23 
1 TACGGC/TACGGC 34 -5 -29, 19 -4 -27, 18 
1 TACGGC/TAGGGC 13 -9 -44, 26 -7 -37, 23 
1 TACGGC/TCGCAC 55 1 -20, 22 1 -19, 21 
1 TACGGC/TCGGGA 31 2 -23, 27 2 -21, 25 
1 TAGGGC/GCGGAC 6 -7 -56, 42 -4 -42, 33 
1 TAGGGC/TCGCAC 6 -15 -64, 34 -9 -46, 29 
1 TCGCAC/GCGGAC 22 -2 -30, 27 -1 -27, 24 
1 TCGCAC/TCGCAC 14 0 -33, 34 0 -29, 29 
1 TCGGGA/GCGGAC 11 -21 -58, 16 -15 -46, 17 
1 TCGGGA/TCGCAC 15 -24 -57, 8 -19 -47, 10 
1 TCGGGA/TCGGGA 6 -8 -57, 40 -5 -42, 33 
1 TACGGC/GCGGAC 63 REF  REF  
* N = 401, excludes 1 woman missing more than 50% of IGFBP-3 SNPs included in diplotype estimation. 
† N = 370, excludes 30 women with less than 90% posterior probability for best diplotype assignment in PHASE software and 1 woman missing  
 plasma IGF-I level. 
 ‡ Units: ng/ml. 
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Group Diplotypes N† 
Maximum 
Likelihood 
Estimates‡ 
95% Confidence 
Interval‡ 
Posterior 
Medians‡ 
95% Posterior 
Limits‡ 
 Intercept  174 160, 188   
2 Rare 5 -50 -102, 2 -28 -67, 11 
2 AGCA/AGCA 12 -22 -57, 14 -16 -46, 14 
2 TACA/AGCA 34 -10 -34, 14 -9 -31, 13 
2 TACA/TACA 12 2 -33, 38 2 -29, 32 
2 TACA/TATA 6 -9 -58, 39 -6 -43, 32 
2 TACA/TGCA 53 0 -21, 21 0 -19, 20 
2 TACA/TGTC 18 12 -18, 42 9 -17, 36 
2 TATA/AGCA 9 22 -18, 62 15 -18, 48 
2 TATA/TGCA 10 22 -16, 61 16 -16, 48 
2 TGCA/TGCA 63 4 -16, 24 3 -16, 22 
2 TGCA/TGTC 61 -8 -28, 12 -7 -26, 12 
2 TGTC/AGCA 32 -3 -27, 21 -2 -25, 20 
2 TGTC/TGTC 10 0 -38, 39 0 -32, 32 
2 TGCA/AGCA 66 REF  REF  
* N = 401, excludes 1 woman missing more than 50% of IGFBP-3 SNPs included in diplotype estimation. 
† N = 391, excludes 9 women with less than 90% posterior probability for best diplotype assignment in PHASE software and 1 woman missing  
   plasma IGF-I level. 
‡ Units: ng/ml. 
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Table A.9. Unadjusted linear regression of IGFBP-3 group-specific diplotypes on plasma IGFBP-3 levels among African 
Americans* 
 
Group Diplotypes N† 
Maximum 
Likelihood 
Estimates‡ 
95% Confidence 
Interval‡ 
Posterior 
Medians‡ 
95% Posterior 
Limits‡ 
 Intercept  4327 4166, 4488   
1 Rare 50 -420 -691, -149 -381 -639, -123 
1 TACGAGG/GCGGAGA 18 -332 -729, 65 -272 -632, 87 
1 TACGAGG/GCGGCAA 15 220 -209, 649 175 -208, 558 
1 TACGAGG/TACGAGG 51 372 103, 641 338 81, 594 
1 TAGGAGA/TACGAGG 10 -28 -541, 485 -21 -459, 418 
1 TAGGAGA/TAGGAGG 7 -740 -1344, -136 -491 -982, 1 
1 TAGGAGG/GCGGAGA 12 -835 -1307, -362 -636 -1049, -224 
1 TAGGAGG/TAGGAGG 34 -487 -797, -178 -430 -720, -139 
1 TCGCAGA/GCGGAGA 10 -242 -755, 271 -177 -616, 262 
1 TCGCAGA/GCGGCAA 9 -681 -1219, -144 -486 -940, -32 
1 TCGCAGA/TACGAGG 68 -182 -429, 65 -168 -405, 69 
1 TCGCAGA/TAGGAGA 6 -719 -1368, -71 -453 -969, 62 
1 TCGCAGA/TAGGAGG 44 -410 -693, -128 -369 -637, -101 
1 TCGCAGA/TCGCAGA 26 -640 -982, -298 -550 -867, -233 
1 TCGCAGA/TCGGAGG 20 -901 -1282, -521 -750 -1097, -403 
1 TCGGAGA/TACGAGG 12 -309 -782, 164 -236 -649, 177 
1 TCGGAGG/TACGAGG 30 25 -299, 349 22 -281, 325 
1 TCGGAGG/TAGGAGG 19 -220 -608, 169 -182 -535, 171 
1 TCGGAGG/TCGGAGG 7 -209 -812, 395 -138 -630, 353 
1 TAGGAGG/TACGAGG 91 REF  REF  
* N = 579, excludes 3 women missing more than 50% of IGFBP-3 SNPs included in diplotype estimation. 
† N = 539, excludes 32 women with less than 90% posterior probability for best diplotype assignment in PHASE software and 8 women missing  
   plasma IGFBP-3 levels. 
‡ Units: ng/ml. 
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Group Diplotypes N† 
Maximum 
Likelihood 
Estimates‡ 
95% Confidence 
Interval‡ 
Posterior 
Medians‡ 
95% Posterior 
Limits‡ 
 Intercept  4060 3947, 4172   
2 AC/AC 7 225 -410, 860 144 -364, 652 
2 CC/AC 28 229 -103, 560 198 -111, 507 
2 CC/CC 57 -344 -590, -98 -317 -553, -81 
2 CT/AC 60 205 -37, 446 189 -43, 421 
2 CT/CT 194 70 -93, 233 67 -93, 228 
2 CT/CC 217 REF  REF  
* N = 579, excludes 3 women missing more than 50% of IGFBP-3 SNPs included in diplotype estimation. 
† N = 563, excludes 8 women with less than 90% posterior probability for best diplotype assignment in PHASE software and 8 women missing  
   plasma IGFBP-3 levels. 
‡ Units: ng/ml.
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Group Diplotypes N† 
Maximum 
Likelihood 
Estimates‡ 
95% Confidence 
Interval‡ 
Posterior 
Medians‡ 
95% Posterior 
Limits‡ 
 Intercept  4106 3959, 4254   
3 Rare 14 -360 -826, 106 -276 -685, 132 
3 AGCA/AGCA 9 49 -521, 620 34 -439, 507 
3 TACA/AGCA 15 55 -397, 507 43 -356, 441 
3 TACA/TACA 10 21 -522, 565 15 -442, 473 
3 TACA/TGCA 43 -261 -553, 31 -233 -509, 43 
3 TATA/AGCA 47 -193 -476, 90 -174 -442, 95 
3 TATA/TACA 40 -89 -389, 211 -79 -362, 204 
3 TATA/TATA 54 257 -12, 526 234 -23, 490 
3 TATA/TGTC 18 -149 -566, 268 -120 -494, 254 
3 TGCA/AGCA 51 74 -200, 349 67 -194, 328 
3 TGCA/TGCA 101 89 -132, 310 84 -130, 297 
3 TGTC/AGCA 6 -1 -692, 690 -1 -536, 535 
3 TGTC/TGCA 13 -279 -761, 203 -211 -629, 208 
3 TATA/TGCA 126 REF  REF  
* N = 579, excludes 3 women missing more than 50% of IGFBP-3 SNPs included in diplotype estimation. 
† N = 547, excludes 24 women with less than 90% posterior probability for best diplotype assignment in PHASE software and 8 women missing  
   plasma IGFBP-3 levels. 
‡ Units: ng/ml. 
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Table A.10. Unadjusted linear regression of IGFBP-3 group-specific diplotypes on plasma IGF-I levels among African 
Americans* 
 
Group Diplotypes N† 
Maximum 
Likelihood 
Estimates‡ 
95% Confidence 
Interval‡ 
Posterior 
Medians‡ 
95% Posterior 
Limits‡ 
 Intercept  175 161, 190   
1 Rare 50 -19 -44, 5 -17 -41, 6 
1 TACGAGG/GCGGAGA 18 48 12, 84 39 6, 71 
1 TACGAGG/GCGGCAA 15 -19 -58, 20 -15 -49, 20 
1 TACGAGG/TACGAGG 51 -6 -31, 18 -6 -29, 17 
1 TAGGAGA/TACGAGG 10 -23 -70, 23 -17 -56, 23 
1 TAGGAGA/TAGGAGG 7 -33 -88, 22 -21 -65, 23 
1 TAGGAGG/GCGGAGA 12 -50 -93, -7 -38 -75, 0 
1 TAGGAGG/TAGGAGG 34 1 -27, 29 1 -25, 27 
1 TCGCAGA/GCGGAGA 10 -8 -54, 39 -5 -45, 34 
1 TCGCAGA/GCGGCAA 9 -33 -82, 16 -23 -64, 18 
1 TCGCAGA/TACGAGG 68 -20 -42, 3 -18 -39, 3 
1 TCGCAGA/TAGGAGA 6 4 -55, 63 2 -44, 48 
1 TCGCAGA/TAGGAGG 44 -10 -35, 16 -9 -33, 16 
1 TCGCAGA/TCGCAGA 26 -31 -62, 0 -26 -55, 2 
1 TCGCAGA/TCGGAGG 20 -21 -55, 14 -17 -48, 14 
1 TCGGAGA/TACGAGG 12 -15 -58, 28 -11 -48, 26 
1 TCGGAGG/TACGAGG 30 -19 -49, 10 -17 -44, 11 
1 TCGGAGG/TAGGAGG 19 3 -32, 38 2 -30, 34 
1 TCGGAGG/TCGGAGG 7 30 -24, 85 20 -24, 64 
1 TAGGAGG/TACGAGG 91 REF  REF  
* N = 579, excludes 3 women missing more than 50% of IGFBP-3 SNPs included in diplotype estimation. 
† N = 539, excludes 32 women with less than 90% posterior probability for best diplotype assignment in PHASE software and 8 women missing  
   plasma IGF-I levels. 
‡ Units: ng/ml. 
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Group Diplotypes N† 
Maximum 
Likelihood 
Estimates‡ 
95% Confidence 
Interval‡ 
Posterior 
Medians‡ 
95% Posterior 
Limits‡ 
 Intercept  162 152, 172   
2 AC/AC 7 -20 -76, 36 -13 -57, 32 
2 CC/AC 28 18 -11, 47 15 -12, 43 
2 CC/CC 57 3 -19, 25 3 -18, 24 
2 CT/AC 60 7 -14, 29 7 -14, 27 
2 CT/CT 194 4 -10, 19 4 -10, 18 
2 CT/CC 217 REF  REF  
* N = 579, excludes 3 women missing more than 50% of IGFBP-3 SNPs included in diplotype estimation. 
† N = 563, excludes 8 women with less than 90% posterior probability for best diplotype assignment in PHASE software and 8 women missing  
   plasma IGF-I levels. 
‡ Units: ng/ml. 
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Group Diplotypes N† 
Maximum 
Likelihood 
Estimates‡ 
95% Confidence 
Interval‡ 
Posterior 
Medians‡ 
95% Posterior 
Limits‡ 
 Intercept  162 150, 175   
3 Rare 14 -25 -65, 16 -19 -54, 16 
3 AGCA/AGCA 9 2 -48, 51 1 -40, 42 
3 TACA/AGCA 15 -11 -50, 28 -9 -43, 26 
3 TACA/TACA 10 2 -45, 49 1 -38, 41 
3 TACA/TGCA 43 -8 -34, 17 -8 -31, 16 
3 TATA/AGCA 47 -9 -34, 15 -8 -31, 15 
3 TATA/TACA 40 -7 -33, 19 -7 -31, 18 
3 TATA/TATA 54 12 -11, 35 11 -11, 33 
3 TATA/TGTC 18 62 26, 98 50 17, 82 
3 TGCA/AGCA 51 7 -17, 31 6 -16, 29 
3 TGCA/TGCA 101 10 -10, 29 9 -10, 27 
3 TGTC/AGCA 6 -35 -95, 25 -21 -68, 25 
3 TGTC/TGCA 13 -1 -43, 40 -1 -37, 35 
3 TATA/TGCA 126 REF  REF  
* N = 579, excludes 3 women missing more than 50% of IGFBP-3 SNPs included in diplotype estimation. 
† N = 547, excludes 24 women with less than 90% posterior probability for best diplotype assignment in PHASE software and 8 women missing  
   plasma IGF-I levels. 
‡ Units: ng/ml. 
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Table A.11. Unadjusted linear regression of IGF-I group-specific diplotypes on plasma IGFBP-3 levels among Caucasians* 
 
Group† Diplotypes N‡ 
Maximum 
Likelihood 
Estimates§ 
95% Confidence 
Interval§ 
Posterior 
Medians§ 
95% Posterior 
Limits§ 
 Intercept  4525 4429, 4620   
1 A/G, A/A 114 -15 -193, 164 -14 -188, 160 
1 G/G 280 REF  REF  
* N = 399, excludes 3 women missing more than 50% of IGF-I SNPs included in diplotype estimation. 
† rs35767 represents entire group because it could not be combined with block 1 SNPs for diplotype estimation. 
‡ N = 394, excludes 4 women missing SNP genotype and 1 woman missing plasma IGFBP-3 level. 
§ Units: ng/ml. 
 
 
 
Group Diplotypes N† 
Maximum 
Likelihood 
Estimates‡ 
95% Confidence 
Interval‡ 
Posterior 
Medians‡ 
95% Posterior 
Limits‡ 
 Intercept  4559 4407, 4711   
2 Rare 10 545 19, 1071 386 -57, 828 
2 AAT/ACT 11 -170 -673, 334 -123 -552, 306 
2 AAT/GCC 23 52 -313, 417 43 -290, 377 
2 AAT/GCT 52 75 -193, 343 68 -187, 323 
2 ACT/GCC 27 -173 -515, 169 -147 -463, 168 
2 ACT/GCT 34 -1 -314, 311 -1 -293, 291 
2 GCC/GCC 29 -185 -518, 147 -159 -467, 149 
2 GCT/GCT 97 -100 -322, 122 -93 -307, 121 
2 GCT/GCC 110 REF  REF  
* N = 399, excludes 3 women missing more than 50% of IGF-I SNPs included in diplotype estimation. 
† N = 393, excludes 5 women with less than 90% posterior probability for best diplotype assignment in PHASE software and 1 woman missing    
   plasma IGFBP-3 level. 
‡ Units: ng/ml. 
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Group Diplotypes N† 
Maximum 
Likelihood 
Estimates‡ 
95% Confidence 
Interval‡ 
Posterior 
Medians‡ 
95% Posterior 
Limits‡ 
 Intercept  4518 4353, 4683   
3 Rare 22 -306 -683, 71 -252 -595, 90 
3 GCTCT/GCTGC 9 -33 -588, 522 -23 -482, 437 
3 GGCCC/AGTGC 21 84 -300, 468 69 -279, 417 
3 GGCCC/GCTCT 26 -42 -395, 311 -35 -359, 289 
3 GGCCC/GCTGC 36 -61 -373, 252 -53 -345, 239 
3 GGCCC/GGCCC 78 82 -162, 326 75 -159, 309 
3 GGCCT/AGTGC 15 -213 -656, 230 -165 -554, 225 
3 GGCCT/GCTCT 25 179 -179, 537 150 -178, 478 
3 GGCCT/GCTGC 24 -202 -566, 163 -168 -501, 165 
3 GGCCT/GGCCT 33 291 -32, 613 251 -48, 551 
3 GGCCT/GGTGT 7 -212 -835, 412 -134 -630, 362 
3 GGCCC/GGCCT 93 REF  REF  
* N = 399, excludes 3 women missing more than 50% of IGF-I SNPs included in diplotype estimation. 
† N = 389, excludes 9 women with less than 90% posterior probability for best diplotype assignment in PHASE software and 1 woman missing    
   plasma IGFBP-3 level. 
‡ Units: ng/ml. 
 
Group Diplotypes N† 
Maximum 
Likelihood 
Estimates‡ 
95% Confidence 
Interval‡ 
Posterior 
Medians‡ 
95% Posterior 
Limits‡ 
 Intercept  4585 4463, 4706   
4 CA/TA, Rare 16 -360 -779, 59 -285 -658, 88 
4 CA/CA 21 -221 -592, 150 -184 -521, 154 
4 CG/CA 119 -23 -214, 167 -22 -208, 164 
4 CG/TA 62 -183 -420, 54 -169 -397, 59 
4 CG/CG 175 REF  REF  
* N = 399, excludes 3 women missing more than 50% of IGF-I SNPs included in diplotype estimation. 
† N = 393, excludes 5 women with less than 90% posterior probability for best diplotype assignment in PHASE software and 1 woman missing    
   plasma IGFBP-3 level. 
‡ Units: ng/ml. 
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Table A.12. Unadjusted linear regression of IGF-I group-specific diplotypes on plasma IGF-I levels among Caucasians* 
 
Group† Diplotypes N‡ 
Maximum 
Likelihood 
Estimates§ 
95% Confidence 
Interval§ 
Posterior 
Medians§ 
95% Posterior 
Limits§ 
 Intercept  171  164, 177   
1 A/G, A/A 114 6 -7, 19 6 -7, 18 
1 G/G 280 REF  REF  
* N = 399, excludes 3 women missing more than 50% of IGF-I SNPs included in diplotype estimation. 
† rs35767 represents entire group because it could not be combined with block 1 SNPs for diplotype estimation. 
‡ N = 394, excludes 4 women missing SNP genotype and 1 woman missing plasma IGF-I level. 
§ Units: ng/ml. 
 
. 
 
Group Diplotypes N† 
Maximum 
Likelihood 
Estimates‡ 
95% Confidence 
Interval‡ 
Posterior 
Medians‡ 
95% Posterior 
Limits‡ 
 Intercept  173 162, 184   
2 Rare 10 3 -35, 41 2 -30, 34 
2 AAT/ACT 11 -7 -44, 29 -5 -36, 26 
2 AAT/GCC 23 8 -18, 34 7 -17, 31 
2 AAT/GCT 52 12 -8, 31 11 -8, 29 
2 ACT/GCC 27 -3 -27, 22 -2 -25, 20 
2 ACT/GCT 34 -13 -35, 10 -11 -32, 10 
2 GCC/GCC 29 -6 -30, 18 -5 -28, 17 
2 GCT/GCT 97 -4 -20, 12 -4 -20, 11 
2 GCT/GCC 110 REF  REF  
* N = 399, excludes 3 women missing more than 50% of IGF-I SNPs included in diplotype estimation. 
† N = 393, excludes 5 women with less than 90% posterior probability for best diplotype assignment in PHASE software and 1 woman missing  
   plasma IGF-I level. 
‡ Units: ng/ml. 
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Group Diplotypes N† 
Maximum 
Likelihood 
Estimates‡ 
95% Confidence 
Interval‡ 
Posterior 
Medians‡ 
95% Posterior 
Limits‡ 
 Intercept  165 153, 176   
3 Rare 22 -24 -51, 3 -20 -44, 5 
3 GCTCT/GCTGC 9 25 -14, 64 17 -15, 50 
3 GGCCC/AGTGC 21 21 -6, 48 17 -8, 42 
3 GGCCC/GCTCT 26 3 -22, 28 3 -20, 26 
3 GGCCC/GCTGC 36 7 -15, 29 6 -15, 27 
3 GGCCC/GGCCC 78 6 -11, 24 6 -11, 23 
3 GGCCT/AGTGC 15 25 -6, 57 20 -8, 48 
3 GGCCT/GCTCT 25 13 -13, 38 11 -13, 34 
3 GGCCT/GCTGC 24 1 -25, 27 1 -23, 24 
3 GGCCT/GGCCT 33 29 6, 52 25 4, 46 
3 GGCCT/GGTGT 7 41 -3, 86 26 -9, 62 
3 GGCCC/GGCCT 93 REF  REF  
* N = 399, excludes 3 women missing more than 50% of IGF-I SNPs included in diplotype estimation. 
† N = 389, excludes 9 women with less than 90% posterior probability for best diplotype assignment in PHASE software and 1 woman missing  
   plasma IGF-I level. 
‡ Units: ng/ml. 
 
Group Diplotypes N† 
Maximum 
Likelihood 
Estimates‡ 
95% Confidence 
Interval‡ 
Posterior 
Medians‡ 
95% Posterior 
Limits‡ 
 Intercept  172 164, 181   
4 CA/TA, Rare 16 -31 -61, -1 -25 -52, 2 
4 CA/CA 21 14 -12, 41 12 -12, 36 
4 CG/CA 119 1 -13, 14 1 -13, 14 
4 CG/TA 62 2 -15, 19 2 -14, 18 
4 CG/CG 175 REF  REF  
* N = 399, excludes 3 women missing more than 50% of IGF-I SNPs included in diplotype estimation. 
† N = 393, excludes 5 women with less than 90% posterior probability for best diplotype assignment in PHASE software and 1 woman missing  
   plasma IGF-I level. 
‡ Units: ng/ml. 
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Table A.13. Unadjusted linear regression of IGF-I group-specific diplotypes on plasma IGFBP-3 levels among African 
Americans* 
 
Group Diplotypes N† 
Maximum 
Likelihood 
Estimates‡ 
95% Confidence 
Interval‡ 
Posterior 
Medians‡ 
95% Posterior 
Limits‡ 
 Intercept  4043 3919, 4167   
1 Rare 9 -841 -1409, -272 -580 -1052, -108 
1 AGG/AGG 99 106 -102, 314 100 -102, 302 
1 AGG/GCG 52 -12 -274, 250 -11 -261, 239 
1 AGG/GGA 31 -3 -327, 320 -3 -305, 299 
1 GCG/GCG 8 -221 -822, 380 -147 -637, 343 
1 GGG/GCG 57 148 -105, 401 136 -106, 378 
1 GGG/GGA 24 7 -355, 368 6 -327, 338 
1 GGG/GGG 105 137 -67, 342 130 -69, 328 
1 AGG/GGG 180 REF  REF  
* N = 580, excludes 2 women missing more than 50% of IGF-I SNPs included in diplotype estimation. 
† N = 565, excludes 7 women with less than 90% posterior probability for best diplotype assignment in PHASE software and 8 women missing  
   plasma IGFBP-3 levels. 
‡ Units: ng/ml. 
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Group Diplotypes N† 
Maximum 
Likelihood 
Estimates‡ 
95% Confidence 
Interval‡ 
Posterior 
Medians‡ 
95% Posterior 
Limits‡ 
 Intercept  3999 3866, 4133   
2 Rare 38 109 -187, 405 97 -182, 377 
2 ATCCC/TCTTT 13 153 -319, 624 117 -295, 529 
2 ATTCC/ATCCC 37 107 -192, 406 95 -187, 377 
2 ATTCC/ATTTT 10 -101 -633, 432 -72 -523, 378 
2 ATTCC/TCTCC 8 -35 -626, 557 -23 -508, 462 
2 ATTCC/TCTCT 15 392 -50, 833 308 -83, 700 
2 ATTCC/TCTTT 119 67 -133, 267 64 -131, 258 
2 ATTCC/TTTCT 34 10 -300, 319 9 -282, 299 
2 ATTCT/ATCCC 6 -212 -891, 466 -129 -659, 400 
2 ATTCT/ATTCC 41 154 -133, 442 138 -134, 411 
2 ATTCT/TCTCT 6 19 -660, 698 12 -518, 541 
2 ATTCT/TCTTT 20 -154 -542, 234 -127 -480, 226 
2 ATTCT/TTTCT 8 186 -405, 778 125 -360, 610 
2 TCTCT/TCTTT 10 73 -460, 605 52 -399, 503 
2 TCTTT/TCTTT 30 179 -147, 505 156 -149, 460 
2 TTTCT/TCTTT 13 783 312, 1255 598 186, 1010 
2 ATTCC/ATTCC 150 REF  REF  
* N = 580, excludes 2 women missing more than 50% of IGF-I SNPs included in diplotype estimation. 
† N = 558, excludes 14 women with less than 90% posterior probability for best diplotype assignment in PHASE software and 8 women missing  
   plasma IGFBP-3 levels. 
‡ Units: ng/ml. 
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Group Diplotypes N† 
Maximum 
Likelihood 
Estimates‡ 
95% Confidence 
Interval‡ 
Posterior 
Medians‡ 
95% Posterior 
Limits‡ 
 Intercept  4083 3915, 4251   
3 Rare 9 -679 -1257, -101 -463 -941, 14 
3 AACC/AACC 7 260 -389, 910 164 -351, 679 
3 AACC/AACT 7 -101 -750, 549 -63 -579, 452 
3 AACC/AGGT 15 371 -89, 832 287 -118, 691 
3 AACC/TACC 11 -423 -950, 105 -304 -752, 143 
3 AACC/TACT 55 -107 -386, 173 -96 -362, 169 
3 AACT/AGGT 6 -217 -915, 481 -129 -668, 410 
3 AACT/TACT 13 9 -481, 498 6 -418, 430 
3 AAGC/AACC 35 -68 -394, 259 -59 -364, 246 
3 AAGC/AACT 9 466 -112, 1044 318 -160, 795 
3 AAGC/AAGC 34 58 -272, 388 50 -257, 358 
3 AAGC/AGGT 24 149 -229, 527 124 -221, 470 
3 AAGC/TACC 28 -99 -455, 257 -84 -412, 244 
3 AAGC/TACT 86 19 -226, 264 18 -218, 253 
3 AGGT/AGGT 10 66 -485, 617 47 -415, 508 
3 AGGT/TACT 47 21 -274, 315 18 -260, 297 
3 TACC/TACC 6 -351 -1049, 347 -209 -748, 329 
3 TACC/TACT 45 3 -296, 302 3 -279, 285 
3 TACT/TACT 98 REF  REF  
* N = 580, excludes 2 women missing more than 50% of IGF-I SNPs included in diplotype estimation. 
† N = 545, excludes 27 women with less than 90% posterior probability for best diplotype assignment in PHASE software and 8 women missing  
   plasma IGFBP-3 levels. 
‡ Units: ng/ml. 
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Group Diplotypes N† 
Maximum 
Likelihood 
Estimates‡ 
95% Confidence 
Interval‡ 
Posterior 
Medians‡ 
95% Posterior 
Limits‡ 
 Intercept  4048 3938, 4158   
4 CA/CA 93 171 -34, 377 162 -38, 362 
4 CA/TA 40 -29 -316, 257 -26 -298, 245 
4 CG/CG 147 -22 -199, 155 -21 -194, 152 
4 CG/TA 45 162 -111, 435 147 -113, 407 
4 TA/TA 8 283 -320, 885 188 -304, 679 
4 CA/CG 232 REF  REF  
* N = 580, excludes 2 women missing more than 50% of IGF-I SNPs included in diplotype estimation. 
† N = 565, excludes 7 women with less than 90% posterior probability for best diplotype assignment in PHASE software and 8 women missing  
   plasma IGFBP-3 levels. 
‡ Units: ng/ml. 
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Table A.14. Unadjusted linear regression of IGF-I group-specific diplotypes on plasma IGF-I levels among African 
Americans* 
 
Group Diplotypes N† 
Maximum 
Likelihood 
Estimates‡ 
95% Confidence 
Interval‡ 
Posterior 
Medians‡ 
95% Posterior 
Limits‡ 
 Intercept  166 155, 176   
1 Rare 9 -68 -117, -20 -48 -88, -7 
1 AGG/AGG 99 0 -18, 17 0 -18, 17 
1 AGG/GCG 52 -5 -28, 17 -5 -26, 17 
1 AGG/GGA 31 -7 -34, 21 -6 -32, 20 
1 GCG/GCG 8 -27 -78, 25 -18 -60, 24 
1 GGG/GCG 57 31 9, 52 28 8, 49 
1 GGG/GGA 24 -2 -33, 29 -2 -30, 27 
1 GGG/GGG 105 -7 -24, 11 -6 -23, 11 
1 AGG/GGG 180 REF  REF  
* N = 580, excludes 2 women missing more than 50% of IGF-I SNPs included in diplotype estimation. 
† N = 565, excludes 7 women with less than 90% posterior probability for best diplotype assignment in PHASE software and 8 women missing  
   plasma IGF-I levels. 
‡ Units: ng/ml. 
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Group Diplotypes N† 
Maximum 
Likelihood 
Estimates‡ 
95% Confidence 
Interval‡ 
Posterior 
Medians‡ 
95% Posterior 
Limits‡ 
 Intercept  162 150, 174   
2 Rare 38 -1 -28, 25 -1 -26, 23 
2 ATCCC/TCTTT 13 25 -17, 66 19 -17, 55 
2 ATTCC/ATCCC 37 -14 -41, 12 -13 -37, 12 
2 ATTCC/ATTTT 10 -5 -52, 42 -3 -43, 36 
2 ATTCC/TCTCC 8 -29 -81, 24 -19 -62, 23 
2 ATTCC/TCTCT 15 29 -10, 68 23 -12, 57 
2 ATTCC/TCTTT 119 8 -10, 26 8 -10, 25 
2 ATTCC/TTTCT 34 6 -21, 33 5 -20, 31 
2 ATTCT/ATCCC 6 -12 -71, 48 -7 -53, 40 
2 ATTCT/ATTCC 41 2 -24, 27 2 -22, 25 
2 ATTCT/TCTCT 6 8 -52, 67 5 -42, 51 
2 ATTCT/TCTTT 20 -3 -37, 31 -2 -33, 29 
2 ATTCT/TTTCT 8 8 -44, 60 5 -37, 48 
2 TCTCT/TCTTT 10 -13 -60, 34 -9 -49, 31 
2 TCTTT/TCTTT 30 12 -17, 41 10 -16, 37 
2 TTTCT/TCTTT 13 21 -20, 63 16 -20, 52 
2 ATTCC/ATTCC 150 REF  REF  
* N = 580, excludes 2 women missing more than 50% of IGF-I SNPs included in diplotype estimation. 
† N = 558, excludes 14 women with less than 90% posterior probability for best diplotype assignment in PHASE software and 8 women missing  
   plasma IGF-I levels. 
‡ Units: ng/ml. 
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Group Diplotypes N† 
Maximum 
Likelihood 
Estimates‡ 
95% Confidence 
Interval‡ 
Posterior 
Medians‡ 
95% Posterior 
Limits‡ 
 Intercept  166 152, 181   
3 Rare 9 -38 -87, 12 -26 -67, 15 
3 AACC/AACC 7 5 -51, 61 3 -41, 48 
3 AACC/AACT 7 -18 -74, 38 -12 -56, 33 
3 AACC/AGGT 15 -4 -43, 36 -3 -38, 32 
3 AACC/TACC 11 -10 -55, 35 -7 -46, 31 
3 AACC/TACT 55 -6 -30, 18 -5 -28, 18 
3 AACT/AGGT 6 -14 -74, 46 -8 -55, 38 
3 AACT/TACT 13 10 -33, 52 7 -29, 44 
3 AAGC/AACC 35 0 -28, 28 0 -26, 26 
3 AAGC/AACT 9 109 59, 159 75 34, 116 
3 AAGC/AAGC 34 8 -21, 36 7 -20, 33 
3 AAGC/AGGT 24 4 -28, 37 4 -26, 33 
3 AAGC/TACC 28 -11 -41, 20 -9 -37, 19 
3 AAGC/TACT 86 -9 -30, 12 -9 -29, 12 
3 AGGT/AGGT 10 18 -29, 65 13 -27, 53 
3 AGGT/TACT 47 2 -23, 28 2 -22, 26 
3 TACC/TACC 6 -28 -88, 32 -17 -63, 30 
3 TACC/TACT 45 -12 -37, 14 -10 -35, 14 
3 TACT/TACT 98 REF  REF  
* N = 580, excludes 2 women missing more than 50% of IGF-I SNPs included in diplotype estimation. 
† N = 545, excludes 27 women with less than 90% posterior probability for best diplotype assignment in PHASE software and 8 women missing  
   plasma IGF-I levels. 
‡ Units: ng/ml. 
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Group Diplotypes N† 
Maximum 
Likelihood 
Estimates‡ 
95% Confidence 
Interval‡ 
Posterior 
Medians‡ 
95% Posterior 
Limits‡ 
 Intercept  162 152, 171   
4 CA/CA 93 4 -14, 22 4 -13, 21 
4 CA/TA 40 38 13, 63 34 11, 57 
4 CG/CG 147 -2 -18, 13 -2 -17, 12 
4 CG/TA 45 -1 -25, 22 -1 -23, 21 
4 TA/TA 8 -1 -52, 51 0 -43, 42 
4 CA/CG 232 REF  REF  
* N = 580, excludes 2 women missing more than 50% of IGF-I SNPs included in diplotype estimation. 
† N = 565, excludes 7 women with less than 90% posterior probability for best diplotype assignment in PHASE software and 8 women missing  
   plasma IGF-I levels. 
‡ Units: ng/ml. 
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Table A.15. Unadjusted prevalence differences of uterine fibroids (any size) with IGFBP-3 group-specific diplotypes among 
Caucasians* 
 
Group Diplotypes 
N (any 
fibroids)† 
total N† 
 Prevalence 
Differences‡ 
95% Confidence 
Intervals‡ 
Posterior 
Medians 
95% Posterior 
Limits 
1 Rare 24 45 -0.024 -0.216, 0.168 -0.015 -0.167, 0.137 
1 GCGGAC/GCGGAC 13 21 0.062 -0.181, 0.304 0.032 -0.142, 0.206 
1 TACGGA/TACGGC 8 22 -0.194 -0.430, 0.043 -0.102 -0.274, 0.070 
1 TACGGA/TCGCAC 5 10 -0.057 -0.391, 0.277 -0.021 -0.221, 0.180 
1 TACGGC/TACGGC 21 33 0.079 -0.127, 0.285 0.047 -0.112, 0.206 
1 TACGGC/TAGGGC 5 13 -0.173 -0.465, 0.120 -0.073 -0.263, 0.117 
1 TACGGC/TCGCAC 28 55 -0.048 -0.230, 0.133 -0.032 -0.179, 0.115 
1 TACGGC/TCGGGA 13 31 -0.138 -0.352, 0.076 -0.080 -0.242, 0.083 
1 TAGGGC/GCGGAC 1 6 -0.391 -0.714, -0.068 -0.146 -0.344, 0.051 
1 TCGCAC/GCGGAC 11 23 -0.079 -0.318, 0.160 -0.041 -0.214, 0.132 
1 TCGCAC/TCGCAC 4 13 -0.250 -0.530, 0.030 -0.111 -0.297, 0.076 
1 TCGGGA/GCGGAC 4 11 -0.194 -0.504, 0.117 -0.076 -0.271, 0.118 
1 TCGGGA/TCGCAC 10 15 0.109 -0.160, 0.378 0.051 -0.133, 0.234 
1 TCGGGA/TCGGGA 4 6 0.109 -0.288, 0.507 0.031 -0.181, 0.243 
1 TACGGC/GCGGAC 34 61 REF  REF  
* N = 401, excludes 1 woman missing more than 50% of IGFBP-3 SNPs included in diplotype estimation. 
† N = 365, excludes 30 women with less than 90% posterior probability for best diplotype assignment in PHASE software and 6 women missing  
   uterine fibroid status. 
‡ Estimated in SASV9.1 using Poisson regression with robust standard errors. 
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Group Diplotypes 
N (any 
fibroids)† 
total N† 
 Prevalence 
Differences‡ 
95% Confidence 
Intervals‡ 
Posterior 
Medians 
95% Posterior 
Limits 
2 Rare 2 5 -0.131 -0.578, 0.315 -0.031 -0.249, 0.187 
2 AGCA/AGCA 8 12 0.135 -0.158, 0.429 0.057 -0.133, 0.247 
2 TACA/AGCA 20 34 0.057 -0.149, 0.263 0.034 -0.125, 0.193 
2 TACA/TACA 6 12 -0.031 -0.339, 0.277 -0.012 -0.207, 0.182 
2 TACA/TATA 2 6 -0.198 -0.594, 0.199 -0.056 -0.268, 0.155 
2 TACA/TGCA 21 51 -0.119 -0.302, 0.063 -0.078 -0.225, 0.069 
2 TACA/TGTC 10 17 0.057 -0.207, 0.321 0.027 -0.155, 0.208 
2 TATA/AGCA 5 9 0.024 -0.323, 0.371 0.008 -0.195, 0.211 
2 TATA/TGCA 5 9 0.024 -0.323, 0.371 0.008 -0.195, 0.211 
2 TGCA/TGCA 28 62 -0.080 -0.254, 0.094 -0.054 -0.196, 0.089 
2 TGCA/TGTC 30 61 -0.039 -0.215, 0.136 -0.026 -0.170, 0.117 
2 TGTC/AGCA 17 32 0.000 -0.212, 0.212  0.000 -0.162, 0.162 
2 TGTC/TGTC 7 10 0.169 -0.140, 0.478 0.067 -0.128, 0.261 
2 TGCA/AGCA 34 64 REF  REF  
* N = 401, excludes 1 woman missing more than 50% of IGFBP-3 SNPs included in diplotype estimation. 
† N = 384, excludes 9 women with less than 90% posterior probability for best diplotype assignment in PHASE software and 8 women missing  
   uterine fibroid status. 
‡ Estimated in SASV9.1 using Poisson regression with robust standard errors. 
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Table A.16. Unadjusted prevalence differences of uterine fibroids (2+ cm) with IGFBP-3 group-specific diplotypes among 
Caucasians* 
 
Group Diplotypes 
N (fibroids 
2+ cm)† 
total N† 
 Prevalence 
Differences‡ 
95% Confidence 
Intervals‡ 
Posterior 
Medians 
95% Posterior 
Limits 
1 Rare|| 16 51 -0.096 -0.273, 0.081 -0.064 -0.209, 0.081 
1 GCGGAC/GCGGAC 7 21 -0.077 -0.313, 0.160 -0.040 -0.212, 0.131 
1 TACGGA/TACGGC 5 22 -0.183 -0.397, 0.032 -0.105 -0.268, 0.057 
1 TACGGA/TCGCAC 3 10 -0.110 -0.420, 0.200 -0.043 -0.238, 0.151 
1 TACGGC/TACGGC 12 33 -0.046 -0.252, 0.159 -0.028 -0.186, 0.131 
1 TACGGC/TAGGGC 4 13 -0.102 -0.382, 0.177 -0.045 -0.232, 0.141 
1 TACGGC/TCGCAC 19 55 -0.064 -0.241, 0.112 -0.043 -0.187, 0.101 
1 TACGGC/TCGGGA 9 31 -0.120 -0.321, 0.082 -0.072 -0.229, 0.085 
1 TCGCAC/GCGGAC 7 23 -0.105 -0.330, 0.119 -0.058 -0.226, 0.109 
1 TCGCAC/TCGCAC 2 13 -0.256 -0.488, -0.024 -0.138 -0.308, 0.032 
1 TCGGGA/GCGGAC 3 11 -0.137 -0.428, 0.154 -0.058 -0.248, 0.131 
1 TCGGGA/TCGCAC 5 15 -0.077 -0.345, 0.192 -0.036 -0.219, 0.147 
1 TCGGGA/TCGGGA 4 6 0.257 -0.140, 0.654 0.073 -0.139, 0.284 
1 TACGGC/GCGGAC 25 61 REF  REF  
* N = 401, excludes 1 woman missing more than 50% of IGFBP-3 SNPs included in diplotype estimation. 
† N = 365, excludes 30 women with less than 90% posterior probability for best diplotype assignment in PHASE software and 6 women missing  
   uterine fibroid status. 
‡ Estimated in SASV9.1 using Poisson regression with robust standard errors. 
|| Includes TAGGGC/GCGGAC diplotype, which was analyzed separately in relation to any fibroids.  However, no women with this diplotype had    
   fibroids 2+ cm, and estimating a prevalence difference for this diplotype resulted in convergences problems for model. 
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Group Diplotypes 
N (fibroids 
2+ cm)† 
total N† 
 Prevalence 
Differences‡ 
95% Confidence 
Intervals‡ 
Posterior 
Medians 
95% Posterior 
Limits 
2 Rare 2 5 0.088 -0.357, 0.532 0.021 -0.197, 0.239 
2 AGCA/AGCA 5 12 0.104 -0.197, 0.405 0.042 -0.150, 0.235 
2 TACA/AGCA 15 34 0.129 -0.073, 0.331 0.078 -0.079, 0.235 
2 TACA/TACA 3 12 -0.062 -0.333, 0.208 -0.029 -0.212, 0.155 
2 TACA/TATA 1 6 -0.146 -0.465, 0.173 -0.055 -0.252, 0.141 
2 TACA/TGCA 11 51 -0.097 -0.257, 0.063 -0.069 -0.203, 0.066 
2 TACA/TGTC 8 17 0.158 -0.105, 0.421 0.075 -0.106, 0.256 
2 TATA/AGCA 5 9 0.243 -0.101, 0.587 0.084 -0.118, 0.286 
2 TATA/TGCA 4 9 0.132 -0.212, 0.476 0.046 -0.157, 0.248 
2 TGCA/TGCA 22 62 0.042 -0.122, 0.207 0.030 -0.108, 0.167 
2 TGCA/TGTC 17 61 -0.034 -0.194, 0.126 -0.024 -0.159, 0.111 
2 TGTC/AGCA 11 32 0.031 -0.169, 0.231 0.019 -0.137, 0.175 
2 TGTC/TGTC 5 10 0.188 -0.143, 0.518 0.068 -0.131, 0.268 
2 TGCA/AGCA 20 64 REF  REF  
* N = 401, excludes 1 woman missing more than 50% of IGFBP-3 SNPs included in diplotype estimation. 
† N = 384, excludes 9 women with less than 90% posterior probability for best diplotype assignment in PHASE software and 8 women missing  
   uterine fibroid status. 
‡ Estimated in SASV9.1 using Poisson regression with robust standard errors. 
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Table A.17. Unadjusted prevalence differences of uterine fibroids (any size) with IGFBP-3 group-specific diplotypes among 
African Americans* 
 
Group Diplotypes 
N (any 
fibroids )† 
total N† 
 Prevalence 
Differences‡ 
95% Confidence 
Intervals‡ 
Posterior 
Medians 
95% Posterior 
Limits 
1 Rare 33 49 -0.038 -0.199, 0.124 -0.027 -0.162, 0.109 
1 TACGAGG/GCGGAGA 11 17 -0.064 -0.310, 0.182 -0.033 -0.208, 0.143 
1 TACGAGG/GCGGCAA 11 15 0.022 -0.220, 0.265 0.011 -0.163, 0.186 
1 TACGAGG/TACGAGG 38 51 0.034 -0.118, 0.186 0.025 -0.105, 0.155 
1 TAGGAGA/TACGAGG 6 10 -0.111 -0.429, 0.207 -0.042 -0.239, 0.154 
1 TAGGAGA/TAGGAGG 5 7 0.003 -0.344, 0.351 0.001 -0.202, 0.204 
1 TAGGAGG/GCGGAGA 7 13 -0.173 -0.459, 0.114 -0.075 -0.263, 0.114 
1 TAGGAGG/TAGGAGG 27 34 0.083 -0.082, 0.248 0.058 -0.080, 0.196 
1 TCGCAGA/GCGGAGA 9 10 0.189 -0.019, 0.397 0.112 -0.048, 0.272 
1 TCGCAGA/GCGGCAA 4 9 -0.267 -0.605, 0.071 -0.094 -0.295, 0.107 
1 TCGCAGA/TACGAGG 52 71 0.021 -0.118, 0.160 0.016 -0.105, 0.138 
1 TCGCAGA/TAGGAGA 6 8 0.039 -0.275, 0.353 0.015 -0.181, 0.211 
1 TCGCAGA/TAGGAGG 33 44 0.039 -0.120, 0.197 0.028 -0.106, 0.162 
1 TCGCAGA/TCGCAGA 23 25 0.209 0.067, 0.351 0.158 0.035, 0.281 
1 TCGCAGA/TCGGAGG 15 20 0.039 -0.173, 0.251 0.023 -0.139, 0.184 
1 TCGGAGA/TACGAGG 8 11 0.016 -0.263, 0.296 0.007 -0.179, 0.193 
1 TCGGAGG/TACGAGG 21 31 -0.034 -0.223, 0.156 -0.021 -0.172, 0.130 
1 TCGGAGG/TAGGAGG 15 19 0.078 -0.127, 0.284 0.047 -0.112, 0.206 
1 TCGGAGG/TCGGAGG 4 7 -0.140 -0.518, 0.239 -0.042 -0.251, 0.166 
1 TAGGAGG/TACGAGG 64 90 REF  REF  
* N = 579, excludes 3 women missing more than 50% of IGFBP-3 SNPs included in diplotype estimation. 
† N = 541, excludes 32 women with less than 90% posterior probability for best diplotype assignment in PHASE software and 6 women missing  
   uterine fibroid status. 
‡ Estimated in SASV9.1 using Poisson regression with robust standard errors. 
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Group Diplotypes 
N (any 
fibroids)† 
total N† 
 Prevalence 
Differences‡ 
95% Confidence 
Intervals‡ 
Posterior 
Medians 
95% Posterior 
Limits 
2 AC/AC 6 7 0.121 -0.145, 0.387 0.057 -0.125, 0.239 
2 CC/AC 19 28 -0.058 -0.240, 0.125 -0.038 -0.185, 0.110 
2 CC/CC 44 58 0.023 -0.102, 0.147 0.018 -0.094, 0.130 
2 CT/AC 40 60 -0.069 -0.202, 0.064 -0.054 -0.172, 0.063 
2 CT/CT 144 195 0.002 -0.083, 0.088 0.002 -0.079, 0.083 
2 CT/CC 159 216 REF  REF  
* N = 579, excludes 3 women missing more than 50% of IGFBP-3 SNPs included in diplotype estimation. 
† N = 564, excludes 8 women with less than 90% posterior probability for best diplotype assignment in PHASE software and 7 women missing  
   uterine fibroid status. 
‡ Estimated in SASV9.1 using Poisson regression with robust standard errors. 
 
Group Diplotypes 
N (any 
fibroids)† 
total N† 
 Prevalence 
Differences‡ 
95% Confidence 
Intervals‡ 
Posterior 
Medians 
95% Posterior 
Limits 
3 Rare 12 14 0.067 -0.130, 0.264 0.041 -0.113, 0.196 
3 AGCA/AGCA 6 9 -0.124 -0.440, 0.193 -0.048 -0.244, 0.149 
3 TACA/AGCA 8 15 -0.257 -0.519, 0.005 -0.122 -0.303, 0.059 
3 TACA/TACA 7 10 -0.090 -0.383, 0.203 -0.038 -0.228, 0.152 
3 TACA/TGCA 31 43 -0.069 -0.221, 0.083 -0.051 -0.181, 0.079 
3 TATA/AGCA 36 47 -0.024 -0.165, 0.116 -0.019 -0.141, 0.104 
3 TATA/TACA 30 40 -0.040 -0.192, 0.112 -0.029 -0.159, 0.101 
3 TATA/TATA 40 52 -0.021 -0.156, 0.114 -0.016 -0.135, 0.103 
3 TATA/TGTC 12 18 -0.124 -0.353, 0.106 -0.067 -0.236, 0.102 
3 TGCA/AGCA 43 53 0.021 -0.106, 0.148 0.017 -0.097, 0.130 
3 TGCA/TGCA 71 104 -0.108 -0.222, 0.007 -0.089 -0.193, 0.015 
3 TGTC/AGCA 5 6 0.043 -0.264, 0.350 0.017 -0.177, 0.211 
3 TGTC/TGCA 8 13 -0.175 -0.449, 0.099 -0.079 -0.264, 0.105 
3 TATA/TGCA 98 124 REF  REF  
* N = 579, excludes 3 women missing more than 50% of IGFBP-3 SNPs included in diplotype estimation. 
† N = 548, excludes 24 women with less than 90% posterior probability for best diplotype assignment in PHASE software and 7 women missing  
   uterine fibroid status. 
‡ Estimated in SASV9.1 using Poisson regression with robust standard errors. 
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Table A.18. Unadjusted prevalence differences of uterine fibroids (2+ cm) with IGFBP-3 group-specific diplotypes among 
African Americans* 
 
Group Diplotypes 
N (fibroids 
2+ cm)† 
total N† 
 Prevalence 
Differences‡ 
95% Confidence 
Intervals‡ 
Posterior 
Medians 
95% Posterior 
Limits 
1 Rare 27 49 -0.027 -0.199, 0.146 -0.018 -0.160, 0.124 
1 TACGAGG/GCGGAGA 10 17 0.010 -0.245, 0.266 0.005 -0.173, 0.184 
1 TACGAGG/GCGGCAA 9 15 0.022 -0.246, 0.290 0.010 -0.173, 0.193 
1 TACGAGG/TACGAGG 30 51 0.010 -0.159, 0.180 0.007 -0.133, 0.147 
1 TAGGAGA/TACGAGG 5 10 -0.078 -0.404, 0.248 -0.029 -0.227, 0.170 
1 TAGGAGA/TAGGAGG 5 7 0.137 -0.213, 0.486 0.046 -0.157, 0.250 
1 TAGGAGG/GCGGAGA 7 13 -0.039 -0.329, 0.250 -0.017 -0.206, 0.172 
1 TAGGAGG/TAGGAGG 23 34 0.099 -0.089, 0.286 0.063 -0.087, 0.213 
1 TCGCAGA/GCGGAGA 9 10 0.322 0.110, 0.534 0.187 0.026, 0.349 
1 TCGCAGA/GCGGCAA 3 9 -0.244 -0.569, 0.080 -0.091 -0.289, 0.107 
1 TCGCAGA/TACGAGG 36 71 -0.071 -0.225, 0.084 -0.051 -0.183, 0.080 
1 TCGCAGA/TAGGAGA 4 8 -0.078 -0.439, 0.283 -0.025 -0.231, 0.180 
1 TCGCAGA/TAGGAGG 25 44 -0.010 -0.188, 0.169 -0.006 -0.152, 0.139 
1 TCGCAGA/TCGCAGA 18 25 0.142 -0.061, 0.346 0.086 -0.072, 0.243 
1 TCGCAGA/TCGGAGG 13 20 0.072 -0.160, 0.305 0.039 -0.132, 0.209 
1 TCGGAGA/TACGAGG 6 11 -0.032 -0.344, 0.279 -0.013 -0.208, 0.182 
1 TCGGAGG/TACGAGG 14 31 -0.126 -0.329, 0.077 -0.076 -0.234, 0.081 
1 TCGGAGG/TAGGAGG 9 19 -0.104 -0.351, 0.143 -0.053 -0.228, 0.123 
1 TCGGAGG/TCGGAGG 2 7 -0.292 -0.642, 0.058 -0.099 -0.302, 0.105 
1 TAGGAGG/TACGAGG 52 90 REF  REF  
* N = 579, excludes 3 women missing more than 50% of IGFBP-3 SNPs included in diplotype estimation. 
† N = 541, excludes 32 women with less than 90% posterior probability for best diplotype assignment in PHASE software and 6 women missing  
   uterine fibroid status. 
‡ Estimated in SASV9.1 using Poisson regression with robust standard errors. 
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Group Diplotypes 
N (fibroids 
2+ cm)† 
total N† 
 Prevalence 
Differences‡ 
95% Confidence 
Intervals‡ 
Posterior 
Medians 
95% Posterior 
Limits 
2 AC/AC 5 7 0.140 -0.201, 0.481 0.049 -0.153, 0.251 
2 CC/AC 13 28 -0.110 -0.306, 0.086 -0.068 -0.222, 0.086 
2 CC/CC 37 58 0.064 -0.076, 0.204 0.049 -0.074, 0.171 
2 CT/AC 34 60 -0.007 -0.149, 0.134 -0.006 -0.129, 0.118 
2 CT/CT 107 195 -0.025 -0.121, 0.071 -0.022 -0.112, 0.068 
2 CT/CC 124 216 REF  REF  
* N = 579, excludes 3 women missing more than 50% of IGFBP-3 SNPs included in diplotype estimation. 
† N = 564, excludes 8 women with less than 90% posterior probability for best diplotype assignment in PHASE software and 7 women missing  
   uterine fibroid status. 
‡ Estimated in SASV9.1 using Poisson regression with robust standard errors. 
 
Group Diplotypes 
N (fibroids 
2+ cm)† 
total N† 
 Prevalence 
Differences‡ 
95% Confidence 
Intervals‡ 
Posterior 
Medians 
95% Posterior 
Limits 
3 Rare 8 14 -0.082 -0.354, 0.191 -0.037 -0.222, 0.147 
3 AGCA/AGCA 3 9 -0.320 -0.639, -0.001 -0.122 -0.318, 0.075 
3 TACA/AGCA 5 15 -0.320 -0.573, -0.067 -0.158 -0.336, 0.020 
3 TACA/TACA 7 10 0.047 -0.249, 0.343 0.019 -0.172, 0.210 
3 TACA/TGCA 28 43 -0.002 -0.167, 0.163 -0.001 -0.139, 0.136 
3 TATA/AGCA 27 47 -0.079 -0.243, 0.086 -0.055 -0.192, 0.082 
3 TATA/TACA 26 40 -0.003 -0.173, 0.167 -0.002 -0.143, 0.138 
3 TATA/TATA 29 52 -0.096 -0.254, 0.063 -0.068 -0.202, 0.066 
3 TATA/TGTC 9 18 -0.153 -0.399, 0.092 -0.078 -0.253, 0.097 
3 TGCA/AGCA 36 53 0.026 -0.125, 0.177 0.019 -0.110, 0.148 
3 TGCA/TGCA 50 104 -0.172 -0.300, -0.045 -0.137 -0.250, -0.023 
3 TGTC/AGCA 4 6 0.013 -0.373, 0.400 0.004 -0.206, 0.214 
3 TGTC/TGCA 5 13 -0.269 -0.546, 0.009 -0.120 -0.306, 0.065 
3 TATA/TGCA 81 124 REF  REF  
* N = 579, excludes 3 women missing more than 50% of IGFBP-3 SNPs included in diplotype estimation. 
† N = 548, excludes 24 women with less than 90% posterior probability for best diplotype assignment in PHASE software and 7 women missing  
   uterine fibroid status. 
‡ Estimated in SASV9.1 using Poisson regression with robust standard errors. 
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Table A.19. Unadjusted prevalence differences of uterine fibroids (any size) with IGF-I group-specific diplotypes among 
Caucasians* 
 
Group† Diplotypes 
N (any 
fibroids)‡ 
total N‡ 
 Prevalence 
Differences|| 
95% Confidence 
Intervals|| 
Posterior 
Medians 
95% Posterior 
Limits 
1 A/G, A/A 59 114 0.008 -0.101, 0.118 0.007 -0.093, 0.107 
1 G/G 139 273 REF   REF   
* N = 399, excludes 3 women missing more than 50% of IGF-I SNPs included in diplotype estimation. 
† rs35767 represents entire group because it could not be combined with block 1 SNPs for diplotype estimation. 
‡ N = 387, excludes 4 women missing SNP genotype and 8 women missing uterine fibroid status. 
|| Estimated in SASV9.1 using Poisson regression with robust standard errors. 
 
 
Group Diplotypes 
N (any 
fibroids)† 
total N† 
 Prevalence 
Differences‡ 
95% Confidence 
Intervals‡ 
Posterior 
Medians 
95% Posterior 
Limits 
2 Rare 5 10 -0.028 -0.352, 0.296 -0.010 -0.208, 0.188 
2 AAT/ACT 3 10 -0.228 -0.527, 0.071 -0.094 -0.285, 0.098 
2 AAT/GCC 10 22 -0.073 -0.302, 0.155 -0.040 -0.209, 0.129 
2 AAT/GCT 25 50 -0.028 -0.195, 0.140 -0.019 -0.158, 0.120 
2 ACT/GCC 14 26 0.011 -0.203, 0.224 0.006 -0.156, 0.169 
2 ACT/GCT 20 34 0.060 -0.130, 0.251 0.038 -0.113, 0.190 
2 GCC/GCC 17 28 0.079 -0.125, 0.283 0.048 -0.110, 0.206 
2 GCT/GCT 46 98 -0.058 -0.195, 0.078 -0.045 -0.165, 0.075 
2 GCT/GCC 57 108 REF   REF   
* N = 399, excludes 3 women missing more than 50% of IGF-I SNPs included in diplotype estimation. 
† N = 386, excludes 5 women with less than 90% posterior probability for best diplotype assignment in PHASE software and 8 women missing        
   uterine fibroid status. 
‡ Estimated in SASV9.1 using Poisson regression with robust standard errors. 
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Group Diplotypes 
N (any 
fibroids)† 
total N† 
 Prevalence 
Differences‡ 
95% Confidence 
Intervals‡ 
Posterior 
Medians 
95% Posterior 
Limits 
3 Rare 11 22 -0.120 -0.351, 0.112 -0.064 -0.234, 0.105 
3 GCTCT/GCTGC 4 8 -0.120 -0.480, 0.241 -0.039 -0.244, 0.167 
3 GGCCC/AGTGC 11 21 -0.096 -0.331, 0.140 -0.051 -0.222, 0.121 
3 GGCCC/GCTCT 14 25 -0.060 -0.278, 0.159 -0.034 -0.198, 0.131 
3 GGCCC/GCTGC 14 35 -0.220 -0.410, -0.029 -0.139 -0.290, 0.012 
3 GGCCC/GGCCC 36 76 -0.146 -0.296, 0.004 -0.107 -0.236, 0.021 
3 GGCCT/AGTGC 6 16 -0.245 -0.502, 0.013 -0.119 -0.298, 0.060 
3 GGCCT/GCTCT 16 24 0.047 -0.166, 0.260 0.027 -0.135, 0.189 
3 GGCCT/GCTGC 11 23 -0.141 -0.368, 0.086 -0.077 -0.246, 0.091 
3 GGCCT/GGCCT 12 33 -0.256 -0.448, -0.064 -0.161 -0.313, -0.009 
3 GGCCT/GGTGT 2 7 -0.334 -0.683, 0.015 -0.113 -0.316, 0.090 
3 GGCCC/GGCCT 57 92 REF  REF  
* N = 399, excludes 3 women missing more than 50% of IGF-I SNPs included in diplotype estimation. 
† N = 382, excludes 9 women with less than 90% posterior probability for best diplotype assignment in PHASE software and 8 women missing        
   uterine fibroid status. 
‡ Estimated in SASV9.1 using Poisson regression with robust standard errors. 
 
 
Group Diplotypes 
N (any 
fibroids)† 
total N† 
 Prevalence 
Differences‡ 
95% Confidence 
Intervals‡ 
Posterior 
Medians 
95% Posterior 
Limits 
4 CA/TA, Rare 9 16 0.019 -0.236, 0.273 0.009 -0.169, 0.187 
4 CA/CA 8 22 -0.180 -0.395, 0.034 -0.104 -0.267, 0.059 
4 CG/CA 62 118 -0.018 -0.135, 0.099 -0.015 -0.121, 0.091 
4 CG/TA 26 59 -0.103 -0.250, 0.044 -0.077 -0.203, 0.050 
4 CG/CG 93 171 REF  REF  
* N = 399, excludes 3 women missing more than 50% of IGF-I SNPs included in diplotype estimation. 
† N = 386, excludes 5 women with less than 90% posterior probability for best diplotype assignment in PHASE software and 8 women missing        
   uterine fibroid status. 
‡ Estimated in SASV9.1 using Poisson regression with robust standard errors. 
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Table A.20. Unadjusted prevalence differences of uterine fibroids (2+ cm) with IGF-I group-specific diplotypes among 
Caucasians* 
 
Group† Diplotypes 
N (fibroids 
2+ cm)‡ 
total N‡ 
 Prevalence 
Differences|| 
95% Confidence 
Intervals|| 
Posterior 
Medians 
95% Posterior 
Limits 
1 A/G, A/A 40 114 0.018 -0.086, 0.121 0.015 -0.081, 0.111 
1 G/G 91 273 REF  REF  
* N = 399, excludes 3 women missing more than 50% of IGF-I SNPs included in diplotype estimation. 
† rs35767 represents entire group because it could not be combined with block 1 SNPs for diplotype estimation. 
‡ N = 387, excludes 4 women missing SNP genotype and 8 women missing uterine fibroid status. 
|| Estimated in SASV9.1 using Poisson regression with robust standard errors. 
 
 
Group Diplotypes 
N (fibroids 
2+ cm)† 
total N† 
 Prevalence 
Differences‡ 
95% Confidence 
Intervals‡ 
Posterior 
Medians 
95% Posterior 
Limits 
2 Rare 3 10 -0.024 -0.321, 0.273 -0.010 -0.201, 0.181 
2 AAT/ACT 2 10 -0.124 -0.387, 0.139 -0.059 -0.240, 0.122 
2 AAT/GCC 8 22 0.040 -0.180, 0.259 0.022 -0.143, 0.187 
2 AAT/GCT 16 50 -0.004 -0.161, 0.152 -0.003 -0.136, 0.130 
2 ACT/GCC 10 26 0.061 -0.146, 0.267 0.036 -0.123, 0.195 
2 ACT/GCT 13 34 0.058 -0.127, 0.244 0.038 -0.111, 0.187 
2 GCC/GCC 11 28 0.069 -0.133, 0.270 0.042 -0.115, 0.199 
2 GCT/GCT 32 98 0.002 -0.126, 0.131 0.002 -0.112, 0.116 
2 GCT/GCC 35 108 REF   REF   
* N = 399, excludes 3 women missing more than 50% of IGF-I SNPs included in diplotype estimation. 
† N = 386, excludes 5 women with less than 90% posterior probability for best diplotype assignment in PHASE software and 8 women missing        
   uterine fibroid status. 
‡ Estimated in SASV9.1 using Poisson regression with robust standard errors. 
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Group Diplotypes 
N (fibroids 
2+ cm)† 
total N† 
 Prevalence 
Differences‡ 
95% Confidence 
Intervals‡ 
Posterior 
Medians 
95% Posterior 
Limits 
3 Rare 9 22 0.029 -0.199, 0.257 0.016 -0.153, 0.184 
3 GCTCT/GCTGC 2 8 -0.130 -0.446, 0.186 -0.050 -0.246, 0.146 
3 GGCCC/AGTGC 10 21 0.096 -0.140, 0.331 0.051 -0.121, 0.222 
3 GGCCC/GCTCT 9 25 -0.020 -0.233, 0.192 -0.012 -0.174, 0.150 
3 GGCCC/GCTGC 10 35 -0.095 -0.274, 0.085 -0.062 -0.208, 0.083 
3 GGCCC/GGCCC 26 76 -0.038 -0.184, 0.107 -0.029 -0.154, 0.097 
3 GGCCT/AGTGC 2 16 -0.255 -0.445, -0.065 -0.162 -0.313, -0.011 
3 GGCCT/GCTCT 9 24 -0.005 -0.223, 0.212 -0.003 -0.167, 0.161 
3 GGCCT/GCTGC 7 23 -0.076 -0.289, 0.137 -0.044 -0.206, 0.118 
3 GGCCT/GGCCT 8 33 -0.138 -0.315, 0.039 -0.092 -0.236, 0.052 
3 GGCCT/GGTGT 1 7 -0.238 -0.515, 0.040 -0.106 -0.292, 0.079 
3 GGCCC/GGCCT 35 92 REF   REF   
* N = 399, excludes 3 women missing more than 50% of IGF-I SNPs included in diplotype estimation. 
† N = 382, excludes 9 women with less than 90% posterior probability for best diplotype assignment in PHASE software and 8 women missing        
   uterine fibroid status. 
‡ Estimated in SASV9.1 using Poisson regression with robust standard errors. 
 
 
Group Diplotypes 
N (fibroids 
2+ cm)† 
total N† 
 Prevalence 
Differences‡ 
95% Confidence 
Intervals‡ 
Posterior 
Medians 
95% Posterior 
Limits 
4 CA/TA, Rare 8 16 0.126 -0.130, 0.381 0.061 -0.117, 0.240 
4 CA/CA 4 22 -0.192 -0.369, -0.016 -0.128 -0.273, 0.016 
4 CG/CA 39 118 -0.044 -0.155, 0.068 -0.036 -0.138, 0.065 
4 CG/TA 16 59 -0.103 -0.238, 0.032 -0.080 -0.198, 0.039 
4 CG/CG 64 171 REF  REF  
* N = 399, excludes 3 women missing more than 50% of IGF-I SNPs included in diplotype estimation. 
† N = 386, excludes 5 women with less than 90% posterior probability for best diplotype assignment in PHASE software and 8 women missing        
   uterine fibroid status. 
‡ Estimated in SASV9.1 using Poisson regression with robust standard errors. 
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Table A.21. Unadjusted prevalence differences of uterine fibroids (any size) with IGF-I group-specific diplotypes among 
African Americans* 
 
Group Diplotypes 
N (any 
fibroids)† 
total N† 
 Prevalence 
Differences‡ 
95% Confidence 
Intervals‡ 
Posterior 
Medians 
95% Posterior 
Limits 
1 Rare 6 9 -0.092 -0.406, 0.223 -0.036 -0.231, 0.160 
1 AGG/AGG 81 101 0.044 -0.056, 0.143 0.038 -0.055, 0.130 
1 AGG/GCG 34 51 -0.092 -0.235, 0.052 -0.069 -0.193, 0.056 
1 AGG/GGA 22 30 -0.025 -0.195, 0.145 -0.017 -0.158, 0.124 
1 GCG/GCG 6 8 -0.008 -0.315, 0.298 -0.003 -0.197, 0.190 
1 GGG/GCG 32 55 -0.176 -0.321, -0.032 -0.132 -0.257, -0.007 
1 GGG/GGA 19 24 0.033 -0.141, 0.207 0.023 -0.120, 0.165 
1 GGG/GGG 75 106 -0.051 -0.157, 0.056 -0.043 -0.141, 0.055 
1 AGG/GGG 138 182 REF  REF  
* N = 580, excludes 2 women missing more than 50% of IGFBP-3 SNPs included in diplotype estimation. 
† N = 566, excludes 7 women with less than 90% posterior probability for best diplotype assignment in PHASE software and 7 women missing  
   uterine fibroid status. 
‡ Estimated in SASV9.1 using Poisson regression with robust standard errors. 
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Group Diplotypes 
N (any 
fibroids)† 
total N† 
 Prevalence 
Differences‡ 
95% Confidence 
Intervals‡ 
Posterior 
Medians 
95% Posterior 
Limits 
2 Rare 28 38 0.025 -0.132, 0.183 0.018 -0.115, 0.152 
2 ATCCC/TCTTT 11 13 0.135 -0.074, 0.344 0.079 -0.081, 0.240 
2 ATTCC/ATCCC 28 37 0.045 -0.111, 0.202 0.033 -0.100,  0.165 
2 ATTCC/ATTTT 7 10 -0.011 -0.305, 0.282 -0.005 -0.195, 0.185 
2 ATTCC/TCTCC 4 8 -0.211 -0.565, 0.143 -0.070 -0.275, 0.134 
2 ATTCC/TCTCT 13 16 0.101 -0.104, 0.306 0.061 -0.098, 0.219 
2 ATTCC/TCTTT 88 119 0.028 -0.079, 0.135 0.024 -0.075, 0.122 
2 ATTCC/TTTCT 23 34 -0.035 -0.208, 0.138 -0.024 -0.166, 0.119 
2 ATTCT/ATCCC 4 6 -0.045 -0.429, 0.339 -0.013 -0.223, 0.196 
2 ATTCT/ATTCC 32 40 0.089 -0.055, 0.232 0.067 -0.058, 0.191 
2 ATTCT/TCTCT 5 6 0.122 -0.185, 0.429 0.049 -0.145, 0.242 
2 ATTCT/TCTTT 14 20 -0.011 -0.225, 0.202 -0.007 -0.169, 0.156 
2 ATTCT/TTTCT 7 8 0.164 -0.077, 0.404 0.085 -0.088, 0.258 
2 TCTCT/TCTTT 6 10 -0.111 -0.424, 0.201 -0.044 -0.239, 0.152 
2 TCTTT/TCTTT 27 31 0.160 0.021, 0.298 0.122 0.001, 0.243 
2 TTTCT/TCTTT 6 14 -0.283 -0.552, -0.014 -0.131 -0.314, 0.052 
2 ATTCC/ATTCC 106 149 REF  REF  
* N = 580, excludes 2 women missing more than 50% of IGFBP-3 SNPs included in diplotype estimation. 
† N = 559, excludes 14 women with less than 90% posterior probability for best diplotype assignment in PHASE software and 7 women missing  
   uterine fibroid status. 
‡ Estimated in SASV9.1 using Poisson regression with robust standard errors. 
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Group Diplotypes 
N (any 
fibroids)† 
total N† 
 Prevalence 
Differences‡ 
95% Confidence 
Intervals‡ 
Posterior 
Medians 
95% Posterior 
Limits 
3 Rare 5 9 -0.214 -0.549, 0.121 -0.077 -0.277, 0.124 
3 AACC/AACC 6 8 -0.020 -0.331, 0.291 -0.008 -0.203, 0.187 
3 AACC/AACT 5 7 -0.056 -0.400, 0.289 -0.019 -0.222, 0.183 
3 AACC/AGGT 6 14 -0.341 -0.613, -0.069 -0.156 -0.340, 0.028 
3 AACC/TACC 7 10 -0.070 -0.366, 0.226 -0.029 -0.220, 0.162 
3 AACC/TACT 39 53 -0.034 -0.179, 0.110 -0.026 -0.151, 0.100 
3 AACT/AGGT 3 7 -0.341 -0.717, 0.034 -0.105 -0.313, 0.103 
3 AACT/TACT 7 13 -0.232 -0.515, 0.052 -0.101 -0.289, 0.086 
3 AAGC/AACC 23 36 -0.131 -0.308, 0.046 -0.087 -0.232, 0.057 
3 AAGC/AACT 6 9 -0.103 -0.422, 0.215 -0.039 -0.236, 0.157 
3 AAGC/AAGC 29 35 0.059 -0.091, 0.208 0.043 -0.085, 0.172 
3 AAGC/AGGT 18 24 -0.020 -0.212, 0.172 -0.013 -0.165, 0.140 
3 AAGC/TACC 22 27 0.045 -0.123, 0.213 0.031 -0.109, 0.170 
3 AAGC/TACT 64 86 -0.026 -0.150, 0.098 -0.021 -0.132, 0.090 
3 AGGT/AGGT 8 10 0.030 -0.231, 0.291 0.014 -0.166, 0.195 
3 AGGT/TACT 38 47 0.039 -0.101, 0.178 0.029 -0.092, 0.151 
3 TACC/TACC 4 6 -0.103 -0.489, 0.283 -0.031 -0.240, 0.179 
3 TACC/TACT 31 45 -0.081 -0.240, 0.077 -0.058 -0.192, 0.076 
3 TACT/TACT 77 100 REF  REF  
* N = 580, excludes 2 women missing more than 50% of IGFBP-3 SNPs included in diplotype estimation. 
† N = 546, excludes 27 women with less than 90% posterior probability for best diplotype assignment in PHASE software and 7 women missing  
   uterine fibroid status. 
‡ Estimated in SASV9.1 using Poisson regression with robust standard errors. 
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Group Diplotypes 
N (any 
fibroids)† 
total N† 
 Prevalence 
Differences‡ 
95% Confidence 
Intervals‡ 
Posterior 
Medians 
95% Posterior 
Limits 
4 CA/CA 71 93 0.071 -0.034, 0.176 0.060 -0.037, 0.157 
4 CA/TA 32 40 0.107 -0.030, 0.245 0.082 -0.038, 0.203 
4 CG/CG 108 147 0.042 -0.051, 0.135 0.037 -0.050, 0.124 
4 CG/TA 35 46 0.068 -0.069, 0.205 0.052 -0.068, 0.173 
4 TA/TA 7 9 0.085 -0.193, 0.363 0.038 -0.148, 0.224 
4 CA/CG 160 231 REF  REF  
* N = 580, excludes 2 women missing more than 50% of IGFBP-3 SNPs included in diplotype estimation. 
† N = 566, excludes 7 women with less than 90% posterior probability for best diplotype assignment in PHASE software and 7 women missing  
   uterine fibroid status. 
‡ Estimated in SASV9.1 using Poisson regression with robust standard errors. 
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Table A.22. Unadjusted prevalence differences of uterine fibroids (2+ cm) with IGF-I group-specific diplotypes among African 
Americans* 
 
Group Diplotypes 
N (fibroids 
2+ cm)† 
total N† 
 Prevalence 
Differences‡ 
95% Confidence 
Intervals‡ 
Posterior 
Medians 
95% Posterior 
Limits 
1 Rare 5 9 -0.043 -0.376, 0.289 -0.016 -0.215, 0.184 
1 AGG/AGG 64 101 0.035 -0.083, 0.153 0.028 -0.078, 0.135 
1 AGG/GCG 25 51 -0.109 -0.263, 0.046 -0.079 -0.210, 0.053 
1 AGG/GGA 17 30 -0.032 -0.223, 0.159 -0.020 -0.172, 0.131 
1 GCG/GCG 3 8 -0.224 -0.567, 0.119 -0.078 -0.280, 0.124 
1 GGG/GCG 23 55 -0.181 -0.329, -0.032 -0.134 -0.261, -0.006 
1 GGG/GGA 15 24 0.026 -0.180, 0.232 0.016 -0.144, 0.175 
1 GGG/GGG 60 106 -0.033 -0.151, 0.085 -0.027 -0.134, 0.080 
1 AGG/GGG 109 182 REF  REF  
* N = 580, excludes 2 women missing more than 50% of IGFBP-3 SNPs included in diplotype estimation. 
† N = 566, excludes 7 women with less than 90% posterior probability for best diplotype assignment in PHASE software and 7 women missing  
   uterine fibroid status. 
‡ Estimated in SASV9.1 using Poisson regression with robust standard errors. 
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Group Diplotypes 
N (fibroids 
2+ cm)† 
total N† 
 Prevalence 
Differences‡ 
95% Confidence 
Intervals‡ 
Posterior 
Medians 
95% Posterior 
Limits 
2 Rare 23 38 0.062 -0.113, 0.236 0.041 -0.102, 0.185 
2 ATCCC/TCTTT 8 13 0.072 -0.205, 0.348 0.032 -0.153, 0.218 
2 ATTCC/ATCCC 16 37 -0.111 -0.290, 0.067 -0.074 -0.219, 0.072 
2 ATTCC/ATTTT 7 10 0.156 -0.139, 0.451 0.065 -0.125, 0.256 
2 ATTCC/TCTCC 4 8 -0.044 -0.399, 0.312 -0.014 -0.219, 0.190 
2 ATTCC/TCTCT 9 16 0.019 -0.237, 0.275 0.009 -0.170, 0.188 
2 ATTCC/TCTTT 68 119 0.028 -0.092, 0.147 0.023 -0.085, 0.131 
2 ATTCC/TTTCT 19 34 0.015 -0.170, 0.200 0.010 -0.139, 0.159 
2 ATTCT/ATCCC 3 6 -0.044 -0.452, 0.364 -0.012 -0.225, 0.201 
2 ATTCT/ATTCC 24 40 0.056 -0.115, 0.228 0.038 -0.103, 0.180 
2 ATTCT/TCTCT 5 6 0.290 -0.019, 0.598 0.115 -0.080, 0.309 
2 ATTCT/TCTTT 11 20 0.006 -0.226, 0.239 0.003 -0.167, 0.174 
2 ATTCT/TTTCT 6 8 0.206 -0.104, 0.517 0.081 -0.114, 0.276 
2 TCTCT/TCTTT 5 10 -0.044 -0.364, 0.276 -0.017 -0.214, 0.180 
2 TCTTT/TCTTT 21 31 0.134 -0.049, 0.317 0.087 -0.061, 0.235 
2 TTTCT/TCTTT 6 14 -0.115 -0.386, 0.156 -0.053 -0.237, 0.131 
2 ATTCC/ATTCC 81 149 REF  REF  
* N = 580, excludes 2 women missing more than 50% of IGFBP-3 SNPs included in diplotype estimation. 
† N = 559, excludes 14 women with less than 90% posterior probability for best diplotype assignment in PHASE software and 7 women missing  
   uterine fibroid status. 
‡ Estimated in SASV9.1 using Poisson regression with robust standard errors. 
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Group Diplotypes 
N (fibroids 
2+ cm)† 
total N† 
 Prevalence 
Differences‡ 
95% Confidence 
Intervals‡ 
Posterior 
Medians 
95% Posterior 
Limits 
3 Rare 3 9 -0.207 -0.530, 0.116 -0.077 -0.275, 0.120 
3 AACC/AACC 3 8 -0.165 -0.514, 0.184 -0.056 -0.259, 0.147 
3 AACC/AACT 3 7 -0.111 -0.491, 0.268 -0.034 -0.242, 0.175 
3 AACC/AGGT 4 14 -0.254 -0.510, 0.002 -0.124 -0.303, 0.055 
3 AACC/TACC 6 10 0.060 -0.259, 0.379 0.023 -0.174, 0.220 
3 AACC/TACT 34 53 0.102 -0.060, 0.263 0.072 -0.064, 0.207 
3 AACT/AGGT 2 7 -0.254 -0.603, 0.094 -0.086 -0.290, 0.117 
3 AACT/TACT 6 13 -0.078 -0.367, 0.210 -0.034 -0.223, 0.155 
3 AAGC/AACC 18 36 -0.040 -0.230, 0.150 -0.025 -0.177, 0.126 
3 AAGC/AACT 5 9 0.016 -0.323, 0.355 0.005 -0.196, 0.207 
3 AAGC/AAGC 24 35 0.146 -0.036, 0.328 0.095 -0.052, 0.242 
3 AAGC/AGGT 14 24 0.043 -0.177, 0.263 0.024 -0.141, 0.190 
3 AAGC/TACC 18 27 0.127 -0.076, 0.330 0.076 -0.081, 0.234 
3 AAGC/TACT 51 86 0.053 -0.090, 0.196 0.040 -0.084, 0.164 
3 AGGT/AGGT 7 10 0.160 -0.140, 0.460 0.065 -0.127, 0.258 
3 AGGT/TACT 30 47 0.098 -0.070, 0.267 0.068 -0.072, 0.207 
3 TACC/TACC 4 6 0.127 -0.263, 0.516 0.037 -0.173, 0.247 
3 TACC/TACT 22 45 -0.051 -0.227, 0.125 -0.034 -0.178, 0.110 
3 TACT/TACT 54 100 REF  REF  
* N = 580, excludes 2 women missing more than 50% of IGFBP-3 SNPs included in diplotype estimation. 
† N = 546, excludes 27 women with less than 90% posterior probability for best diplotype assignment in PHASE software and 7 women missing  
   uterine fibroid status. 
‡ Estimated in SASV9.1 using Poisson regression with robust standard errors. 
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Group Diplotypes 
N (fibroids 
2+ cm)† 
total N† 
 Prevalence 
Differences‡ 
95% Confidence 
Intervals‡ 
Posterior 
Medians 
95% Posterior 
Limits 
4 CA/CA 56 93 0.061 -0.057, 0.179 0.050 -0.057, 0.157 
4 CA/TA 25 40 0.084 -0.079, 0.247 0.059 -0.078, 0.195 
4 CG/CG 82 147 0.017 -0.086, 0.120 0.014 -0.081, 0.109 
4 CG/TA 26 46 0.024 -0.133, 0.181 0.017 -0.116, 0.150 
4 TA/TA 6 9 0.126 -0.189, 0.440 0.049 -0.147, 0.244 
4 CA/CG 125 231 REF  REF  
* N = 580, excludes 2 women missing more than 50% of IGFBP-3 SNPs included in diplotype estimation. 
† N = 566, excludes 7 women with less than 90% posterior probability for best diplotype assignment in PHASE software and 7 women missing  
   uterine fibroid status. 
‡ Estimated in SASV9.1 using Poisson regression with robust standard errors. 
 
 
 
